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Summary 
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Summary 
The intestine is a pivotal organ which is divided into two anatomical parts: the small 
intestine and the large intestine (colon and rectum). Both parts are made up of single-
layered epithelium. This epithelium is composed of villi (protrusions) – found only in the 
small intestine - and crypts (invaginations) leading to an increase of the surface of the 
intestinal lumen whereby the uptake of nutrients and water is improved. Every five days, 
the intestinal epithelium is renewed whereby both, crypts and eventually villi, are filled up 
with new cells. The homeostasis of the crypts/villi relies on adult stem cells (SCs), 
especially crypt base columnar (CBC) cells, which are located at the base of the crypts. 
These are regulated by an active Wnt signaling pathway. A deregulation of the Wnt 
signaling pathway leads to cancer formation found in humans almost exclusively in the 
colon and rectum. Colorectal cancer (CRC) is worldwide the third most common cause for 
cancer related deaths. In the majority of CRC, origin and progress are caused by mutations 
in the adenomatous polyposis coli (APC) gene which encodes an essential component of 
the β-catenin destruction complex that is the central element of the Wnt signaling pathway. 
As a consequence of these mutations, the executor of the Wnt signaling pathway, β-
catenin, which is in this context a transcription factor, cannot be downregulated any more. 
As a consequence target genes of β-catenin are expressed in an unregulated manner. These 
target genes regulate features of stem cell biology which confer cancer stemness, 
metastasis, EMT (epithelial-mesenchymal transition), chemoresistance and other 
characteristics to colorectal tumor cells. Interestingly, APC mutations have only an effect 
when they occur in the adult stem cells. Thus, the descendend tumor cells show 
characteristics of these cells and have been termed cancer stem cells (CSCs). Like adult 
stem cells in the normal crypt CSCs are the origin of cancer and are characterized by an 
activated - here deregulated - Wnt signaling pathway and thus, by the aforementioned 
features. Clinically, cancer death is caused in most cases by metastasis which is treated by 
chemotherapy from which most if not all CRCs escape by the development of 
chemoresistance which is an intrinsic feature of the CSCs. Therefore, CSC specific 
targeted therapies might be a promising therapeutic tool for a successful treatment of 
CRCs. One possibility is the interference of CSC sustaining molecules as these molecules 
are involved in the induction and maintenance of CSCs.  
Here, a promising molecule is olfactomedin-4 (OLFM4) which was discussed to be 
a CSC marker. But the role of OLFM4 as a CSC marker and important factor for 
tumorigenesis has been controversially described. Therefore, I investigated in the first part 
of my thesis the role of OLFM4 in CRC cells. I demonstrate that OLFM4 was expressed 
only in two out of 14 CRC cell lines. The assumption that OLFM4 was only expressed in 
cells with characteristics of CSCs and thus, was not detected in the cell lines as they 
possess only a small proportion of CSCs, was not confirmed. I found that CSCs showed a 
reduced OLFM4 expression and thus, OLFM4 was not coexpressed with other SC markers. 
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These results indicate that OLFM4 is not a marker of CSCs in CRC. In order to analyze the 
functional role of OLFM4 in CRC cells, I overexpressed OLFM4 lentivirally. However, 
the overexpression of OLFM4 and thus, high OLFM4 protein levels did not influence the 
expression of CSC, EMT or differentiation marker. Likewise, OLFM4 did not play a 
functional role for proliferation, stemness and metastatic features. Therefore, this study 
demonstrates that OLFM4 is not a CSC marker and has no functional role for the driving 
activity in the process of colorectal carcinogenesis.  
Additionally, I evaluated in the second part of my thesis the role of the 
microRNAome (miRNAome) in colorectal carcinogenesis, the influence on CSC features 
and whether the miRNAome might be a tool for specific CSC targeted therapies. 
microRNAs (miRNAs) are generally downregulated in tumors whereby the miRNA loss 
promotes tumorigenesis. As the majority of the CRC cases are driven by an APC mutation 
in the SC compartment, I used for my investigations a mouse model with a conditional Apc 
knockout in CBC cells which develops efficiently intestinal adenomas. This mouse model 
was crossed with another mouse model harboring a conditional knockout of the essential 
miRNA generator Dicer1 to investigate the role of a loss of the miRNAome in murine Wnt 
driven intestinal tumors. In this part of my study I demonstrated that hetero- and 
homozygous deletion of Dicer1 in CBC cells, in combination with an Apc knockout, 
enhances significantly the number of adenomas. Moreover, deletion of Dicer1 resulted in 
smaller adenomas caused by reduced proliferation. Further analysis of DICER1 deletion in 
human CRC cell lines revealed that loss of DICER1 and thus, miRNAs led likewise to a 
decreased proliferation. Additionally, I showed that loss of miRNAs increased the 
expression/protein levels of CSC markers and CSC features indicating that loss of DICER1 
promotes tumorigenesis. Moreover, I translated these mouse model/cell culture results into 
human colonic normal and tumor tissue as well as CRC. In a collection of different tissues 
(normal tissue, adenomas and cancers of stages I to IV), increased DICER1 levels were 
seen from normal tissue to adenomas followed by decreased levels during carcinoma 
progression. Increased levels of DICER1 were also found in the murine Wnt driven 
adenomas. In support with this I provided finally evidence that DICER1 expression is 
regulated by the Wnt signaling pathway thus already early in the beginning of the 
colorectal tumorigenesis. Thus, this data showed that DICER1 is a tumor suppressor in 
intestinal cancer and the loss of DICER1 and hence, of the miRNAome, influences CSC 
marker expression and marker protein levels as well as proliferation and CSC features. 
Therefore, the miRNAome might possibly become a therapeutic target for CSC targeted 
therapy. 
Zusammenfassung 
 
3 
Zusammenfassung 
Der Darm ist ein lebenswichtiges Organ, das in zwei anatomische Teile geteilt ist: den 
Dünndarm und den Dickdarm (Kolon und Rektum), die beide aus einem einschichtigen 
Epithel bestehen. Dieses Epithel besteht aus Villi (Ausstülpungen) - nur im Dünndarm 
vorhanden - und Krypten (Einstülpungen) und führt zu einer Vergrößerung der Oberfläche 
des intestinalen Lumens, wodurch die Aufnahme von Nährstoffen und Wasser verbessert 
wird. Alle fünf Tage wird das intestinale Epithel erneuert, wodurch Krypten und 
schließlich auch Villi mit neuen Zellen aufgefüllt werden. Die Homöostase der Krypten/ 
Villi beruht auf adulten Stammzellen (SZ), insbesondere „crypt base columnar“ (CBC)-
Zellen, die an der Kryptenbasis angesiedelt sind und durch einen aktiven Wnt Signalweg 
reguliert werden. Eine Deregulierung des Wnt-Signalweges führt zur Bildung von Krebs, 
welcher bei Menschen hauptsächlich im Kolon und Rektum auftritt. Unter den Krebsarten 
stellt das kolorektale Karzinom (KRK) weltweit die dritthäufigste Ursache für Krebstod 
dar. Meist sind sowohl das Auftreten als auch die Progression des KRK durch Mutationen 
im Adenomatous polyposis coli (APC)-Gen verursacht, das eine essentielle Komponente 
des β-catenin-Abbaukomplexes und daher eine zentrale Komponente des Wnt-Signalweges 
ist. Als Konsequenz kann der Transkriptionsfaktor des Wnt-Signalweges, β-catenin, nicht 
mehr herunterreguliert werden, wodurch β-catenin-Zielgene unreguliert exprimiert werden. 
Diese Zielgene regulieren wichtige Eigenschaften von Krebszellen wie Krebs-
Stammzelligkeit, Metastasierung, EMT (Epitheliale-mesenchymale Transition), 
Chemoresistenz sowie weitere Eigenschaften. Interessanter Weise haben APC-Mutationen 
nur einen Einfluss, wenn sie in adulten SZ auftreten. Die von diesen SZ abstammenden 
Tumorzellen weisen Charakteristika dieser Zellen auf und werden Krebsstammzellen 
(KSZ) genannt. KSZ sind verantwortlich für die Krebsbildung, charakterisiert durch einen 
aktivierten Wnt-Signalweg und daher durch die zuvor genannten Eigenschaften. Die 
häufigste Ursache für den Krebstod sind Metastasen. Metastasen werden mit 
Chemotherapie behandelt, wobei sich in den meisten Fällen KSZ dieser Behandlung durch 
die Entwicklung von Chemoresistenz entziehen können. Chemoresistenz ist eine 
intrinsische Eigenschaft von KSZ. Daher könnten Therapien, welche spezifisch KSZ 
angreifen, einen vielversprechenden Therapieansatzpunkt darstellen. Eine Möglichkeit 
dafür ist die Beeinträchtigung stammzellunterstützender Moleküle, da diese in die 
Induktion und Aufrechterhaltung von KSZ involviert sind.  
Ein vielversprechendes Molekül ist olfactomedin-4 (OLFM4), das bereits als SZ-
Marker diskutiert wurde. Aber die Rolle von OLFM4 als SZ-Marker und als wichtiger 
Faktor für die Tumorigenese wurde bisher kontrovers beschrieben. Daher habe ich im 
ersten Teil meiner Doktorarbeit die Rolle von OLFM4 in KRK-Zellen untersucht. Ich 
zeigte, dass OLFM4 nur in zwei von 14 Zelllinien exprimiert wurde. Die Annahme, dass 
OLFM4 nur in Zellen mit KSZ-Eigenschaften exprimiert wird und daher in Zelllinien nicht 
detektiert wird, da diese nur einen kleinen Anteil an KSZ besitzen, wurde nicht bestätigt. 
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Des Weiteren habe ich herausgefunden, dass KSZ eine reduzierte OLFM4-Expression 
zeigen, wodurch OLFM4 nicht zusammen mit anderen SZ-Markern exprimiert wurde. 
Diese Ergebnisse deuten darauf hin, dass OLFM4 kein Marker von KSZ im KRK ist. Um 
die funktionelle Rolle von OLFM4 in KRK-Zellen zu untersuchen, habe ich OLFM4 
lentiviral überexprimiert. Jedoch beeinflusste eine Überexpression von OLFM4 und somit 
hohe OLFM4-Proteinlevel nicht die Expression von KSZ-, EMT- und 
Differenzierungsmarkern. Ebenso spielte OLFM4 keine funktionelle Rolle in der 
Proliferation, KSZ- sowie Metastasierungs-Eigenschaften. Daher zeigt diese Studie, dass 
OLFM4 kein KSZ-Marker ist und keine funktionelle Rolle als treibende Kraft im 
kolorektalen Karzinogeneseprozess hat. 
 Im zweiten Teil meiner Doktorarbeit habe ich die Rolle des miRNAoms in der 
kolorektalen Karzinogenese und seinen Einfluss auf KSZ-Eigenschaften untersucht mit 
dem Ziel, ob das miRNAom einen Ansatzpunkt für eine spezifische KSZ-Therapie 
darstellen könnte. miRNAs sind in Tumoren generell herunterreguliert, was darauf 
schließen lässt, dass ein miRNA-Verlust die Tumorigenese begünstigt. Da die Mehrheit 
der KRK-Fälle durch eine APC-Mutation im SZ-Kompartment angetrieben wird, habe ich 
für meine Untersuchungen ein Mausmodell mit einem konditionalen Apc-Knockout in den 
CBC-Zellen verwendet, welches effizient intestinale Adenome entwickelt. Dieses 
Mausmodell wurde mit einem anderen Mausmodell mit einem konditionalen Knockout des 
miRNA-Generators Dicer1 gekreuzt. Damit konnte die Rolle eines miRNAom-Verlustes in 
murinen intestialen Tumoren, welche vom Wnt-Signalweg angetrieben werden, untersucht 
werden. In diesem Teil meiner Studie zeige ich, dass eine hetero- und homozygote 
Deletion von Dicer1 in CBC-Zellen, in Kombination mit einem Apc-Knockout, signifikant 
die Adenomzahl erhöhte. Außerdem resultierte eine Dicer1-Deletion in einer kleineren 
Adenomgröße, was durch eine verringerte Proliferation verursacht wurde. Eine 
weiterführende Analyse der DICER1-Deletion in humanen KRK-Zelllinien zeigte, dass ein 
Verlust von DICER1 und folglich miRNAs ebenso zu einer verringerten Proliferation 
führte. Außerdem erhöhte ein miRNA-Verlust die Expression/Proteinlevel von KSZ-
Markern und KSZ-Eigenschaften. Diese Ergebnisse zeigen, dass ein Verlust von DICER1 
die Tumorigenese fördert. Um diese Zellkultur/Mausmodell-Ergebnisse auf den Menschen 
zu übertragen, habe ich humanes Normal-, Adenom- und Krebsgewebe (Stadium I bis IV) 
von KRK-Patienten analysiert. Dabei nahm das DICER1-Proteinlevel vom Normalgewebe 
zu den Adenomen zu. Während der Karzinomprogression nahm das DICER1-Proteinlevel 
jedoch von den Adenomen bis hin zum Karzinom ab. Einen Anstieg des DICER1-
Proteinlevels habe ich auch in murinen Wnt-getriebenen Adenomen gefunden. Daher 
erbringe ich schlussendlich einen Nachweis, dass die DICER1-Expression vom Wnt-
Signalweg und daher früh in der Tumorigenese reguliert wird. Folglich zeigen diese Daten, 
dass DICER1 im Darmkrebs ein Tumorsuppressor ist und ein Verlust von DICER1 und 
somit des miRNAoms KSZ-Markerexpression und Markerproteinlevel sowie Proliferation 
und KSZ-Eigenschaften beeinflusst. Daher könnte das miRNAom möglicherweise einen 
Ansatzpunkt für Therapien, welche spezifisch KSZ angreifen, darstellen. 
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1 Introduction 
1.1 The intestine is a pivotal organ  
An intact intestine is essential for all metazoa as it mainly performs the digestion and 
resorption of water whereby food and drinks are broken down into the basic nutrients. 
Subsequently, these are absorbed into the blood stream, transported to cells all over the 
body and used for the generation of energy, growth and cell repair 
(http://www.niddk.nih.gov/Pages/default.aspx). For the efficient uptake of nutrients, the 
intestine has developed a specific structure which is subsequently explained. 
 
1.1.1 Structure of the intestine 
The intestinal tract is divided into two anatomical parts: the small intestine and the large 
intestine (colon and rectum). Furthermore, the small intestine is sectioned from proximal to 
distal in the duodenum, jejunum and ileum (Barker et al., 2008). In the small intestine, the 
food is mixed with digestive juices coming from the pancreas and bile by peristaltic action 
of the intestinal musculature. Nutrients are absorbed and the remainings are transported 
into the large intestine. Here, water is mainly absorbed and additionally, the remaining 
nutrients are metabolized and absorbed by enterocytes. Thereby stool is generated which is 
pushed out by peristaltic bowel movement (http://www.niddk.nih.gov/Pages/default.aspx).  
The epithelium of the intestine possesses a characteristic and functional structure. 
In the small intestine, the epithelium shows protrusions which are known as villi and 
invaginations named crypts (Fevr et al., 2007). Each crypt is surrounded by villi like a 
crown which leads to an increase of the epithelial surface resulting in an enhanced contact 
between epithelium and the intestinal lumen and thus, improving the uptake of nutrients. In 
contrast, the epithelium of the colon contains only crypts which are larger as in the small 
intestine (Pinto and Clevers, 2005) (Fig. 1A).   
In both, the small and the large intestine, the epithelium consists of a single layer of 
epithelial cells (Pinto and Clevers, 2005). This epithelium is renewed roughly every five 
days as epithelial cells migrate from the bottom towards the top of the crypts in the small 
intestine or the surface epithelium of the colon respectively, where they become apoptotic 
and are finally shed into the lumen of the intestine (Pinto and Clevers, 2005). The life cycle 
of intestinal cells spans from their generation at the crypt base via proliferation, 
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differentiation, apoptosis and shedding into the lumen. During these five days, crypts or 
crypt/villi units are renewed completely. Thus, new cells have to substitute the upwards 
migrated and thus, vanishing cells to make sure that the barrier, defending and absorptive 
functions of the intestinal mucosa is continued (Pinto and Clevers, 2005). The cellular 
characteristics, functions, their migration and the homeostasis of the intestinal epithelium 
are subsequently described in more detail.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. The structure of the intestinal epithelium and an intestinal crypt.  
(A) The epithelium of the small intestine is built of villi and crypts. The large intestine possesses only crypts. 
This structure is organized by adult stem cells which are located at the base of the crypt. The transit-
amplifying (TA) cells stem from the stem cells and differentiate into Paneth, absorptive, goblet and 
enteroendocrine cells. The arrow indicates the upwards migration of cells out of the crypt (Crosnier et al., 
2006). (B) Intestinal crypt structure with cycling, LGR5 positive stem cells (crypt base columnar (CBC) 
cells) and quiescent, BMI1 positive stem cells at the +4 position. Additionally depicted are TA cells and 
mesenchymal cells (Li and Clevers, 2010). 
 
 
1.1.2 Intestinal cell types  
Multipotent stem cells (SCs) are responsible for the renewal and fill-up resulting in the 
crypt homeostasis. SCs are located at the base of the crypts in the SC niche (Pinto and 
Clevers, 2005). In the small intestine two potential pools of SCs were found: 1) at the base 
of intestinal crypts, SCs are located which show high proliferative activity and are named 
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due to their morphological appearance crypt base columnar (CBC) cells (Clevers, 2013). 
They are characterized by high amounts of the SC marker leucine-rich-repeat-containing 
G-protein coupled receptor 5 (LGR5) (Barker et al., 2007) (Fig. 1B). 2) Besides these 
actively proliferating CBC cells, another pool of SCs was found at the +4 position of the 
crypt. These SCs are characterized by low proliferation (Yan et al., 2012) and by high 
amounts of the SC marker B lymphoma Mo-MLV insertion region 1 (BMI1) (Fig. 1B) (Li 
and Clevers, 2010). BMI1 positive SCs do not contribute to the homeostatic regeneration 
of the small intestine but seem to represent a back-up reservoir which becomes activated 
by the small intestine after gross cell damage like radiation injury. Thus, these SCs can 
reconstitute the pool of the radiation-sensitive CBC cells (Potten et al., 2009; Yan et al., 
2012). 
During the crypt homeostasis, CBC cells divide about every 24 h asymmetrically to 
give rise to CBC and transit amplifying (TA) cells (Pinto and Clevers, 2005). TA cells 
proliferate quickly and divide every 12 h for four to five times before they start to 
differentiate (Marshman et al., 2002; Pinto and Clevers, 2005). By this fast proliferation 
the amount of crypt cells is massively increased. The subsequent derivatives of TA cells 
are non-proliferative, accumulate in the crypts and differentiate into the four different cell 
types: enterocytes, enteroendocrine cells, goblet cells, and small intestinal Paneth cells 
(Gregorieff and Clevers, 2005) (Fig. 1A). Among these cell types, the enterocytes which 
are specialized for absorption of nutrients are the most abundant cell type (Crosnier et al., 
2006). Enterocytes, hormone-secreting enteroendocrine and mucus-secreting goblet cells 
migrate upwards to the top of the villi or the surface epithelium of the colon (Gregorieff 
and Clevers, 2005; Pinto and Clevers, 2005). Paneth cells stay in the base of the crypt 
(Fig. 1B) and reside there for about 20 days (Pinto and Clevers, 2005). They protect the 
host from intestinal pathogens by the secretion of antimicrobial peptides and enzymes 
(Clevers and Bevins, 2013) and provide the niche for the SCs (Sato et al., 2011).  
 
 
1.1.3 Regulation of the crypt homeostasis by different pathways 
The intestinal crypt/villus homeostasis is regulated by different pathways (Fig. 2A). Most 
important is the canonical Wnt signaling pathway, subsequently termed Wnt signaling 
pathway, which controls SCs, proliferation and differentiation (Brabletz et al., 2009; van 
de Wetering et al., 2002).  
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An active Wnt signaling pathway sustains a proliferative and dedifferentiated 
phenotype (van de Wetering et al., 2002; van den Brink and Hardwick, 2006). The activity 
of the Wnt signaling pathway is strongest at the base of the crypt and declines in a gradient 
towards the tip of the crypt (van de Wetering et al., 2002). Wnt is provided by 
extraepithelial Wnt sources (Schuijers and Clevers, 2012) such as mesenchymal cells 
(intestinal subepithelial myofibroblasts (ISEMFs)) which are located around the SC niche 
and by Paneth cells which are located in the SC niche (Sato et al., 2011). The Paneth cells 
in turn are maturated by the Wnt signaling pathway (van Es et al., 2005a) (Fig. 2A). A 
disruption of the Wnt signaling pathway activity disturbs the development of the intestinal 
SC compartment (Korinek et al., 1998) or stops crypt proliferation (Fevr et al., 2007; 
Kuhnert et al., 2004; van Es et al., 2012). Furthermore, the Wnt signaling pathway is 
involved in the migration of the intestinal epithelial cells by regulating the expression of 
EFNB1 (ephrin-B1) and its receptors EPHB2 and EPHB3 (ephrin type-B receptor 2/3). 
Active Wnt signaling pathway represses EFNB1 and induces EPHB2 and EPHB3 resulting 
in the expression of EFNB1 at the top of the crypt and EPHB2 and EPHB3 at the crypt 
base. This leads to the repulsion of cells and therefore, to migration and proper cell 
positioning (Batlle et al., 2002; Crosnier et al., 2006). 
However, other pathways are also important for the modulation of the homeostasis 
(Brabletz et al., 2009). Another pathway involved in the homeostasis is the Hedgehog 
signaling (HH) pathway which induces differentiation (van den Brink and Hardwick, 
2006). As the expression of its morphogen indian hedgehog (IHH) is negatively regulated 
by the Wnt signaling pathway, the HH signaling pathway activity declines from the top of 
the crypt to the base of the crypt. Thus, the centers of Wnt and HH signaling are opposed 
resulting in two counteracting gradients. Moreover, the HH signaling pathway in turn 
restricts Wnt to the crypt base (van den Brink and Hardwick, 2006) (Fig. 2A, B). IHH is 
expressed and the morphogen is synthesized from non-proliferative epithelial cells in the 
intestine (Gregorieff and Clevers, 2005).  
Furthermore, the BMP (bone morphogenetic protein) pathway plays also a role in 
crypt/villus homeostasis as it is required for differentiation and maturation of intestinal 
cells (Vanuytsel et al., 2013). Its morphogen BMP is expressed and BMP is synthesized by 
mature epithelial cells (Gregorieff and Clevers, 2005). The inhibitors of the BMP pathway, 
noggin (NOG) and gremlin, are expressed and synthesized in ISEMFs. As they bind BMP 
this results in an inhibition of the BMP pathway in this area of the crypt. Thus, BMP 
signaling declines - like HH signaling - in a gradient from the top to the base of the crypt. 
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Another parallel is that the BMP signaling pathway can inhibit the Wnt signaling pathway 
via activation of PTEN (phosphatase and tensin homolog; member of the PI3K 
(phosphatidylinositol-4,5-bisphosphate 3-kinase) pathway) and thus, inhibition of the 
serine/threonine kinase AKT (v-akt murine thymoma viral oncogene homolog) which 
consequently cannot induce the Wnt signaling pathway (Brabletz et al., 2009).  
Moreover, the Notch pathway is active in the SC and TA compartment (Brabletz et 
al., 2009). It is important to maintain, together with Wnt signaling, undifferentiated, 
proliferative cells (van Es et al., 2005b) and is also involved in the differentiation of 
absorptive enterocytes. However, for the differentiation of the secretory lineage, an 
inhibition of the Notch pathway is required (Vanuytsel et al., 2013). The Notch pathway is 
inhibited by the Hippo pathway which is active in post-mitotic differentiated cells and 
inhibits proliferation. In the TA and SC compartment, the Hippo pathway is inactive and 
thus, its transcription factors yes-associated protein (YAP)/transcriptional coactivator with 
PDZ-binding motif (TAZ) can translocate to the nucleus and be transcriptionally active. 
Furthermore, YAP can activate the Notch and Wnt signaling pathway (Fig. 2A, B) 
(Vanuytsel et al., 2013).  
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Fig. 2. Schematic representation of the major signaling pathways of the crypt/villus homeostasis and its 
interaction. 
(A) The homeostasis of the intestinal crypts and villi requires several pathways. The dominant force among 
these pathways is the Wnt singaling pathway which sustains proliferation and dedifferentiation. It declines 
from the base to the top of the crypt. The Hedgehog pathway (HH) induces differentiation and declines from 
the top of the crypt to the base of the crypt. Furthermore, the BMP pathway is required for differentiation and 
maturation of intestinal cells and declines also from the top to the base of the crypt. The Notch pathway is 
active in the SC and TA compartment, maintains undifferentiated, proliferative cells and is also involved in 
the differentiation of absorptive enterocytes. The Hippo pathway is active in post-mitotic differentiated cells 
and inhibits proliferation. (B) The pathways which are active in the crypt/villus compartment interact with 
each other and can activate or repress other pathways. In this picture, the interaction leading to a SC 
phenotype is shown. Dotted lines show interactions which were observed in colon cancer cell lines and are 
possibly also involved in normal SC signaling. Solid lines show interactions known to occur in normal 
intestinal SCs. Modified from (Brabletz et al., 2009; Vanuytsel et al., 2013). 
 
1.1.4 The Wnt signaling pathway in the intestine 
Since the Wnt signaling pathway is the most important pathway in the crypt/villus 
homeostasis, I focus subsequently on this pathway. The central effector molecule of the 
Wnt signaling pathway is the transcription factor β-catenin which has two different roles in 
epithelial cells. In the inactive state of the Wnt signaling pathway (in non-proliferative, 
differentiated intestinal cells that are located apically of TA cells (Schuijers and Clevers, 
2012; van de Wetering et al., 2002)), β-catenin molecules are withdrawn from the Wnt 
signaling pathway as they interact with cadherin 1 (E-cadherin) at the plasma membrane 
(Thiery, 2002) and associate via α-catenin with the actin cytoskeleton to form adherens 
junctions (Conacci-Sorrell et al., 2002). Functionally, this recruitment to the adherens 
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junctions stabilizes cell-cell adhesions (Conacci-Sorrell et al., 2002) resulting in an 
epithelial phenotype (Thiery, 2002). In this complex, β-catenin is protected from 
degradation (Fig. 3A) (Moon et al., 2004). The remaining β-catenin molecules which are 
not associated with adherens junctions are sequestered by a destruction complex which 
consists of adenomatous polyposis coli (APC), glycogen synthase kinase 3 (GSK3), casein 
kinase 1 (CK1) and AXIN. This sequestration by the destruction complex leads to a 
phosphorylation of β-catenin by CK1 and GSK3 (Moon et al., 2004) near the N-terminus at 
various highly conserved serine/threonine residues of β-catenin (Clevers, 2006; Gregorieff 
and Clevers, 2005). Phosphorylated β-catenin is subsequently recognized by the E3 
ubiquitin ligase complex, polyubiquitinated and degraded finally in the 28S-proteasome 
(Conacci-Sorrell et al., 2002). Therefore, only low cytoplasmic and especially nuclear 
levels of β-catenin exist in such cells and thus, the target genes of β-catenin are not 
expressed under basal conditions (Fig. 3A) (Clevers, 2006; Moon et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. The canonical Wnt signaling pathway. 
(A) In the inactive state of the Wnt signaling pathway, Wnt ligands are absent and some β-catenin molecules 
are recruited to adherens junctions (AJ) to stabilize cell-cell adhesions and thus, the epithelial phenotype. β-
catenin molecules which are not associated with AJ are recruited by a destruction complex (AXIN, GSK3, 
CK1 and APC), phosphorylated by CK1 and GSK3 at the N-terminus and subsequently proteosomally 
degraded. Modified from (Conacci-Sorrell et al., 2002; Moon et al., 2004). (B) In the active state, Wnt 
ligands bind to frizzled receptors whereby the destruction complex is bound to the membrane, AXIN is 
degraded, GSK3 is inhibited by DSH and GBP and subsequently, β-catenin is stabilized. Here, it works in 
cooperation with DNA-binding factors of the TCF/LEF-1 family of the HMG (high mobility group factor) 
family and other coactivators like CBP or p300 as a multi-enhancosome complex as a strong cis-acting 
transcription factor. (Moon et al., 2004)  
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In the active state of the Wnt signaling pathway (found in cells at the crypt base and TA 
cells) (Fig. 3B), an excess of Wnt ligands compared to the inhibitors is present whereby 
Wnts bind to their receptors, members of the frizzled family, and to the co-receptors LDL 
receptor-related proteins 5 and 6 (LRP5 and LRP6). By this interaction, the phosphoprotein 
dishevelled (DSH) is activated and recruited to the membrane and thus, AXIN and the 
destruction complex are bound to the membrane. By subsequent degradation of AXIN, 
inhibition of GSK3 by DSH and recruiting of the GSK3 inhibitor GSK3 binding protein 
(GBP) to the complex, the phosphorylation and degradation of β-catenin are decreased. 
Thus, levels of β-catenin molecules increase (Moon et al., 2004) and eventually β-catenin 
is transported by a yet not completely understood mechanism from the cytoplasm into the 
nucleus most likely either by interaction with lymphoid enhancer-binding factor 1 (LEF1) 
(Henderson and Fagotto, 2002) or by binding directly to components of the nuclear pore 
complex (Fagotto et al., 1998). This results in the nuclear accumulation of β-catenin in the 
nucleus. Here, β-catenin can cooperate with the DNA binding T-cell specific transcription 
factors (TCF) and LEF transcription factors which are then no longer associated with co-
repressors of the groucho (GRO) family (Clevers and Nusse, 2012). This cooperation, 
together with the binding of the coactivator CREB binding protein (CREBBP; CBP) or 
E1A binding protein p300 (EP300; p300) (Hecht et al., 2000) and a variety of other factors 
like legless or pygopus (Townsley et al., 2004) results in a multi-protein activator complex 
that upregulates the expression of β-catenin target genes (Fig. 3B) (Moon et al., 2004). 
 
 
1.2 Alterations of the intestinal homeostasis result in colorectal cancer 
1.2.1 Epidemiology and risks of cancer 
The homeostasis of the intestine is tightly regulated and disturbances in this regulation 
result in uncontrolled cell growth causing cancer. Cancer is one of the leading causes of 
disease and death worldwide. In 2012, approximately 14.1 million new cancer cases 
occurred worldwide, 8.2 million people died in consequence of cancer 
(World_Cancer_Factsheet, 2008, 2012). The incidences of cancer are higher in Western 
countries than in developing countries (World_Cancer_Factsheet, 2008, 2012) which is 
mainly caused by: 1) variations in the age structure of the populations, 2) the life style such 
as nutrition, alcohol or tobacco (Global_Cancer_Facts_and_Figures, 2nd edition). 
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Colorectal cancer (CRC) is in regard to the incidence of cancer cases as well as in the 
mortality among the three most common cancers worldwide (Fig. 4) 
(World_Cancer_Factsheet, 2012). Similar to the general risk of cancer, the risk of CRC 
rises with age. The lifestyle that means smoking, alcohol consumption, obesity paired with 
few physical exercise as well as high amounts of red and especially processed meat 
increase the risk for CRC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 World cancer burden. 
(A) Incidence and (B) mortality rates are shown for both genders worldwide in 2012. Colorectal cancer is one 
of the leading causes for cancer cases and deaths (World_Cancer_Factsheet, 2012). 
 
Because of the high risk and mortality rate of CRC, it is important to understand how this 
disease works on the molecular level. Therefore, it is a good basis to understand the 
regulation of intestinal cells and to compare what is deregulated in CRC. One reasonable 
approach is to focus on genetic syndromes (Global_Cancer_Facts_and_Figures, 2nd 
edition) as these usually harbor mutations in relevant genes which are important for the 
disease. For CRC, mainly two syndroms are known. 
 
1.2.2 Forms of hereditary CRC 
One hereditary cancer syndrome is the Lynch syndrome which is known as hereditary 
nonpolyposis colorectal cancer (HNPCC) when it becomes manifest in the gut. Around 3–
4% of all cases of CRC are caused by this syndrome. Patients inheriting this syndrome 
have a lifetime risk of 80% to develop CRC. HNPCC is characterized by heterozygous 
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germline mutations in one of the four DNA mismatch repair (MMR) genes mutS homolog 
2 (MSH2), mutS homolog 6 (MSH6), human mutL homolog 1 (MLH1) and postmeiotic 
segregation increased 2 (S. cerevisiae) (PMS2) (Rustgi, 2007). According to the two hit 
model, the remaining wildtype MMR allele is lost or functionally inactivated by somatic 
genetic alterations during lifetime CRCs of HNPCC patients (loss of function mutation). 
This results in a defective MMR system producing errors that arise during replication or 
maintenance DNA repair which can no longer be repaired. Thus, plenty mutations 
accumulate especially in mononucleotide microsatellite sequences which are the substrate 
for the MMR system. Therefore, this type of defect in caretaker genes results in 
microsatellite instability (MSI). When repetitive microsatellites are located in coding 
sequences of genes, defects usually lead to frameshift mutations, e.g. in receptors 
responsible for growth suppression such as the transforming growth factor β (TGFβ)-
receptor II resulting in growth of tumors (de la Chapelle, 2004; Kinzler and Vogelstein, 
1996).  
Another hereditary form of CRC is familial adenomatous polyposis (FAP) which 
causes about 0.2–1% of all cases of CRC (de la Chapelle, 2004; Rustgi, 2007). FAP is 
genetically associated with mutations on chromosome 5q21. Here, the gene encoding the 
tumor suppressor APC, a component of the β-catenin destruction complex of the Wnt 
signaling pathway, is located which was identified to be the driver of CRC (Kinzler et al., 
1991; Rustgi, 2007). As a tumor suppressor, the second APC allele is inactivated (loss of 
function) by point mutation or loss of heterozygosity (Crabtree et al., 2003) so that the 
patients develop already in early adolescence hundreds to thousands of small adenomatous 
polyps in the colon and rectum (Fig. 5). Therefore, the penetrance to develop CRC is 
practically 100% for these patients already at a young age (de la Chapelle, 2004). Although 
genetically recessive, FAP is considered phenotypically as a dominant disease due to the 
high penetrance (Rustgi, 2007).  
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Fig. 5. Familial adenomatous polyposis (FAP). 
(A) Normal mucosa of the colon. (B) Multiple polyps (adenomas) in the colon of a FAP patient (Weinberg, 
2007). 
 
Besides the hereditary forms, also sporadic abnormalities lead to CRC which resemble 
phenotypically the hereditary forms HNPCC and FAP. Among the sporadic cases, about 
13% are caused by a mutation in an oncogene like BRAF (serine/threonine-protein kinase 
B-Raf) (http://www.nature.com/tcga/) which induces upregulation of DNA methyl 
transferases (DNMT) (Carragher et al., 2010). This results in hypermethylation of CpG 
islands (CIMP) which can result in MSI caused by hypermethylation of MLH1 (Pino and 
Chung, 2010; Weisenberger et al., 2006). These cases resemble phenotypically HNPCC 
patients. About 80% of sporadic CRC cases are caused by mutations in the APC gene 
(Kinzler and Vogelstein, 1996) and resemble phenotypically FAP patients. As the CRC 
cases with APC mutations are associated with a worse outcome due to the development of 
metastases than the MSI phenotype (Pino and Chung, 2010), I focus in the following on 
the former cases. 
 
1.2.3 Initiation of CRC by an activated Wnt signaling pathway 
1.2.3.1 Mutations of the Wnt signaling pathway 
When both alleles of the APC gene harbor mutations, APC may become functionally 
inactive whereby the β-catenin destruction complex does not work anymore properly. The 
importance of the Wnt signaling pathway for the development of CRC is underlined by the 
fact that β-catenin, the functional driver of the Wnt signaling pathway, is found to be 
mutated in about 50% of the cases of CRC without APC mutations. For the β-catenin gene 
(CTNNB1), which is an oncogene, a single point mutation is sufficient for its activation 
(gain of function) (Pino and Chung, 2010). Mutations affect the serine/threonine residues 
in the N-terminus of the protein which are essential targets for the degradation via the APC 
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destruction complex (Clevers, 2006). Thus, by these mutations β-catenin is protected from 
a regulatable and thus proper destruction. Both, mutations in the APC or CTNNB1 gene, 
disturb the regulation of the Wnt signaling pathway (see 1.1.4) and lead to an activation of 
the Wnt signaling pathway. Thus, β-catenin becomes permanently stabilized, independent 
of the binding of Wnt ligands, accumulates in the cytoplasm and can eventually translocate 
into the nucleus and drive transcription of various target genes (Clevers, 2006; Pino and 
Chung, 2010).  
 
1.2.3.2 β-catenin target genes 
β-catenin target genes are involved in or directly confer most of the hallmarks of cancer 
(Fig. 6). The hallmarks of cancer resemble essential properties of cells that have to be 
gained for the transformation of normal into cancer cells to survive, become tumorigenic 
and finally malignant (Hanahan and Weinberg, 2011). Among the hallmarks of cancer are 
proliferation which is controlled by the β-catenin target genes v-myc avian 
myelocytomatosis viral oncogene homolog (MYC) (He et al., 1998), cyclin D1 (CCND1) 
(Shtutman et al., 1999) but also cyclin-dependent kinase inhibitor 2A (CDKN2A) 
(Wassermann et al., 2009) and induction of angiogenesis which is induced by the 
expression and synthesis of vascular endothelial growth factor (VEGF) (Zhang et al., 
2001b). Furthermore, resistance to apoptosis is mediated by baculoviral inhibitor of 
apoptosis repeat-containing 5 (BIRC5) (Zhang et al., 2001a), invasion and metastasis by 
matrix metalloproteinase 7 (MMP7) (Brabletz et al., 1999), urokinase-type plasminogen 
activator (PLAU) (Hiendlmeyer et al., 2004) and tenascin C (TNC) (Beiter et al., 2005) and 
stemness by cluster of differentiation 44 molecule (CD44) (Wielenga et al., 1999) and 
LGR5 (Barker et al., 2007). Epithelial-mesenchymal transition (EMT) is induced by zinc 
finger E-box binding homeobox 1 (ZEB1) (Sanchez-Tillo et al., 2011) and 
chemoresistance by ATP-binding cassette, sub-family B (MDR/TAP) 1 (ABCB1) 
(Yamada et al., 2000). Moreover, replicative immortality is mediated by telomerase 
reverse transcriptase (TERT) (Hoffmeyer et al., 2012; Jaitner et al., 2012). This list may not 
be complete as more and more β-catenin target genes involved in the regulation of the 
hallmarks of cancer are found every day. For a more complete list see 
(http://web.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes). The influence of β-
catenin on various hallmarks of cancer points out the importance of the Wnt signaling 
pathway in the process of colorectal carcinogenesis. 
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Fig. 6. The influence of β-catenin on hallmarks of cancer and its target genes. 
An active Wnt signaling pathway and thus, nuclear β-catenin influences most of the hallmarks of cancer by 
the expression of its target genes. These hallmarks with some corresponding target genes are listed. 
 
1.2.3.3 Other mutations in CRC 
The Wnt signaling pathway and its target genes are very important for CRC, however, for 
colorectal carcinogenesis the accumulation of further genetic changes is required (Kinzler 
and Vogelstein, 1996). Thereby the inactivation of the APC gene is frequently the initial hit 
in the majority of cases of colorectal carcinogenesis (Fig. 7). Therefore, APC has been 
named the gatekeeper of colorectal carcinogenesis (Fearon and Vogelstein, 1990; Kinzler 
and Vogelstein, 1996). The activation of the Wnt signaling pathway leads to 
hyperproliferation of affected epithelial cells what results in the development of early 
adenomas. In the further process of carcinogenesis the APC mutated tumor cells acquire 
additional mutations in other oncogenes and tumor suppressor genes what is known as the 
multistep carcinogenesis model (Kinzler and Vogelstein, 1996). Originally, due to the 
combination of different caretaker systems of DNA repair the general mutation rate of the 
human genome is quite low (1 nucleotide per 109 bp and thus about 2 to 3 mutations per 
round of replication) (Weinberg, 2007). Therefore, tumor cells have to gain intrinsic 
chromosomal instability (CIN) to be able to acquire additional mutations resulting in the 
multiple mutations observed in CRCs (Pino and Chung, 2010). Interestingly, mutations of 
the APC gene also contribute in this manner as loss of APC function is also related to 
chromosomal instability since APC also plays a role in the attachment of microtubules to 
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the kinetichor region of chromosomes during their segregation in mitosis (Kaplan et al., 
2001). Furthermore, the shortening of telomeres by hyperproliferation of the tumor cells 
leads also to CIN (Hanahan and Weinberg, 2011; Romanov et al., 2001). However, the 
upregulation of TERT by β-catenin (Hoffmeyer et al., 2012; Jaitner et al., 2012) later in the 
process of carcinogenesis leads to an elongation of the telomeres and thus, to a 
stabilization of the chromosome.  
Frequently, mutations in the oncogene Kirsten rat sarcoma viral oncogene homolog 
(KRAS) are seen quite early at the stage of intermediate adenomas. Additionally, parts of 
the chromosome 18q, that include e.g. the tumor suppressor mothers against 
decapentaplegic homolog 4 (SMAD4), are lost and mutations of the tumor suppressor 
tumor protein p53 (TP53; the guardian of the genome) as well as other mutations are 
frequently observed in CRCs and conduce to the multistep process of carcinogenesis up to 
the formation of metastases (Fig. 7) (Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 
1996). As the genetic alterations may somehow be also associated with the loss of the APC 
gene function, this is another reason besides the early timepoint in the carcinogenesis of 
CRCs why APC is considered to be the gatekeeper in this process (Kinzler and Vogelstein, 
1996).  
 
 
 
 
Fig. 7. The multistep carcinogenesis model of colorectal cancer. 
A mutation in APC/CTNNB1 and thus, activation in the Wnt signaling pathway is the initial hit in most 
CRCs. By this mutation, the affected epithelial cells become hyperproliferative and adenomas are formed. 
Additionally, loss of APC leads to increased CIN (chromosomal instability). Cells acquire additional 
mutations such as KRAS, TP53 and loss of parts of 18q. These additional mutations conduce to the multistep 
process of carcinogenesis up to the formation of metastases. Adapted from (Kinzler and Vogelstein, 1996; 
Weinberg, 2007). 
 
1.2.3.4 Wnt signaling pathway activity in human tumors - the β-catenin paradox 
Translating these findings into human tumors it turns out that the situation is more 
complex. Although the activating mutation of the Wnt signaling pathway is an early event 
in the tumorigenesis and therefore, all tumor cells possess this mutation, only a subset of 
the tumor cells shows a nuclear localization of β-catenin and thus, expression of β-catenin 
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target genes indicating an additional regulating force. This phenomenon is called β-catenin 
paradox (Fodde and Brabletz, 2007). The tumor cells with nuclear β-catenin reside near the 
stroma (stromal myofibroblasts) of the invasive front of CRCs which provides Wnt and 
other cytokines and growth factors such as hepatocyte growth factor (HGF) (Vermeulen et 
al., 2010) and seem to be responsible for the tumor progression and metastases formation 
(Fodde and Brabletz, 2007). In central areas of the tumor, however, tumor cells show 
cytoplasmatic β-catenin, are differentiated (Brabletz et al., 2005) and have lost the 
tumorigenic potential (Vermeulen et al., 2010). Therefore, there are two different 
populations of cancer cells in a tumor: the cells without nuclear β-catenin which are 
located in the central parts of the tumor and the cells with nuclear β-catenin and thus, 
expression of β-catenin target genes which reside at the interface between normal and 
neoplastic tissue and represent the minority of cancer cells.  
 
1.2.3.5 Cancer stem cells 
For the sake of simplification, all cells with properties of cancer stem cells (CSCs) are 
termed subsequently CSCs. 
Nuclear β-catenin, reflecting an active Wnt signaling pathway, defines cancer cells 
as CSCs (Vermeulen et al., 2010). CSCs are regarded as the origin of cancer (Barker et al., 
2007). The existence of CSCs was first discovered in the acute myeloid leukemia (Bonnet 
and Dick, 1997) but later found also in solid tumors (Al-Hajj et al., 2003; Singh et al., 
2004) such as CRC (Ricci-Vitiani et al., 2007). CSCs are characterized by several 
fundamental proterties. 1)  Only a few cells down to a single cell (Vermeulen et al., 2010) 
can initiate a tumor when implanted into immunodeficient recipient mice (O'Brien et al., 
2007; Ricci-Vitiani et al., 2007). 2) Furthermore, CSCs are characterized by asymmetric 
division. By this they self-renew and generate differentiated cells at the same time 
(Marjanovic et al., 2013). 3) CSCs can proliferate and grow unlimited (Frank et al., 2010). 
4) In CRC, CSCs can be defined and isolated due to their different marker profile 
characterized by high amounts of SC markers such as prominin 1 (PROM1, CD133) 
(O'Brien et al., 2007; Ricci-Vitiani et al., 2007), aldehyde dehydrogenase 1 (ALDH1A1; 
subsequently termed as ALDH1) (Huang et al., 2009) or CD44 (Du et al., 2008). Most 
importantly they initiate tumor growth with high incidences compared to tumor cells 
without high levels of these markers. All these features such as activity of the Wnt 
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signaling pathway activity, self-renewal, unlimited growth, initiation of new tumors and 
high amounts of SC markers are defined as cancer stemness features.  
The CSC model implies that only CSCs which are a small fraction of tumor cells 
can drive the growth and progression of the tumor. Therefore, a cellular hierarchy with the 
CSCs at the top exists in tumors. The CSCs yield by asymmetric cell division both CSCs 
and differentiated cells by which the tumor mass grows (Fig. 8) (Marjanovic et al., 2013). 
CSCs originate from adult stem cells by oncogenic transformation (Barker et al., 2009). 
Alternatively, CSCs can also develop in an inflammatory context as inflammatory 
regulators can induce EMT by which tumor cells can be shifted into a state of cancer 
stemness (Marjanovic et al., 2013). This was shown for the inflammatory factor NF-κB 
(nuclear factor 'kappa-light-chain-enhancer' of activated B-cells) which enhanced Wnt 
signaling pathway and thus, induced EMT or dedifferentiation and acquisition of tumor-
initiating capacities (Schwitalla et al., 2013). Alternatively, signals from the environment 
(stromal myofibroblast derived factors) like HGF can also induce EMT and thereby the 
transdifferentiation of more differentiated tumor cells in CSCs which can initiate tumor 
growth (Vermeulen et al., 2010). Taken together, differentiated cells (non-CSCs) can 
transdifferentiate to create CSCs by a dedifferentiation process caused by intrinsic (e.g. 
mutation) or extrinsic features (e.g. environmental stimuli) throughout tumorigenesis. This 
is known as the plastic CSC model (Fig.8) (Marjanovic et al., 2013).  
 
 
 
 
 
 
 
Interestingly, the features of stemness which include proliferation are regulated by β-
catenin target genes (Du et al., 2008; He et al., 1998; Shtutman et al., 1999). These genes 
are activated early and can be expressed throughout all progression steps. Additional 
mutations like KRAS (Horst et al., 2012) or environmental signals can further boost the 
Wnt signaling pathway (Brabletz et al., 2009; Vermeulen et al., 2010). Histologically, 
tumor cells with nuclear localization of β-catenin are found focally all over the tumor in 
small nests and predominantly as a small rim at the invasive front of CRCs (Brabletz et al., 
2001; Brabletz et al., 2005) (Fig. 9). Only the cells at the invasive front seem to have a 
Self-renewal CSC 
non-CSC plastic non-CSC 
Bidirectional 
conversions 
Fig. 8. The plastic CSC model.  
This model describes that not only differentiated 
cells (non-CSCs) arise from the CSCs but rather 
bidirectional conversions exist. Thereby, also non-
CSCs can shift to CSCs throughout tumorigenesis. 
Adapted from (Marjanovic et al., 2013). 
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functional role as their amounts correlate very well with poor prognosis (Ueno et al., 
2002). Thus, two types of CSCs were defined, namely the stationary CSCs (SCS cells) 
found in the central areas of CRCs and the migratory CSCs (MCS cells) found frequently 
at the invasive front of CRCs (Fig. 9). Due to their exposed location these cells are 
attributed to be malignant as they can obviously migrate and invade the normal stroma 
containing blood and lymph vessels. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Concept of stationary and migrating cancer stem cells (SCS and MCS cells).  
Cells with nuclear localization of β-catenin are characterized by stemness and proliferation and are named 
CSCs. At the invasion front, CSCs show a boost of Wnt signaling pathway acticity. Here, CSCs are 
characterized by growth arrest (CDKN2A), EMT (ZEB1) and prerequisites for metastasis (migration and 
invasion). These CSCs are named MCS cells and require properties which enable them to the process of 
metastasis (Brabletz et al., 2009). 
 
 
1.2.3.6 Epithelial mesenchymal transition (EMT) 
Interestingly, induction of EMT in tumor cells is related to the induction of properties of 
cancer stemness (Mani et al., 2008). Originally, EMT and the reverse process, 
mesenchymal-epithelial transition (MET), are known to be important processes in the 
embryogenesis during gastrulation but also wound healing (Thiery, 2003; Thiery et al., 
2009). Different transcription factors such as snail family zinc finger 1 (SNAI1; SNAIL), 
snail family zinc finger 2 (SNAI2; SLUG), twist family bHLH transcription factor 1 
(TWIST1; TWIST), and ZEB1/2 (Hanahan and Weinberg, 2011) are known to be 
responsible for the induction of the EMT process and these are considered to be master 
switches of EMT. Thus, simply by the presence of high amounts of these transcription 
factors, tumor cells undergo EMT and acquire malignant properties such as invasiveness, 
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motility, resistance to apoptosis and expression of genes encoding for matrix-degrading 
enzymes (Cheng et al., 2007; Hanahan and Weinberg, 2011; Huber et al., 2005). Again β-
catenin is also involved in the regulation of EMT either by translocation of β-catenin from 
adherens junctions to the nucleus or by induction of the expression of factors like SLUG 
(Conacci-Sorrell et al., 2003) and ZEB1 (Spaderna et al., 2008). This leads passively (loss 
of β-catenin from the zonula adherens) or actively (influencing the expression of EMT 
master switches) to EMT. SLUG and ZEB1 in turn repress the expression of E-cadherin 
(CDH1) and consequently, E-cadherin becomes absent thus, resulting in the loss of 
adherens junctions (Brabletz et al., 2005). As adherens junctions are an important 
component of the polarity mediating apical junctional complex, loss of adherens junctions 
disturbs cell polarity (Royer and Lu, 2011). Furthermore, the protein complexes par-3 
family cell polarity regulator (PARD3), crumbs (CRB) and scribbled planar cell polarity 
protein (SCRIB) which participate in the apicobasal polarity are repressed by EMT 
transcriptions factors such as SNAIL and ZEB1 (Thiery et al., 2009). These changes lead 
to the loss of cell polarity. Additionally, nuclear β-catenin induces the expression of the 
mesenchymal markers vimentin (VIM) (Gilles et al., 2003) and fibronectin (FN1) (Gradl et 
al., 1999). These changes taking place during EMT lead to a cell morphology change from 
a polygonal epithelial phenotype to a more spindly mesenchymal phenotype (Hanahan and 
Weinberg, 2011). Thus, the cells detach from each other and cell sheets dissasemble 
(Hanahan and Weinberg, 2011; Spaderna et al., 2008). As the expression of e.g. N-
cadherin (CDH2), normally expressed during organogenesis in mesenchymal cells and in 
migrating neurons, is moreover acquired during the process of EMT, the cells gain 
invasion and migration capacities (Hanahan and Weinberg, 2011) which are important for 
metastasis.  
 
1.2.3.7 Metastasis 
Tumor budding that means tumor cells at the invasion front (MCS cells) are correlated 
with metastases and poor survival (Brabletz et al., 2005; Christofori, 2006; Ueno et al., 
2002). For metastases formation, different gene programs are required. Besides the 
previously described EMT program which supports the tumor cells at the invasion front to 
disseminate from the primary tumor to metastatic sites and also to form micrometastases 
(Hanahan and Weinberg, 2011), stemness associated genes enable tumor cells to colonize 
foreign tissues and to form metastases (Brabletz et al., 2005). Metastases formation and 
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invasion can be grouped in different succeeding steps. The cancer cells at the invasion 
front migrate and invade due to EMT into the host stroma and intravasate finally into 
lymphatic and blood vessels. There, the cells circulate until they extravasate from the 
lumina of the vessels into organ parenchyma. In distant tissues CSCs can form 
micrometastases (Hanahan and Weinberg, 2011; Talmadge and Fidler, 2010). For the 
outgrowth of the metastases, the tumor cells regain differentiation. Whereas CSCs at the 
invasion front (MCS cells) are dedifferentiated due to EMT and show growth arrest due to 
expression of the β-catenin target gene CDKN2A (Jung et al., 2001; Wassermann et al., 
2009), cells require cellular differentiation and proliferation for the outgrowth of 
metastases. Thus, they undergo MET at metastatic sites which becomes apparent by the 
reexpression of CDH1 (Brabletz et al., 2005).  
 
1.2.3.8 Chemoresistance 
Metastases of CRCs are usually targeted by chemotherapy. Unfortunately, metastasis 
related deaths are caused due to the resistance of the tumor cells to chemotherapeutics 
(Marjanovic et al., 2013). Interestingly, CSCs are characterized by intrinsic 
chemoresistance (Brabletz et al., 2005). Therefore, whereas the majority of tumor cells is 
killed by chemotherapy, CSCs resist the chemotherapy and stay alive (Dean et al., 2005). 
β-catenin target genes are involved in chemoresistance. For example the increased 
expression of ATP binding cassette (ABC) transporters such as ABCB1 (Yamada et al., 
2000) leads to improved efflux of drugs (Dean et al., 2005; Frank et al., 2010) as ABC 
transporter can actively transport drugs and cytotoxic agents out of the cells to protect 
these (Dean et al., 2005). Furthermore, tumor cells that withstand chemotherapy show a 
higher expression of genes associated with stemness (Hanahan and Weinberg, 2011) such 
as CD44 (Wielenga et al., 1999) and EMT (Creighton et al., 2009; Singh and Settleman, 
2010) such as ZEB1 (Sanchez-Tillo et al., 2011). Since CSCs survive chemotherapy, this 
results in an accumulation of CSCs in colon tumors (Dylla et al., 2008). Due to its drug 
resistance, CSCs can enable a relapse of the tumor (Singh and Settleman, 2010).  
 
Taken together, CSCs are the kingpin in the process of colorectal carcinogenesis. Cancer 
stemness is equivalent to metastases formation, EMT and chemoresistance (Mani et al., 
2008; Singh and Settleman, 2010). In the colorectum, tumor cells with characteristics of 
CSCs are characterized by the nuclear localization of β-catenin and can therefore be 
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identified also histologically. Mostly, a direct connection between chemoresistance and 
metastasis and the question whether chemoresistance induces metastasis have not be 
clarified so far but it might be speculated that they are also related to each other as two 
other facets of cancer stemness (Fig. 10). 
 
 
 
 
 
 
 
 
 
 
 
1.2.4 Treatment of CRC 
1.2.4.1 Classical chemotherapy 
Classical chemotherapy affects rapidly dividing cells what tumor cells are believed to be. It 
can be used for the treatment of cancer before (neo-adjuvant setting) and/or after surgery 
(adjuvant therapy), after recurrence or after metastasis (adjuvant second and following 
lines of therapy). For the treatment of CRC, the antimetabolite drug 5-fluoruracil (5-FU) is 
widely used which is a fluoropyrimidine where the 5’-hydrogen is replaced by a fluorine. 
In living cells, 5-FU is converted into active metabolites which can disrupt DNA 
replication and DNA repair as well as inhibit thymidylate synthetase (Longley et al., 2003). 
However, as cancers often become resistant to therapies the reason for this might be the 
CSCs which are known to be resistant to classical chemotherapeutics (Marjanovic et al., 
2013). Thus, most anticancer drugs destroy only the bulk of the tumor cells whereas CSCs 
survive. Therefore, the tumor can start growth again out of the CSC compartment, increase 
its size and finally form metastases (Fig. 11). In the cases of resistance to classical 
chemotherapy few or no therapeutic alternatives exist (Fanali et al., 2014; Marjanovic et 
al., 2013). 
 
 
Fig. 10. Model of the CSC features.  
CSCs are characterized by the features 
cancer stemness, metastasis, EMT and 
chemoresistance. Most of these features 
are associated with each other and are all 
influenced by the other features (solid 
lines). Only the direct connection between 
chemoresistance and metastasis is not yet 
clarified (dotted line). 
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1.2.4.2 CSC targeted therapy 
An alternative and a promising therapeutic concept might become CSC targeted therapies 
that kill the driving force of tumors and thus, leading to their regression (Fig. 11) (Fanali et 
al., 2014; Frank et al., 2010). As CSCs are characterized by the features cancer stemness, 
EMT, metastasis and chemoresistance and most if not all of these features are connected 
with each other, these features are suitable as a target for the CSC targeted therapy. There 
are several different possible approaches for CSC targeted therapies: 1) One therapeutic 
approach is to reverse resistance mechanisms that are active in CSCs such as the blockade 
of multidrug resistance ABC transporters which results in decreased resistance (Frank et 
al., 2005). 2) Another approach to target CSCs is the differentiation of CSCs whereby the 
cells undergo a MET and loose, therefore, cancer stemness features and chemoresistance 
(Singh and Settleman, 2010). For example, the compound salinomycin (Gupta et al., 2009) 
and microRNAs (miRNAs) such as let-7 (Yu et al., 2007) led to differentiation of CSCs 
whereby the expression of CSC markers and the tumor growth decreased. Moreover, 
BMP4 activated differentiation and stimulated apoptosis in CSCs led in combination with 
chemotherapeutics to complete, long-term regression of tumors (Todaro et al., 2010). 3) A 
third approach for the targeting of CSCs is the interference of CSC sustaining molecules. 
The blockade of the SC marker CD44 inhibited tumor formation (Yang et al., 2008). CSC 
sustaining molecules are suitable as a therapeutic target since their expression is often 
restricted to SCs such as CSCs. Because various CSC sustaining molecules are known as 
SC factors, the investigation of these factors concerning their role in CRC and thus, 
therapeutic relevance might be a promising tool. And as stemness is associated with the 
Fig. 11. CSC-specific therapy as a 
new therapeutic approach.  
Most anticancer drugs kill only the 
bulk population but the resistant 
CSC pool survives and can 
repopulate the tumor. In contrast, 
therapies that target specificly 
CSCs can kill CSCs whereby the 
tumor regresses. Modified from 
(Fanali et al., 2014). 
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other CSC features metastasis, EMT and chemoresistance, the interference with stemness 
should also influence the other features. 
 
 
1.3 Olfactomedin-4 (OLFM4) and its role in cancer 
One molecule that is discussed as a CSC marker is olfactomedin-4 (OLFM4). OLFM4 was 
originally described as a SC marker in the human intestine. OLFM4 is expressed in CBC 
cells which are also characterized by the expression of the SC marker LGR5. Therefore, a 
comparable role of OLFM4 was discussed (van der Flier et al., 2009). Since CSCs can 
originate by oncogenic transformation from normal tissue SCs such as the CBC cells 
(Barker et al., 2009), the investigation of SC markers whether they are CSC sustaining and 
therefore, suitable for CSC targeted therapy is a promising approach.  
 
1.3.1 Characterization of OLFM4 
OLFM4 (also GW112, hGC-1 or OlfD) belongs to the olfactomedin (OLFM) family which 
is connected with various functions such as cell adhesion, cytoskeleton organization, cell 
proliferation, dorsal-ventral patterning and apoptosis. The OLFM4 gene is located on the 
chromosome 13q14.3, is 23 kb long and composed of five exons. The translated protein 
consists of 510 amino acids, has a signal peptide and a molecular mass of about 54 kDa. 
After translation, the protein undergoes post-translational modifications which come along 
with the loss of the signal peptide and with the N-linked glycosylation at six glycosylation 
motifs. At the C-terminus, the protein contains the olfactomedin domain that is involved in 
the interaction of OLFM4 with cadherins (Fig. 12) (Grover et al., 2010; Zhang et al., 
2002).  
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Fig. 12. Gene and protein structure of OLFM4.  
The gene is composed of five exons and is translated in a protein with 510 amino acids. This protein 
undergoes post-translational modifications such as glycosylations. At the C-terminus of the protein, the 
olfactomedin domain is located. Modified from (Grover et al., 2010). 
 
 
The intracellular localization of the OLFM4 protein is unclear since different studies 
reported different results. In one study, the protein was found to be localized in the 
mitochondria and in the nuclei (Zhang et al., 2004), in another study a localization of 
OLFM4 in the peri-nuclear cytoplasm and at the cell membrane was observed. It functions 
as an extracellular matrix glycoprotein (Grover et al., 2010; Zeng et al., 2005), interacts 
with lectins and cadherins and facilitates thereby cell adhesion (Liu et al., 2006). OLFM4 
expression is regulated by the transcription factor NF-κB that is involved in the regulation 
of immune and inflammatory signals (Kim et al., 2010). High amounts of OLFM4 protein 
were found in the prostate, the small intestine and the colon (Grover et al., 2010; Tomarev 
and Nakaya, 2009). In the normal intestinal mucosa, OLFM4 is preferentially expressed at 
the crypt base in the stem cell niche in CBC cells of the small intestine and colon whereby 
a comparable role of OLFM4 with LGR5 was discussed (van der Flier et al., 2009). 
However, another investigation proposed that OLFM4 is not associated with LGR5 
positive CBC cells and consequently, no analogous role of OLFM4 and LGR5 can be 
declared (Ziskin et al., 2013). A knockout of Olfm4 in mice did not show any detectable 
phenotype (Schuijers et al., 2014). In contrast, the knockout of Lgr5 was neonatally lethal 
(Morita et al., 2004) which is indicative of different roles of OLFM4 and LGR5. 
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1.3.2 OLFM4 in association with cancer 
1.3.2.1 The role and expression/protein levels of OLFM4 are dependent on the 
cancer type 
The mRNA expression and protein levels of OLFM4 in tumors depend on the tissue. A 
higher expression of OLFM4 compared to normal tissue was reported in several cancer 
tissues such as breast, lung, pancreatic and stomach cancer tissue (Koshida et al., 2007; 
Zhang et al., 2004). In contrast, OLFM4 expression was reduced or undetectable in 
prostate cancer and correlated with advanced tumor stages (Chen et al., 2011; Li et al., 
2013). This reduced expression together with another study in which OLFM4 protein 
levels were described as a prognostic biomarker for differentiation in gastric cancer (Liu et 
al., 2007) are unexpected results for a SC marker. Moreover, OLFM4 negative tumors 
were associated with a worse survival rate of patients than OLFM4 positive gastric tumors 
(Luo et al., 2011; Oue et al., 2009) which was unexpected for a possible marker of cancer 
stemness. Thus, in most of these studies, OLFM4 did not act like a CSC marker since the 
expression of CSC markers is usually connected with advanced tumor stages and poor 
survival. 
An inconsistent role of OLFM4 in cancer cell lines was also described. OLFM4 
acted as an anti-apoptotic protein in different cancer types such as cervix or gastric cancer 
(Kim et al., 2010; Liu et al., 2012; Zhang et al., 2004), however this was not observed in 
pancreatic cancer cells (Kobayashi et al., 2007). On the one hand, OLFM4 was described 
as a tumor promoter because OLFM4 was necessary for proliferation, anchorage-
independent growth and growth as xenografts in gastric cancer cell lines (Kobayashi et al., 
2007; Liu et al., 2012). On the other hand, OLFM4 was described as a tumor suppressor 
because it suppressed proliferation, tumor growth, invasiveness and metastases formation 
in prostate cancer and melanomas (Chen et al., 2011; Park et al., 2012). Thus, the role and 
function of OLFM4 is also unclear in different cancer cell lines. 
 
 
1.3.2.2 The role of OLFM4 in CRC 
In CRC, a higher expression of OLFM4 compared to normal tissue was reported (Koshida 
et al., 2007). In contrast, well-differentiated colorectal tumors exhibited an increased 
OLFM4 expression and OLFM4 protein levels, whereas poorly differentiated tumors and 
metastases showed a reduced OLFM4 expression/OLFM4 protein levels (Besson et al., 
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2011; Liu et al., 2008; Wentzensen et al., 2004). At the invasion front, both, reduction of 
OLFM4 (Liu et al., 2008) and no loss or reduction of OLFM4 (Seko et al., 2010) were 
observed. Moreover, OLFM4 protein amounts were described in CRC as nonmetastatic 
marker (Besson et al., 2011) and OLFM4 negative tumors had a worse survival rate than 
OLFM4 positive tumors (Seko et al., 2010) which is again not indicative for a possible 
marker of cancer stemness. Furthermore, it was reported that high amounts of OLFM4 
protein caused an alteration in the actin cytoskeleton and the cell morphology and a 
suppression of cell adhesion and migration (Liu et al., 2008). Hence, based on these 
studies, the role of OLFM4 in CRC is not yet completely understood. Further 
investigations have to show whether OLFM4 is a CSC marker (van der Flier et al., 2009) 
and thus, has a prognostic impact in CRC or whether OLFM4 is not a CSC marker (Ziskin 
et al., 2013). Moreover, its functional role has to be further examined to clarify whether 
OLFM4 is a driver or only a passenger in CRC. The investigation of OLFM4 as a CSC 
marker and its influence in CRC on CSC features would help to clarify its utility as a 
therapeutic target for CSC therapy.  
 
 
1.4 Non-coding RNAs in colorectal cancer 
Besides the previously described role of β-catenin in the transcription of mRNAs which 
plays a crucial role in CSC biology, a role of β-catenin in the transcription of non-coding 
RNAs (ncRNAs) is also conceivable. However, until now, the involvement of the 
transcription factor β-catenin in the expression of ncRNAs has only been minorly 
investigated. ncRNAs control gene expression (Mattick and Makunin, 2006) and comprise 
e.g. miRNAs, small nucleolar RNAs (snoRNAs), PIWI-interacting RNAs (piRNAs) and 
large intergenic non-coding RNAs (lincRNAs) (Esteller, 2011). 
 
1.4.1 The microRNAome  
Among these ncRNAs, the miRNAs are mostly investigated (Esteller, 2011). Mammalian 
miRNAs can modulate more than 60% of genes that are coding for proteins (Melo and 
Kalluri, 2012) and mediate mostly gene silencing by controlling the translation of mRNAs 
into proteins (Esteller, 2011; Vasudevan et al., 2007). Thereby, a large number of target 
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mRNAs can be downregulated by the same miRNA. Over 1000 miRNAs exist in the cells 
of higher plants and animals (Filipowicz et al., 2008) and are involved in most cellular 
processes  (Esteller, 2011). In cancer cells a global downregulation of miRNAs takes place 
(Lu et al., 2005). A transcriptional regulation leading to loss of the microRNAome 
(miRNAome) is possible. In this context, a transcriptional role of β-catenin in miRNA 
repression was reported in a study in which β-catenin repressed the tumor suppressor 
miRNA let-7 (Cai et al., 2013). Further miRNA targets of β-catenin are possible which 
repression might e.g. lead to an upregulation of oncogenes, stemness sustaining molecules 
or EMT transcription factors and thus, to tumor promotion. As miRNAs repress e.g. EMT 
and metastatic features (Korpal et al., 2008; Siemens et al., 2011), a transcriptional 
repression of the miRNAome by β-catenin would support CSC features. Thus, 
downregulation of the miRNAome might be an additional feature that characterizes CSCs.  
Besides a possible transcriptional repression of miRNAs, a downregulation of 
DROSHA (drosha, ribonuclease type III) or DICER1 (dicer 1, ribonuclease type III) or 
mutations in XPO5 (exportin 5) or TRBP (TAR RNA-binding protein), that are 
components of the miRNA biogenesis, were reported (Lujambio and Lowe, 2012). 
Because the miRNA biogenesis is essential for a functioning miRNAome, disruption of the 
miRNA biogenesis leads to a loss of the miRNAome which might again result in increased 
CSC features such as EMT and metastatic features (Korpal et al., 2008; Siemens et al., 
2011). Thus, investigations of the loss of the miRNAome might clarify whether the 
miRNAome might be a promising target for CSC targeted therapy. 
 
1.4.2 miRNA biogenesis 
The working miRNA biogenesis is an essential prerequisite for the maturation and thus, 
function of the miRNAome. During the canonical biogenesis, miRNAs pass through 
different steps (Fig. 13). In the beginning, primary miRNAs (pri-miRNAs) are transcribed 
by the RNA polymerase II from miRNA genes (Esquela-Kerscher and Slack, 2006). One 
pri-miRNA can comprise sequences for different miRNAs. Afterwards, the pri-miRNAs 
are folded into hairpin structures that consist of base-paired stems that do not match 
perfectly. Next, the RNAse III enzyme DROSHA processes together with its partner 
DiGeorge syndrome critical region gene 8 (DGCR8) the pri-miRNAs to about 70 
nucleotide hairpins, the pre-miRNAs (Filipowicz et al., 2008). Subsequently, exportin 5 
transports the pre-miRNAs from the nucleus to the cytoplasm where they are further 
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processed. DICER1 interacts with TRBP and cleaves off the loop of the hairpin of the pre-
miRNAs whereby 20-25 nucleotides long miRNA-miRNA*-duplexes are produced 
(Barca-Mayo and Lu, 2012; Esquela-Kerscher and Slack, 2006). Subsequently, the 
passenger strand (miRNA*) is degraded and the other strands are loaded onto the 
argonaute (AGO) proteins containing miRNA-associated multiprotein RNA-induced 
silencing complex (miRISC) and functions as mature miRNA (Dueck and Meister, 2010). 
The mature miRNA binds to complementary sites in the mRNA target. If the miRNAs can 
bind with imperfect complementarity, the protein translation of the target gene is repressed. 
The binding sites for this mechanism are commonly found in the 3´ untranslated regions 
(3´UTR). In the case of perfect complementarity, the cleavage of the mRNA is induced. 
These binding sites are commonly found in the open reading frame (ORF) of the targeted 
mRNA. The interaction between miRNA and mRNA target takes place by the pairing of 
the nucleotides 2–8 of the miRNAs, the ´seed´ region, with the mRNA target site (Esquela-
Kerscher and Slack, 2006). 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3 DICER1 
During miRNA biogenesis, DICER1 possesses different functions and thus, a central role. 
DICER1 cleaves during miRNA biogenesis precursor miRNA (pre-miRNA) hairpins into 
Fig. 13. The canonical biogenesis of 
miRNAs.  
Pri-miRNAs are transcribed from the 
miRNA gene by the RNA Polymerase II. 
Subsequently, the pri-miRNAs are 
processed by DROSHA together with 
DGCR8. The resultant pre-miRNAs are 
transported by XPO5 from the nucleus to 
the cytoplasm. There, the hairpin of the pre-
miRNAs is cleaved by DICER1 together 
with TRBP into a miRNA-miRNA* duplex 
without hairpin. The mature strand is 
incorporated into the miRISC, the 
passenger strand (miRNA*) is degraded. 
An imperfect complementary binding 
between miRNA and mRNA results in 
translational repression (binding in the 
3´UTR), a perfect complementary binding 
results in mRNA cleavage (binding in the 
ORF). Modified from (Barca-Mayo and Lu, 
2012)) 
3´ UTR ORF 
Translational repression mRNA cleavage 
DROSHA 
XPO5 
DICER1 
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mature miRNAs, is responsible for loading of small RNAs onto AGO proteins in the RNA-
induced silencing complex (RISC) and additionally, DICER1 is involved in the protein-
protein interactions between the RISC-loading complex and other complexes (Foulkes et 
al., 2014). Thus, DICER1 has an essential role in the biogenesis of miRNAs and is 
therefore a good target to investigate the influence of a disruption of the miRNA 
biogenesis and thus, the loss of the miRNAome in cancer. 
The DICER1 gene is located on chromosome 14q32.13 and consists of 27 exons 
(Fig. 14A). The multi-domain enzyme of 219 kDa assembles in a L-like structure. At the 
upper half of the L, the Platform and PAZ (piwi, argonaute, zwille) domains are located 
and form binding pockets for the 5´-phosphate and 3´-overhang parts of a dsRNA 
substrate, respectively. At the lower half of the L, both RNase III domains, RNase IIIa and 
RNase IIIb, are located which build a dimer and form the catalytic core. Each strand of the 
dsRNA substrate is cleaved by one RNase III domain. The helicase domain is placed at the 
bottom of the L, folds a clamp-like structure and is probably designated to reorganize and 
wind around the dsRNA (Fig. 14B) (Foulkes et al., 2014). 
 
 
 
 
 
 
 
 
 
Fig. 14. Structure and domains of DICER1.  
(A) Schema of the unfolded protein structure. DICER1 is constituted of 27 exons and is encoding several 
domains. (B) Domain organization of the folded, L-shaped DICER1 protein. Colors of the domains 
correspond with those of the linear form in (A). Platform and PAZ domains build binding pockets for the 5´-
phosphate and 3´-overhang parts of a dsRNA substrate, respectively. RNase IIIa and IIIb domains build a 
dimer and the catalytic core for the cleavage of the dsRNA substrate. The clamp-like helicase domain 
reorganizes and winds around the dsRNA. Modified from (Foulkes et al., 2014). 
 
 
For the investigation of the consequences of a DICER1 disruption and thus, miRNAome 
loss several models exist. One example is a cell culture model in which the helicase 
domain (exon 5) of DICER1 is disrupted and thus, the DICER1 function is impaired. 
Hence, these cells show an impaired miRNA biogenesis. Furthermore, a conditional, Cre 
A B 
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inducible knockout mouse model was generated as the complete loss of DICER1 in the 
embryogenesis resulted in early lethality at embryonic day 7.5 (Bernstein et al., 2003). For 
that reason, loxP (flox, fl) sites are inserted around the second RNaseIII domain of Dicer1. 
The floxed Dicer1 alleles can be removed in any tissue in which the Cre recombinase 
(Cre) is expressed. By the recombination, mediated by the Cre recombinase, a gene region 
encoding 90 aa is removed and thus, the enzymatic activity of DICER1 is destroyed. 
Hence, the miRNA biogenesis is disturbed and almost no mature miRNA levels are still 
detectable (Harfe et al., 2005). Thus, these models are suitable tools for the investigation of 
the role of DICER1 and thus, the miRNAome in the biology of colorectal tumorigenesis.  
 
1.4.4 DICER1 and miRNAs in cancer 
The function of DICER1 in cancer development and progression depends on the tissue 
type. In human lung, ovarian and colorectal cancer, a deletion or decreased expression of 
DICER1 took place and was associated with poorly differentiated tumors, advanced tumor 
stages and reduced survival (Faggad et al., 2010; Faggad et al., 2012; Karube et al., 2005; 
Kumar et al., 2009; Merritt et al., 2008). Hence, DICER1 and thus, the miRNAome had a 
tumor suppressive influence in these contexts. This is in agreement with cell culture 
studies. For example in breast cancer, sarcoma, lung cancer and CRC cell lines, 
knockdown of DICER1 led to inhibition of cell growth, increased apoptosis (Bu et al., 
2009; Ravi et al., 2012) and enhanced sensitivity to the chemotherapeutic cisplatin (Bu et 
al., 2009). Additionally, the downregulation of DICER1 in lung cancer cell lines was 
associated with EMT (Hinkal et al., 2011; Iliou et al., 2014; Martello et al., 2010), cell 
migration and invasion (Martello et al., 2010) and the downregulation of specific miRNAs 
in colorectal CSCs led to increased stemness (Bitarte et al., 2011). These results suggest 
that DICER1 and thus, the miRNAome act as tumor suppressors. 
In support with this, most of the studies of Dicer1 knockout in mouse models 
showed similar results. In these studies, loss of DICER1 and thus, loss of the miRNAome 
led to cellular transformation, a higher tumor formation, more invasiveness of the tumors 
and a reduced survival (Kumar et al., 2007; Kumar et al., 2009). Moreover, deletion of 
Dicer1 accelerated in vivo intestinal inflammation-associated tumorigenesis in a CRC 
mouse model (Yoshikawa et al., 2013). These tumor promoting features have been 
reported both after hetero- and homozygous deletion of Dicer1 (Kumar et al., 2007), but 
also after only heterozygous deletion (Kumar et al., 2009; Lambertz et al., 2010). In 
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contrast, in a B-cell lymphoma mouse model, a loss of DICER1 inhibited lymphoma 
development (Arrate et al., 2010). In most of the mouse models, however, DICER1 and 
thus, the miRNAome was recognized as an important tumor suppressor.  
Human CRCs are mostly driven by the Wnt signaling pathway (Pino and Chung, 
2010). However, loss of DICER1 and thus, the miRNAome has not yet been investigated 
in this context. A mouse model with an activated Wnt signaling pathway combined with a 
disruption of Dicer1 and thus, loss of the miRNAome would reflect the human situation 
best. To follow this idea, two independend recombinational steps would have to be 
integrated. Therefore, a good approach is to activate the Wnt signaling pathway by the 
knockout of the tumor suppressor Apc and additionally, to delete the whole miRNAome of 
the cell by the knockout of Dicer1. This might especially be a good approach as it was 
shown that changes in the miRNAome as a whole are transferable to the biology of the 
tumor entity as mentioned before. Thus, this approach might help to clarify the question 
whether the miRNAome might be a target for CSC therapy. 
 
 
1.5 Aims of the study 
CSCs are the driver of intestinal cancer and are responsible for metastases formation and 
chemoresistance. Furthermore, these cells are characterized by the features cancer 
stemness and EMT. Because CSCs can escape classical chemotherapy, targeted therapy for 
CSCs could be an alternative to chemotherapy. For the specific targeting of CSCs, the four 
aforementioned CSC features are suitable for treatment. As most of these features are 
connected with each other, the interference of one feature might influence also most of the 
other features.  
 
Due to the importance of functional SC markers (CSC sustaining molecules) as potential 
additional targets for therapeutic intervention I investigated in this study 
1) whether OLFM4 is, as discussed, a SC marker.  
2) Subsequently, I analyzed the expression of OLFM4 in cells with CSC features and 
in CRC cell lines.  
3) Additionally, I examined the effects of high amounts of OLFM4 protein on CSC 
features such as proliferation, stemness, EMT and metastasis. For that purpose, I 
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investigated the influence of high amounts of OLFM4 protein concerning SC, EMT 
and differentiation marker expression/protein levels and on the functional level that 
means proliferation, activity of the Wnt signaling pathway, ALDH1 activity, tumor 
initiation and metastasis features. 
 
 
In a second experimental approach I focused on the role of the miRNAome in colorectal 
carcinogenesis and the influence on CSC features. 
1) Therefore, I established a mouse model which allowed the combined knockout of 
Apc and thus, Wnt signaling pathway activation in CBC cells together with 
knockout of Dicer1 and thus, loss of the miRNAome. This mouse model should 
help to understand the role of the influence of the miRNAome in Wnt driven 
adenomas in a complex in vivo situation including microenvironmental factors. 
2) To shed more light on the underlying mechanism I employed CRC cell lines with a 
homozygous disruption of DICER1 to study CSC, EMT and metastases marker 
expression/protein levels and also on a functional level proliferation and CSC 
features such as stemness, chemoresistance and metastastic properties.  
3) Furhermore, I translated these results into human CRC disease. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Chemical Company 
5-fluorouracil (5-FU) Sigma-Aldrich; medac GmbH 
acrylamide rotiphorese gel30 Carl Roth GmbH 
agar Carl Roth GmbH 
agarose Biozym 
ammoniumpersulfate (APS) Sigma-Aldrich 
dimethylformamide Carl Roth GmbH 
ampicillin Sigma-Aldrich 
dimethyl sulfoxide (DMSO) Sigma-Aldrich 
eosin Y Sigma-Aldrich 
ethylenediaminetetraacetic acid solution (EDTA) Sigma-Aldrich 
ethanol Carl Roth GmbH 
ethidium bromide Sigma-Aldrich 
formaldehyde Carl Roth GmbH 
glutaraldehyde 50 % Carl Roth GmbH 
glycine Carl Roth GmbH 
hydrochloric acid solution (HCl) 1N Sigma-Aldrich 
isopropanol Carl Roth GmbH 
kanamycin Sigma-Aldrich 
lysogeny broth (LB) medium Carl Roth GmbH 
magnesium chloride (MgCl2) Carl Roth GmbH 
methanol Carl Roth GmbH 
methyl cellulose Sigma-Aldrich 
non-fat dry milk Bio-Rad 
NP40 Sigma-Aldrich 
paraformaldehyde Sigma-Aldrich 
polybrene Sigma-Aldrich 
potassium chloride (KCl) Carl Roth GmbH 
potassium dihydrogen phosphate (KH2PO4) Sigma-Aldrich 
potassium hexacyanoferrate(III) (K3Fe(CN)6) Sigma-Aldrich 
potassium hexacyanoferrate(III) trihydrate 
      (K3Fe(CN)6 x 3H2O) 
Sigma-Aldrich 
hydrochloric acid Merck 
sodium chloride (NaCl) Carl Roth GmbH 
sodium deoxycholate Sigma-Aldrich 
sodium dodecyl sulfate (SDS) Sigma-Aldrich 
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sodium hydroxide (NaOH)  Merck 
sodium phosphate dibasic heptahydrate  
      (Na2HPO4-7H2O) 
Sigma-Aldrich 
tamoxifen Sigma-Aldrich 
TBE (tris/borate/EDTA) Thermo Scientific 
tetramethylethylendiamin (TEMED) Carl Roth GmbH 
tris base Carl Roth GmbH 
tris hydrochloride (Tris-HCl) Carl Roth GmbH 
Triton-X100 Sigma-Aldrich 
trypan blue Sigma-Aldrich 
Tween-20 AppliChem GmbH 
sunflower seed oil from Helianthus annuus Sigma-Aldrich 
X-Gal (5-bromo-4-chloro-3-indoxyl-β-D-galacto- 
      pyranoside) 
Carl Roth GmbH 
xylene Carl Roth GmbH 
 
2.1.2 Reagents and Kits 
Reagent or Kit Company 
AEC (3-Amino-9-ethylcarbazole) solution Invitrogen 
ALDEFLUOR™ Kit Stemcell Technologies 
CellTiter 96® Non-Radioactive Cell Proliferation 
      Assay 
Promega 
Complete® protease inhibitor Roche 
DAB+ (3,3'-diaminobenzidine) Chromogen Dako 
DCTM Protein Assay Bio-Rad 
DCS Crystal MausBlock DCS 
dNTP Mix, 10 mM each Thermo Scientific 
dual luciferase reporter assay Promega 
DyeEx 2.0 Spin Kit Qiagen 
Epitope Retrieval Solution (ERS6)  Novocastra 
ExiLENT SYBR Green Master Mix Exiqon 
FastDigest BamHI Thermo Scientific 
FastDigest NotI Thermo Scientific 
FirePol DNA polymerase Solis BioDyne 
Fugene 6 Promega 
Gateway LR Clonase Enzyme Mix  Life Technologies 
Hematoxyline Gill´s Formula Vector 
HiDi (highly deionized) formamide Life Technologies 
Hot Start Taq DNA polymerase Fermentas 
Immobilon™ Western Chemiluminescent HRP  
      (Horseradish peroxidase) substrate  
      (ECL (Enhanced chemi-luminescence)) 
Millipore 
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ImmPRESS Reagent Kit anti-rabbit Ig  Vector 
ImmPRESS Reagent Kit anti-mouse Ig  Vector 
Kaiser's glycerol gelatine Merck 
KOD DNA polymerase Novagen 
Lipofectamine RNAi Max Invitrogen 
MinElute PCR Purification Kit Qiagen 
mitomycin C Sigma-Aldrich 
miRNeasy Mini Kit Qiagen 
ProLong Gold antifade reagent with DAPI  
      (4’,6’-diamidino-2-phenylindole) 
Life Technologies 
propidium iodide (PI) solution Sigma-Aldrich 
ProTaqs IV Antigen Enhancer Quartett 
Proteinase Type XXIV Sigma-Aldrich 
protein block Dako 
PureYieldTM Plasmid Midiprep System Promega 
QIAamp® DNA FFPE Tissue Kit  Qiagen 
QIAprep Spin Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
RevertAid Reverse Transcriptase Thermo Scientific 
RiboLock RNase Inhibitor Thermo Scientific 
RNAse A Sigma-Aldrich 
RNeasy Mini Kit Qiagen 
rotiload loading buffer Carl Roth GmbH 
shrimps alkaline phosophatase (SAP) Thermo Scientific 
streptavidin HRP Novocastra 
Target Retrieval Solution  Dako 
Universal cDNA Synthesis Kit II Exiqon 
Universal Probe Library  Roche 
VectaMount Mounting Medium Vector 
XT ultraView DAB Kit Ventana Medical Systems 
 
 
2.1.3 Consumables 
Consumables Company 
cell culture flasks, plates, dishes Corning Incorporated 
cover slips Carl Roth GmbH 
filter Sartorius AG 
ibidi chamber ibidi 
needles B. Braun Melsungen AG 
pipette tips  Biozym Scientific GmbH 
plates for luciferase reporter assay Thermo Scientific 
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PVDF (polyvinylidene difluoride)-membrane 0.2 µm Bio-Rad 
scalpel Bayha GmbH 
superfrost microscope slides Thermo Scientific 
syringes B. Braun Melsungen AG 
 
 
 
2.1.4 Devices 
Device Company 
ABI 3130 Life Technologies 
Axiovert 200M microscope Zeiss 
balance Sartorius 
BD Accuri C6 flow cytometer Becton & Dickinson 
centrifuges Eppendorf, Thermo Scientific 
CF440 Imager Kodak 
DMD108 Leica 
FACS Aria® Cell Sorter Becton & Dickinson 
incubator Thermo Scientific 
laminar flow hood Thermo Scientific 
LightCycler® 480 Roche 
microscope cell culture Zeiss 
Mini Trans-Blot® Cell system Bio-Rad 
Nanodrop Thermo Scientific 
PCR devices  Eppendorf 
pipettes Eppendorf 
Stemi SV6 Zeiss 
Tissue Tek TEC Sakura 
Tissue Tek Prisma Sakura 
Varioskan Thermo Scientific 
Ventana Benchmark XT autostainer Ventana Medical Systems, Roche 
 
 
2.1.5 Cell culture 
Medium Company 
DMEM (Dulbecco's Modified Eagle's medium) Biochrom AG 
FCS (fetal calf serum) Biochrom AG 
FGFb (fibroblast growth factor basic) Life Technologies 
penicillin/streptomycin Biochrom AG 
PBS (phosphate buffered saline) Biochrom AG 
RPMI (Roswell Park Memorial Institute medium) Biochrom AG 
StemProR hESC SFM medium Life Technologies 
trypsin Biochrom AG 
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2.1.6 DNA and protein size standards 
Size standard Company 
GeneRuler 100 bp DNA Ladder Thermo Scientific 
GeneRuler 1 kb DNA Ladder Thermo Scientific 
GeneRuler Low Range DNA Ladder Thermo Scientific 
PageRuler Plus Prestained Protein Ladder Thermo Scientific 
 
 
2.1.7 Oligonucleotides 
2.1.7.1 Cloning primers 
Name Sequence 
BamHI-Kozak-CAT-FW 5´ CATGGATCCGCCGCCACCATGGAGAAAAAAATCAC 
      TGG 3´ 
CAT NotI- REV 5´ GTAGCGGCCGCAGCGCCCCGCCCTGCCACTCATC 3´ 
BamHI-Kozak-OLFM4- 
      FW 
5´ CATGGATCCGCCGCCACCATGAGGCCCGGCCTCTCA 
      TTTC 3´ 
OLFM4-NotI-REV 5´ TAGCGGCCGCAGCTGGGGCTTCTGCAAGACAG 3´ 
 
2.1.7.2 Sequencing primers 
Name Sequence 
OLFM4 Seq 1 FW 5´ CAGCTCCAGCCGCAGCTTAG 3´ 
OLFM4 Seq 2 REV 5´ GTGGTGTCTGGCAGGGAAAC 3´ 
OLFM4 Seq 3 FW 5´ GGTAGAAGTGAAGGAGATGG 3´ 
OLFM4 Seq 4 FW 5´ GTTCAGCTCAACTGGAGAGG 3´ 
OLFM4 Seq 5 FW 5´ CTTTGCTGTGGATGAGAATGG 3´ 
OLFM4 Seq 6 FW 5´ CTCATTTCTCCTAGCCCTTC 3´ 
 
2.1.7.3 qPCR primers 
2.1.7.3.1 qPCR primers for miRNA  
hsa-miR-21-5p LNA™ PCR primer set (Exiqon) 
hsa-miR-200a-3p LNA™ PCR primer set (Exiqon) 
SNORD48 (hsa) (Exiqon) 
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2.1.7.3.2 qPCR primers for mRNA
Name Sequence UPL Final conc. 
ALDH1 FW  5´ CCAAAGACATTGATAAAGCCATAA 3´ #82 300 nM 
ALDH1 REV 5´ CACGCCATAGCAATTCACC 3´ #82 50 nM 
ACTB FW 5´ CCAACCGCGAGAAGATGA 3´ #64 900 nM 
ACTB REV 5´ CCAGAGGCGTACAGGGATAG 3´ #64 300 nM 
AXIN2 FW 5´ CCACACCCTTCTCCAATCC 3´ #36 900 nM 
AXIN2 REV 5´ TGCCAGTTTCTTTGGCTCTT 3´ #36 900 nM 
CD44 FW 5´ GGTCCCATACCACTCATGGA 3´ #39 300 nM 
CD44 REV 5´ TCCTTATAGGACCAGAGGTTGTG 3´ #39 900 nM 
CDH1 FW  5´ CCCGGGACAACGTTTATTAC  3´ #35 300 nM 
CDH1 REV 5´ GCTGGCTCAAGTCAAAGTCC 3´ #35 600 nM 
CTNNB1 FW 5´ AGCTGACCAGCTCTCTCTTCA 3´ #21 900 nM 
CTNNB1 REV 5´ CCAATATCAAGTCCAAGATCAGC 3´ #21 900 nM 
DICER1 FW 5´ TGTTCCAGGAAGACCAGGTT 3´ #8 900 nM 
DICER1 REV 5´ ACTATCCCTCAAACACTCTGGAA 3´ #8 300 nM 
HPRT1 FW 5´ TGACCTTGATTTATTTTGCATACC 3´ #73 900 nM 
HPRT1 REV 5´ CGAGCAAGACGTTCAGTCCT 3´ #73 900 nM 
KRT20 FW  5´ TGTCCTGCAAATTGATAATGCT 3´  #66 300 nM 
KRT20 REV 5´ AGACGTATTCCTCTCTCAGTCTCATA 3´ #66 300 nM 
LGR5 FW 5´ AATCCCCTGCCCAGTCTC 3´ #25 300 nM 
LGR5 REV 5´ CCCTTGGGAATGTATGTCAGA 3´ #25 300 nM 
MUC2 FW 5´ CATCTGTTCCATTACGACACG 3´ #77 300 nM 
MUC2 REV 5´ GGTGGTAGTGGTGAAGGAGGT 3´ #77 300 nM 
OLFM4 FW 5´ ATCAAAACACCCCTGTCGTC  3´ #24 900 nM 
OLFM4 REV 5´ GCTGATGTTCACCACACCAC 3´ #24 900 nM 
PROM1 FW  5´ TCCACAGAAATTTACCTACATTGG 3 #83 300 nM 
PROM1 REV 5´ CAGCAGAGAGCAGATGACCA 3´ #83 300 nM 
SNAI1 FW 5´ GCTGCAGGACTCTAATCCAGA 3´ #11 300 nM 
SNAI1 REV 5´ ATCTCCGGAGGTGGGATG 3´  #11 300 nM 
SNAI2 FW 5´ TGGTTGCTTCAAGGACACAT 3´ #7 900 nM 
SNAI2 REV 5´ GTTGCAGTGAGGGCAAGAA 3´ #7 900 nM 
VIM FW 5´ TACAGGAAGCTGCTGGAAGG 3´ #13 900 nM 
VIM REV 5´ ACCAGAGGGAGTGAATCCAG 3´  #13 600 nM 
ZEB1 FW 5´ GGGAGGAGCAGTGAAAGAGA 3´ #3 300 nM 
ZEB1 REV 5´ TTTCTTGCCCTTCCTTTCTG 3´ #3 300 nM 
 
2.1.7.4 Genotyping primers 
Name Sequence System 
Apc FW 5´ GTTCTGTATCATGGAAAGATAGGTGGTC 3´ mouse 
Apc REV 5´ CACTCAAAACGCTTTTGAGGGTTGATTC 3´ mouse 
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Dicer1 FW 5´ CCTGACAGTGACGGTCCAAAG 3´  mouse 
Dicer1 REV  5´ CATGACTCTTCAACTCAAACT 3´ mouse 
DICER1 ex5 FW    5´ TCCCATGCTTTCCTGATTTC 3´ cell line 
DICER1 ex5 REV 5´ CTGCAGCCAAACTCCCAATA 3´ cell line 
Lgr5-CreERT2 FW 5´ CTGCTCTCTGCTCCCAGTCT 3´ mouse 
Lgr5-CreERT2 WT REV 5´ ATACCCCATCCCTTTTGAGC 3´ mouse 
Lgr5-CreERT2 MUT REV 5´ GAACTTCAGGGTCAGCTTGC 3´ mouse 
ROSA26 LacZ FW 5´ AAAGTCGCTCTGAGTTGTTAT 3´ mouse 
ROSA26 LacZ REV 1 5´ GCGAAGAGTTTGTCCTCAACC 3´ mouse 
ROSA26 LacZ REV 2 5´ GGAGCGGGAGAAATGGATATG 3´ mouse 
 
2.1.7.5 Mouse recombination primers 
Name Sequence 
Apc FW1 5´ CCTGTTCTGCAGTATGTTATCATTC 3´ 
Apc FW2 5´ CTATCAGGACATAGCGTTGG 3´ 
Apc REV 5´ AAGACACCAAGTCCAAAGCACAC 3´ 
Dicer1 WT FW 5´ CTCATTCTCTCAGCTCAGTGG 3´ 
Dicer1 WT REV 5´ GTCAGAATGAAAACGCGTC 3´ 
Dicer1 Rec FW 5´ CCTGGACGCGATAACTTCG 3´ 
Dicer1 Rec REV  5´ CCTCAGCACCGAGTTCACAG 3´ 
 
2.1.7.6 siRNA Sequences 
Name Sequence 
si Ctrl. AllStars Negative Control siRNA (Qiagen) 
si CTNNB1 1 5´ CAGGAUGAUCCUAGCUAUAUCGU 3´ (Hs_CTNNB1_9, 
Qiagen) 
si CTNNB1 2 5´ CUCGGGAUGUUCACAACCGAA 3´  (Hs_CTNNB1_5, 
Qiagen) 
si Ctrl. 2 (si GFP) 5´AAGCUACCUGUUCCAUGGCCA 3´    
si CTNNB1 3 5´AGCUGAUAUUGAUGGACAG 3´ 
si CTNNB1 4 5´AGUUGUGGUUAAGCUCUU 3´ 
 
2.1.8 Antibodies 
2.1.8.1 Primary antibodies 
Name Source Clone Dilution Company Use 
β-actin mouse mAb AC-15 1:2000 Sigma-Aldrich WB 
β-catenin mouse mAb 14 1:300 BD Biosciences IHC 
   1:10000  WB 
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β-catenin rabbit mAb E247 1:10000 Epitomics IF 
CD26-PE mouse mAb FR10-11G9 1:11 Miltenyi Biotec FACS 
CD133/1-PE   mouse mAb AC133 1:11 Miltenyi Biotec FACS 
cl. caspase 3   rabbit pAb  1:100 Cell Signaling IHC 
DICER1 rabbit pAb  1:80 Novus Biologicals IHC 
DICER1 rabbit pAb  1:1000 Sigma-Aldrich WB 
   1:75  IHC 
E-cadherin mouse mAb 4A2C7 1:1000 Invitrogen WB 
KI-67 mouse mAb MIB-5 1:150 Dako IHC 
lysozyme rabbit pAb  1:14000 Dako IHC 
V5 mouse mAb  1:3000 Novex WB 
vimentin mouse mAb V5 1:1000 Dako WB 
 
2.1.8.2 Secondary antibodies 
Name Source Dilution Company Use 
Alexa Fluor® 488-  
   conjugate IgG (H+L) 
rabbit pAb 1:500 Life-Technologies IF 
Biotinylated rabbit anti-rat, 
   mouse adsorbed  
rabbit pAb 1:100 Vector IHC 
Mouse anti-rabbit IgG 
   H+L), HRP conjugate 
mouse pAb 1:1000 Pierce WB 
Rabbit anti-mouse IgG 
   (H+L), HRP conjugate 
rabbit pAb 1:10000 - 1:30000 Thermo Scientific WB 
 
2.1.9 Plasmids 
Plasmid Source 
8xGTIIC-luciferase Addgene (Plasmid 34615) 
pcDNA3-CAT Invitrogen (Life Technologies) 
pcl-neo-β-catenin-∆45 B. Vogelstein 
pCMV-Renilla Promega 
pEGFP-dnTCF-4  A. Jung 
pEF-ENTR A Addgene (Plasmid 17427) 
pGL3-basic Promega 
pGL3-DICER1-Prom Addgene (Plasmid 25851) 
pLenti X1 Puro DEST Addgene (Plasmid 17297) 
Super8xFOPFlash R. T. Moon 
Super8xTOPFlash R. T. Moon 
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2.1.10 Bacteria 
Bacteria Company 
Library Efficiency DH5α Competent Cells Thermo Fisher Scientific 
One Shot Stbl3TM Chemically Competent E.coli Thermo Fisher Scientific 
Subcloning Efficiency DH5α Competent Cells Thermo Fisher Scientific 
 
2.1.11 Cell lines 
Cell line Description/ Source 
293T human embryonic kidney cell line / DSMZ 
Caco2 human colorectal adenocarcinoma cell line / DSMZ 
coCSC-AS3 primary colorectal tumor cell line / A. Schäffauer 
coCSC-AS4 primary colorectal tumor cell line / A. Schäffauer 
Colo320 human colorectal adenocarcinoma cell line / DSMZ 
DLD1 human colorectal adenocarcinoma cell line / DSMZ 
HCT15 human colorectal adenocarcinoma cell line / DSMZ 
HCT116 human colorectal carcinoma cell line / DSMZ 
HCT116 +/+, ex5 human colorectal carcinoma cell line; w/o / with disruption 
of the helicase domain (ex5) of DICER1 / B. Vogelstein 
(Cummins et al., 2006) 
HT29 human colorectal adenocarcinoma cell line / DSMZ 
LOVO human colorectal adenocarcinoma cell line / DSMZ 
LS174T human colorectal adenocarcinoma cell line / DSMZ 
RKO human colon carcinoma cell line / ATCC 
RKO +/+, ex5 human colon carcinoma cell line; w/o / with disruption of the 
helicase domain (ex5) of DICER1 / B. Vogelstein (Cummins 
et al., 2006) 
SW403 human colorectal adenocarcinoma cell line / DSMZ 
SW480 human colorectal adenocarcinoma cell line / ATCC 
SW620 human colorectal adenocarcinoma cell line / ATCC 
SW1222 human colon carcinoma cell line / ATCC 
T84 human colorectal carcinoma cell line / ATCC 
 
2.1.12 Mouse strains 
Mouse strain Description/ Source 
Lgr5-EGFP-IRES-CreERT2 genetically modified C57BL/6 mouse line; contains a Cre 
recombinase under the Lgr5 promoter which can only enter 
the nucleus after tamoxifen induction; in the following text 
also termed as Lgr5-CreERT2/ N. Barker, stock kindly 
supplied by H. Hermeking (Barker et al., 2007) 
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Rosa26-LSL-LacZ genetically modified C57BL/6 mouse line; contains a lacZ 
gene (encodes β-galactosidase) that is expressed under the 
Rosa26-promoter; a STOP sequence, flanked by loxP sites, 
is located in front of the lacZ gene which were removed by 
Cre recombinase; in the following text also referred to as 
Rosa26/ M. Schneider (Barker et al., 2007) 
Apcfl genetically modified C57BL/6 mouse line; exon 14 of the 
Apc gene is flanked by loxP sites and can be removed by 
Cre recombinase/ H. Clevers (Shibata et al., 1997) 
Dicer1fl genetically modified C57BL/6 mouse line; RNaseIII2 
domain of the Dicer1 gene is flanked by loxP sites and can 
be removed by Cre recombinase/ B. Harfe (Harfe et al., 
2005) 
 
Crossed mouse lines used in the experiments: 
 
Lgr5-
CreERT2 
Rosa26-
LacZ Apc Dicer1 abbreviation investigation 
group 
size 
+ fl/fl fl/fl +/+ Lgr5(+)-Apc tumor formation 6 
- fl/fl fl/fl +/+ Lgr5(-)-Apc control 3 
+ fl/fl fl/fl fl/+ Lgr5(+)-Apc-Dicer1het tumor formation 6 
- fl/fl fl/fl fl/+ Lgr5(-)-Apc-Dicer1het control 3 
+ fl/fl fl/fl fl/fl Lgr5(+)-Apc-Dicer1hom tumor formation 6 
- fl/fl fl/fl fl/fl Lgr5(-)-Apc-Dicer1hom control 3 
+ fl/fl +/+ fl/+ Lgr5(+)-Dicer1het tumor formation 6 
- fl/fl +/+ fl/+ Lgr5(-)-Dicer1het control 3 
+ fl/fl +/+ fl/fl Lgr5(+)-Dicer1hom tumor formation 6 
- fl/fl +/+ fl/fl Lgr5(-)-Dicer1het control 3 
 
Table 1. Required mouse lines for the experiment.  
The different mouse strains are described concerning genotype, abbreviation, reason for the respective mouse 
strain in the investigation and group size. + (Lgr5-CreERT2): positive for Lgr5-CreERT2, - (Lgr5-CreERT2): 
negative for Lgr5-CreERT2; fl: floxed; + (Apc, Dicer1): wildtype 
 
In mice negative for Lgr5-CreERT2 (Lgr5(-)) recombination did not take place whereby 
they did not form tumors (control). The mice described above were kept in the Institute of 
Pathology, LMU, Munich, according to conditions of the German law for husbandry of 
laboratory animals. For in vivo experiments, the mice were introduced in the experimental 
procedures at the age of 8–12 weeks. 
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2.1.13 Software 
Software Company 
C-Flow Plus Software Becton & Dickinson 
dChip software Dana-Farber Institute 
CorelDRAW Graphics Suite Corel Corporation 
Gene Construction Kit Textco 
Geneious Biomatters Ltd. 
ImageJ NIH 
NCBI http://www.ncbi.nlm.nih.gov/ 
Office Microsoft 
Photoshop Adobe Systems Incorporated 
Universal ProbeLibrary Assay 
      Design Center 
http://lifescience.roche.com/webapp/wcs/stores/servlet/ 
      CategoryDisplay?catalogId=10001&tab=Assay+ 
      Design+Center&identifier=Universal+Probe+Library 
      &langId=-1 
 
2.1.14 Buffer 
All buffers were prepared with dH2O. 
 
Buffer Composition  
10x PBS (pH 7.4) NaCl 80 g 
 KCl 2 g 
 Na2HPO4-7H2O 26.8 g 
 KH2PO4 2.4 g 
 H2O ad 1000 ml 
 adjust to pH 7.4   
   
Lysis buffer Tris-HCl 1M, pH 8.0 10 ml 
 
NaCl 5M 4 ml 
 
EDTA 0.5M 1 ml 
 
SDS 10% 2 ml 
 
H2O nuclease free 83 ml 
 
  
RIPA lysis buffer Tris-HCl, pH 8.0 50 mM 
 
NaCl 250 mM 
 
NP40 1% 
 
sodium deoxycholate 0.5% (w/v) 
 
SDS 0.1 % 
 
Complete® protease inhibitor  
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4x Tris-HCl (pH 6.8) Tris base 6.05 g 
 
H2O 40 ml 
 
adjust to pH 6.8   
 
H2O ad 100 ml 
 
filter using 0.45 µm filter  
 
SDS 0.4 g 
 
  
4x Tris-HCl (pH 8.8) Tris base 91 g 
 
H2O 300 ml 
 
adjust to pH 8.8  
 
H2O ad 500 ml 
 
filter using 0.45 µm filter  
 
SDS 2.0 g 
 
  
5x Laemmli buffer Tris base 15.1 g 
 
glycine 72 g 
 
SDS 5 g 
 
H2O ad 1000 ml 
 
  
10x TBS Tris-HCl 15.76 g 
 
NaCl 7.57 g 
 
H2O ad 1000 ml 
 
adjust to pH 7.5   
 
  
1x TBS/T (0.1%) 1x TBS 1000 ml 
 
Tween 10% 10 ml 
 
  
10x Transfer buffer Tris base 30.2 g 
 
glycine 144.2 g 
 
H2O ad 900 ml 
 
  
1x Transfer buffer 10x Transfer buffer  100 ml 
 
H2O 800 ml 
 
methanol 100 ml 
 
 
  
Fixative glutaraldehyde 3% 6.7 ml 
 
formaldehyde 37% 2.7 ml 
 
NP40 20 µl 
 
1x PBS 90.5 ml 
 
  
Staining solution K3Fe(CN)6 (500 mM) 0.5 ml 
 
K4Fe(CN)6x3H2O (500 mM) 0.5 ml 
 
MgCl2 (1 M) 0.1 ml 
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X-Gal 100 mg 
 
dimethylformamide 2 ml 
 
PBS 1x 46.9 ml 
 
NP40 10 µl 
 
sodium deoxycholate 50 mg 
 
  
4% Paraformaldehyde paraformaldehyde 1.6 g 
 
H2O 20 ml 
 
NaOH 1N 40 µl 
 
place in hot water until dissolved  
 
10x PBS 4 ml 
 
H2O 16 ml 
 
  
5 % Blotting blocker blotting grade blocker, non-fat dry milk 5 g 
 
1x TBS/T (0.1%) 100 ml 
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2.2 Methods 
2.2.1 Methods used for working with DNA 
2.2.1.1 Cloning techniques 
2.2.1.1.1 Amplification of PCR products 
To generate an OLFM4 expressing plasmid, OLFM4 encoding PCR (polymerase chain 
reaction) products (1561 bp) were amplified by PCR using LS174T cDNA (50 ng/µl) as a 
template. CAT (chloramphenicol acetyltransferase) encoding PCR products (810 bp) were 
amplified with pcDNA-CAT (10 ng/µl) as a template (for the cloning of the control vector). 
The PCR reaction proceeds in a cyclic order of denaturation of the DNA, annealing of the 
primers and elongation. For this amplification, KOD DNA polymerase (Novagen) was 
utilized because of its proof reading activity. The components and PCR conditions are 
listed below, primer sequences in 2.1.7.1.  
 
Component Volume Final conc. 
10x buffer  2 µl 1x 
MgSO4 (25 mM) 1.2 µl 1.5 mM 
dNTPs (2 mM each) 2 µl 0.2 mM each 
primer mix (20 µM each) 0.3 µl 0.3 µM each 
template 1 µl  
KOD Hot Start DNA polymerase (1 U/µl) 0.4 µl 0.02 U/µl 
H2O 13.1 µl  
 20 µl  
 
 
 
    
 
 
 
 
2.2.1.1.2 Digest and ligation  
After the PCR reaction, the PCR products were digested with FastDigest enzymes (BamHI 
and NotI, Thermo Scientific), following manufacturer´s instructions, and purified with the 
PCR conditions: Temperature Time 
 
 
 95 °C 2 min  
 95 °C 20 sec  
 60 °C 30 sec 30 cycles 
 70 °C CAT: 30 sec, OLFM4: 40 sec  
 70 °C 10 min  
 4°C hold  
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QIAquick PCR Purification Kit (Qiagen), following manufacturer´s instructions 
(QIAquick Spin Handbook - QIAquick PCR Purification Kit Protocol - using a 
microcentrifuge). 3 µg of the vector (pEF-ENTR A) were also digested with FastDigest 
enzymes (BamHI and NotI) and subsequently, dephosphorylated with SAP according to 
manufacturer´s instructions to prevent a religation of the vector without an insert. The 
plasmids were separated by agarose gel electrophoresis (see 2.2.1.5) to separate the 
digested plasmids from the plasmids where digestion did not work. The digested plasmids 
were cut out of the gel and purified using the QIAquick Gel Extraction Kit (Qiagen, 
QIAquick Spin Handbook - QIAquick Gel Extraction Kit Protocol - using a 
microcentrifuge). Subsequently, OLFM4/CAT was subcloned via BamHI and NotI 
restriction sites into the pEF-ENTR A vector (Campeau et al., 2009) using T4 DNA ligase 
(Thermo Scientific) over night following manufacturer´s instructions, transformed (see 
2.2.1.1.3) and OLFM4/CAT encoding plasmids (pEF-ENTR A-OLFM4/CAT) were isolated 
(see 2.2.1.1.4). Then, pEF-ENTR A-OLFM4/CAT was cloned via the LR recombination 
reaction (GATEWAY®-technology, Life Technologies) into pLentiX1-DEST-PGK-Puro-
vector which contains C-terminal His and V5 tags (Campeau et al., 2009), following the 
manufacturer’s instructions. The LR reaction product was transformed into E. coli (Stbl3) 
(see 2.2.1.1.3), plated on agar plates with the appropriate antibiotics and incubated over 
night at 37°C. Plasmids were isolated from colonies (see 2.2.1.1.4). Resulting DNA was 
digested (FastDigest enzymes, Thermo Scientific), separated by agarose gel 
electrophoresis (see 2.2.1.5) to control the band sizes and positives clones were sequenced 
by Sanger sequencing (see 2.2.1.6). 
 
2.2.1.1.3 Transformation 
For the amplification of plasmids, plasmids were transformed into DH5α 
(Library/Subloning Efficiency DH5α Competent Cells, Thermo Fisher Scientific) or E. coli 
bacteria (One Shot Stbl3TM Chemically Competent E. coli, Thermo Fisher Scientific; for 
unstable inserts such as lentiviral DNA), according to manufacturer´s instructions, and 
plated out on agar plates with the appropriate antibiotics (kanamycin 50 µg/ml, ampicillin 
100 µg/ml). The agar plates were incubated over night at 37°C. The next day, single 
colonies were inoculated in LB medium with the appropriate antibiotics (kanamycin 
50 µg/ml, ampicillin 100 µg/ml). 
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2.2.1.1.4 DNA preparation 
To isolate plasmids from bacteria, single colonies were picked from the agar plates (see 
2.2.1.1.3), inoculated in LB medium as a liquid bacterial culture with appropriate 
antibiotics (kanamycin 50 µg/ml, ampicillin 100 µg/ml) and incubated over night at 37°C. 
Minipreparation (4 ml LB medium) of plasmid DNA was done using QIAprep Spin 
Miniprep Kit (Qiagen) employing the QIAcube (QIAcube Standard Protocol: QIAprep 
Mini - Standard). For midipreparation (200 ml LB medium), the PureYieldTM Plasmid 
Midiprep System (Promega) was utilized, both following manufacturer´s instructions. 
 
2.2.1.2 Genomic DNA isolation and genotyping of cell lines   
To verify the DICER1 disruption (DICER1ex5) in cell lines, the cell lines RKO (+/+, ex5) 
and HCT116 (+/+, ex5) were harvested and genomic DNA was isolated from the cells by 
the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s instructions 
(QIAamp® DNA Mini and Blood Mini Handbook - Appendix B: Protocol for Cultured 
Cells). 5 µl of the isolated genomic DNA (diluted to 40 ng/µl in H2O) was utilized as 
template in the following genotyping PCR reaction. PCR products were amplified with the 
Maxima Hot Start Taq DNA polymerase (Fermentas) because no proof reading activity 
was required. The PCR product size of wildtype (+/+) cell lines was 444 bp, of ex5 cell 
lines 564 bp. The components and PCR conditions are listed below, primer sequences in 
2.1.7.4.   
   
Component Volume Final conc. 
10x buffer  2.5 µl 1x 
MgCl2 (25 mM) 1.5 µl 1.5 mM 
dNTPs (10 mM each) 0.5 µl 0.2 mM each 
primer mix (20 µM each) 0.5 µl 0.4 µM each 
template (40 ng/µl) 5 µl  
Maxima Taq Hot Start DNA polymerase (5 U/µl) 0.2 µl 0.04 U/µl 
H2O 14.8 µl  
 
 
25 µl  
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2.2.1.3 Genomic DNA isolation and genotyping of mouse tail biopsies 
For genotyping of the mouse lines, mouse tail tip biopsies were obtained from 4-12 weeks 
old mice. Subsequently, the biopsies were lyzed in tissue lysis buffer with proteinase K 
(final concentration 0.1 µg/µl) over night at 56°C and 450 rpm. Then, the lyzed tissue was 
centrifuged 10 min at maximum speed and the supernatant including the genomic DNA 
was transferred into a new tube. For genotyping of the mouse lines FIREPol DNA 
polymerase (Solis BioDyne) and 0.2 µl of the isolated genomic DNA was utilized. The 
PCR components and PCR conditions are listed below, primer sequences in 2.1.7.4. 
 
Component Volume Final conc. 
10x buffer B 2 µl 1x 
MgCl2 (25 mM) 1.2 µl 1.5 mM 
dNTPs (10 mM each) 0.4 µl 0.2 mM each 
primer mix (20 µM each) 0.4 µl 0.4 µM each 
template  0.2 µl  
FIREPol DNA polymerase (5 U/µl) 0.16 µl 0.04 U/µl 
H2O 15.64 µl  
 20 µl  
PCR conditions Temperature Time 
 
 
 95°C 4 min  
 95°C 30 sec  
 58°C 30 sec 40 cycles 
 72°C 1 min  
 72°C 10 min  
 4°C hold  
PCR conditions Temperature Time 
 
 
 95°C 4 min  
 95°C 30 sec  
 anneal. temp. (see below) 30 sec 40 cycles 
 72°C elong. time (see below)  
 72°C 10 min  
 
 
 
 
 
4°C hold  
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2.2.1.4 Verification of the recombination after tamoxifen induction 
For the verification whether the adenomas (2.2.5.1) showed recombination of the Apc and 
Dicer1 genes, PCR was performed using genomic DNA as the template. For that purpose, 
the paraffin was removed from the slices by incubating 3 times for 10 min in xylene and 
3 times for 10 min in absolute ethanol. Regions with and without adenomas were scratched 
out independently from each other with a scalpel blade and transferred directly into a tube 
containing ATL buffer and proteinase K, according to the manufacturer’s instructions. 
Genomic DNA was isolated using the QIAamp® DNA FFPE Tissue Kit (Qiagen) 
employing the QIAcube according to the QIAcube Standard Protocol: QIAamp DNA 
FFPE Tissue - FFPE tissue sections - Standard. For the subsequent PCR reaction, Maxima 
Hot Start Taq DNA polymerase (Fermentas) was utilized because no proof reading activity 
was required. Information on primers and PCR conditions are listed below, primer 
sequences in 2.1.7.5. As template, 1 µl of the previously isolated DNA was utilized. To 
increase the amount of the PCR product, a nested PCR was done. Therefore, 1 µl of the 
previous PCR product was utilized as template, the other components and conditions were 
identical to the previous PCR; components and conditions are listed below. The PCR 
product size of Apc wildtype (WT) was 1300 bp, of Apc recombination (Rec) 350 bp, of 
Dicer1 wildtype 84 bp and of Dicer1 Rec 207 bp. Apc wildtype and recombination 
products were produced in one PCR reaction (primers: Apc FW1, Apc FW2, Apc FW3). 
 
 
 
 
 
 
 
 
 
Primer Anneal. temp. Elong. time PCR product size 
Lgr5-CreERT2 66.0°C 30 sec WT: 298 bp, Rec: 174 bp 
ROSA26LacZ 61.6°C 1 min WT: 650 bp, fl: 350 bp 
Apc 60.2°C 40 sec  WT: 226 bp, fl: 314 bp 
Dicer1 60.2°C 30 sec WT: 351 bp, fl: 420 bp 
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Component Volume Final conc. 
10x buffer  2 µl 1x 
MgCl2 (25 mM) 1.2 µl 1.5 mM 
dNTPs (10 mM each) 0.4 µl 0.2 mM each 
primer mix (20 µM each) 0.4 µl 0.4 µM each 
template 1 µl  
Maxima Taq Hot Start DNA polymerase (5 U/µl) 0.16 µl 0.04 U/µl 
H2O 14.84 µl  
 20 µl  
 
 
 
 
 
 
2.2.1.5 Agarose gel electrophoresis  
To determine the size of the PCR products, the amplified DNA fragments were separated 
by agarose gel electrophoresis. For the analysis of the size, 5 µl of DNA size standard and 
1% or 2% agarose gels were used. For that purpose, 1 g or 2 g of agarose were dissolved in 
100 ml 0.5x TBE (Thermo Scientific) by heating. The evaporated liquid was filled up with 
H2O and the liquid was cooled down to 50–60°C. Subsequently, 3 µl ethidium bromide 
were added and the mixture was poured into the gel sledge. 
 
2.2.1.6 Sanger sequencing  
To verify that the amplified and cloned plasmids have the correct sequence, specific 
sequences were amplified by PCR and the PCR products were subsequently utilized for 
Sanger sequencing. The components and PCR conditions are listed below, primer 
sequences in 2.1.7.2. 
 
  
PCR conditions: Temperature Time 
 
 
 95°C 4 min  
 95°C 30 sec  
 58°C 30 sec  
 72°C Apc: 1 min 30 sec 
Dicer1 WT: 20 sec 
Dicer1 Rec: 30 sec 
50 cycles 
 72°C 10 min  
 4°C hold  
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Component Volume Final conc. 
BigDye Terminator V3.1 1 µl  
sequencing buffer (5x) 2 µl 1x 
primer (10 µM) 0.5 µl 0.5 µM 
template (DNA) 500 ng  
H2O ad 10 µl  
 10 µl  
    
 
 
 
 
PCR products were purified (DyeEx 2.0 Spin Kit; Qiagen) and 4 µl of the purified PCR 
products were finally mixed with 16 µl HiDi formamide. The sequencing was performed 
by Sanger sequencing (ABI 3130; Life technologies) following the manufacturer’s 
instructions.  
 
2.2.2 Methods used for working with RNA 
2.2.2.1 Quantitative reverse transcriptase PCR (RT-qPCR) 
2.2.2.1.1 RT-qPCR of miRNAs 
To detect and quantify the expression of miRNAs, cells were harvested and miRNAs were 
isolated using miRNeasy Mini Kit (Qiagen) which was performed in the QIAcube 
according to the QIAcube Standard Protocol: miRNeasy Mini - Animal tissues and cells - 
Aqueous phase - Part A+B. Isolated miRNAs were diluted to 5 ng/µl and reverse 
transcribed with the Universal cDNA Synthesis Kit II (Exiqon). The components and 
reverse transcription (RT) conditions are listed below. 
 
 
 
 
 
PCR conditions: Temperature Time 
 
 
 96°C 10 sec 
50 cycles 
 60°C 1 min 30 sec 
Component Volume 
 
Final conc. 
miRNA (5 ng/µl) 2 µl 1 ng/µl 
H2O 5 µl  
reaction buffer 5x 2 µl 1x 
enzyme mix 1 µl  
 10  µl  
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The cDNA was diluted 1:80 in H2O and used for qPCR analysis. The qPCR components 
and conditions are listed below, primer sets in 2.1.7.3.1. The qPCR reaction was performed 
using a LightCycler 480 device (Roche). 
 
 
 
 
  
 
 
 
 
 
2.2.2.1.2 RT-qPCR of mRNAs 
To detect and quantify mRNA expression, cells were harvested and total RNA was isolated 
using RNeasy Mini Kit (Qiagen) which was performed in the QIAcube according to the 
QIAcube Standard Protocol: RNeasy Mini - Animal cells - QIAshredder DNase digest. 
Subsequently, cDNA was generated from 300-4000 ng mRNA using the RevertAid 
Reverse Transcriptase (Thermo Scientific). The components of the RT and RT conditions 
are listed below.  
 
 
 
 
 
RT conditions Temperature Time 
 
 42°C 60 min 
 95°C 5 min 
 4°C hold 
Component Volume 
 
ExiLENT SYBR Green master mix 2x 5  µl 
primer mix set 1  µl 
diluted cDNA template 4  µl 
 10  µl 
qPCR conditions Temperature Time 
 
 
 95°C 10 sec  
 95°C 10 sec  
 60°C 1 min 45 cycles 
 72°C 1 sec  
 melting curve   
 cooling   
Pre-Mix: Component Volume 
 
 RNA 300-4000 ng 
 H2O ad 11.5 µl 
 random hexamer primer mix 1 µl 
 
 12.5 µl 
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Subsequently, the following components were added to the Pre-mix. 
 
 
 
 
 
 
 
 
 
 
 
 
The cDNA was diluted in H2O to 10–50 ng/µl and used for qPCR analysis. qPCR was 
done using Light Cycler 480 Probes Master kits together with specific primer pairs and 
Universal Probe Library (UPL) Probes (Roche). The components of the qPCR and qPCR 
conditions are listed below, primer sequences and UPL probes in 2.1.7.3.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT preincubation Temperature Time 
 
 65°C 5 min 
 chill on ice  
Component Volume 
 
Final conc. 
Pre-mix 12.5 µl  
Thermo Scientific RiboLock RNase 
inhibitor 
0.5 µl  
dNTP mix 10 mM each 2 µl 1 mM 
RevertAid reverse transcriptase 1 µl  
 20 µl  
RT conditions Temperature Time 
 
 25°C 10 min 
 42°C 60 min 
 70°C 10 min 
 4°C hold 
Component Volume 
 
Final conc. 
Roche probe master 2x 5 µl 1x 
primer FW (100 µM) 0.005-0.09 µl  50-900 nM (see 2.1.7.3.2) 
primer REV (100 µM) 0.005-0.09 µl 50-900 nM (see 2.1.7.3.2) 
probe UPL 0.1 µl  
H2O ad 8 µl  
cDNA template 2 µl  
 10 µl  
qPCR conditions Temperature Time 
 
 
 95°C 10 sec  
 95°C 10 sec  
 60°C 15 sec 45 cycles 
 72°C 1 sec  
 40°C 10 sec  
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For Cp (crossing point) values, the second derivative maximum method was chosen and 
determined using a LightCycler 480 device (Roche). Gene expression alterations were 
calculated as relative values on the basis of the expression levels of the reference genes 
ACTB (β-actin) and/or HPRT1 (hypoxanthine phosphoribosyltransferase 1) (Pfaffl, 2001). 
All measurements were done in triplicates and repeated at least twice in independent 
experiments. 
 
2.2.2.2 Expression analysis 
For gene expression analysis, cDNA was measured employing a LightCycler 480 device 
(Roche) and gene expression alterations were calculated as relative values on the basis of 
ACTB (see 2.2.2.1.2). The normalized values of the different gene expressions were all 
calculated relative to the expression of the cell line HCT116-CAT-V5. For analysis of 
resulting values, the dChip software (Dana-Farber Institute) was used.  
 
2.2.3 Methods used for working with proteins 
2.2.3.1 Immunofluorescence analysis 
The cellular localization of β-catenin was detected with a specific β-catenin antibody by 
immunofluorescence (IF). For that purpose, cells were seeded in 6 well plates on glass 
cover slides and cultivated for 48 h. After 48 h, cells were fixed on the cover slides in 4% 
paraformaldehyde in PBS for 10 min, washed 3 times in PBS, permeabilized with 0.2% 
Triton X100 in PBS for 20 min and washed 2 times in PBS. Subsequently, the cells were 
blocked with freshly filtered FBS (fetal bovine serum) (100%) for 1 h. Then, the fixed cells 
were stained with the β-catenin antibody (diluted in PBS/FBS 1:1) for 1 h, washed 3 times 
in 0.05% Tween 20 in PBS, stained with the secondary antibody (Alexa Fluor® 488) 
(diluted in 1:1 PBS/ FBS) for 1 h and washed 2 times in 0.05% Tween 20 in PBS. After 
that, the slides were covered with ProLong Gold antifade reagent with DAPI and cover 
slips and subsequently analyzed using an Axiovert 200M microscope (Zeiss). As negative 
control, a staining without primary antibody was done for all stainings. Antibodies are 
listed in 2.1.8. 
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2.2.3.2 Western Blot 
For the detection and quantification of specific proteins, Western Blot analysis was 
performed. For that purpose, cells were washed with PBS, scraped off in RIPA lysis buffer 
and transferred into a reaction tube. After 20 min lysis on ice, lysates were sonicated and 
centrifuged at 16,000  g for 15 min at 4°C. The supernatants were transferred in a new 
tube and the protein concentration of the lysates was determined using the DCTM Protein 
Assay (Bio-Rad) following the manufacturer’s instructions. Rotiload loading buffer was 
added to 40 µg of each lysate in a ratio of 1:4, mixed, heated for 5 min at 95°C, loaded on 
10% SDS-polyacrylamide gels and separated in Laemmli buffer (1x) for 1 h 30 min at 
120 V. 5 µl PageRuler™ Plus Prestained Protein Ladder (Thermo Fisher Scientific) was 
loaded for the determination of the protein molecular weight.  
 
10% SDS-polyacrylamide gel: 
 
 
 
 
 
 
 
 
 
 
After their separation, proteins were transferred onto PVDF-membranes (0.2 µm, Bio-Rad) 
in Transfer buffer (1x) using the Mini Trans-Blot® Cell system (Bio-Rad) for 1 h at 100 V. 
After the transfer of the proteins on the membrane, the membrane was blocked with 5% 
Blotting blocker and stained with the primary antibody (diluted in 5% Blotting blocker) 
over night at 4°C. Subsequently, the membrane was washed 3 times with TBS/T (0.1%) 
and stained with the secondary antibody (diluted in 5% Blotting blocker) for 1 h at room 
temperature (RT). Then, the membrane was washed 3 times with TBS/T (0.1%) and 
detection was done with Immobilon™ Western Chemiluminescent HRP Substrate (ECL) 
(Millipore). Resulting light signals were recorded employing a CF440 Imager (Kodak). 
Antibodies are listed in 2.1.8. 
 
Stacking gel: acrylamide rotiphorese gel 30% 5.00 ml 
 4xTris-HCl, pH 8.8 3.75 ml 
 H2O  6.25 ml 
 APS 10% 0.20 ml 
 TEMED 0.04 ml 
 
Resolving gel: acrylamide rotiphorese gel 30% 0.65 ml 
 
4xTris-HCl, pH 6.8 1.25 m 
 
H2O 3.05 ml 
 
APS 10% 0.10 ml 
 
TEMED 0.02 ml 
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2.2.4 Methods used for working with cells 
2.2.4.1 Cell culture 
CRC cell lines were cultivated in DMEM with 10% FCS in the presence of 100 U/ml 
penicillin and 0.1 mg/ml streptomycin at 5% CO2, only the cell line Colo320 was 
cultivated in RPMI with 10% FCS. Primary tumor cell lines were directly generated from 
fresh human colorectal carcinoma tissue, which was supplied by Klaus-Peter Janssen 
(Technische Universität, Munich), and performed as described in (Kreso and O'Brien, 
2008) (Generating single-cell suspension from human colon cancer tissue). Established 
primary tumor cell lines were cultivated as described in (Kreso and O'Brien, 2008) 
(Culturing colon cancer cells as spheres) in Ultra-low attachment surface culture flasks 
with StemProR hESC SFM medium in the presence of 0.01 µg/ml FGFb. 
 
2.2.4.2 Virus production, conditional expression 
For the generation of cell pools with conditional expression of OLFM4 as well as CAT, 
cells were lentivirally transduced. To produce lentiviral particles, 293T cells were seeded 
and transfected in 60 mm ø dishes with 3.68 µg transfer vector (for plasmid cloning see 
2.2.1.1) together with 3.68 µg pCMV8.9 and 0.74 µg pVSV.G plasmids using Fugene 6 
(Promega) according to manufacturer´s instructions. 48 h after transfection, virus was 
harvested, the cell culture supernatant was filtered using sterile 0.45 µm filter and mixed 
with polybrene (8 µg/ml) and the CRC cell lines were infected with the filtered 
supernatant. For the subsequent selection of the infected cells, the cells were treated with 
different concentrations of puromycin (1–2.5 µg/ml; Sigma-Aldrich). 
 
2.2.4.3 Wnt3a production 
To activate the canonical Wnt signaling pathway, Wnt3a conditioned medium was added 
to the cells for 24 h. For the production of Wnt3a, L Wnt3a cells and L cells (for control 
conditioned medium) were split 1:20 from a T75 cell culture flask in 10 cm ø dishes with 
6 ml medium (DMEM with 10% FCS) and cultivated for 4 days. After 4 days, the medium 
was harvested and filtered through sterile 0.2 µm filter. After this first batch, the medium 
was replenished (6 ml) and the cells were incubated for additional 3 days. After filtering 
the second batch, both batches were pooled and stored at 4°C before the conditioned 
medium was added to the cells.  
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2.2.4.4 Knockdown of CTNNB1 using siRNAs 
To achieve the knockdown of CTNNB1 in cultivated HCT116 cells, the cells were 
transfected with 30–50 nM siRNA specific for either CTNNB1 siRNA or with a non-
targeting siRNA (control) using Lipofectamine RNAiMAX (Invitrogen), following 
essentially the manufacturer’s instructions. 24 h after transfection, the cell culture medium 
was changed. To measure the effects of the knockdown, cells were harvested 72 h after 
transfection and effects were measured on mRNA (see 2.2.2.1.2) and protein level (see 
2.2.3.2). 
 
2.2.4.5 Luciferase reporter assay 
To analyze the activity of promoters in vitro, reporter gene constructs were utilized in a 
luciferase reporter assay. For the determination of the transcriptional activity of β-
catenin/TCF4-responsive promoters, the DICER1 promoter as well as the TEAD (TEA-
domain-containing family) responsive promoter, the reporter plasmids were transiently 
transfected in the absence or presence of exogenous overexpressing plasmids. 2.5x104 cells 
were seeded in 24 cluster well plates. 24 h after seeding, cells were transfected with either 
120-300 ng of firefly luciferase reporter plasmid or with 120–150 ng of firefly luciferase 
reporter plasmid together with 150–160 ng of overexpressing plasmids. In each case, 25-
40 ng of the renilla luciferase reporter plasmid pCMV-Renilla (Promega) was additionally 
transfected for the normalization of results. The transfection was performed using 
Fugene 6 Transfection Reagent (Promega) according to the manufacturer´s instructions. 
After 24-48 h, Dual luciferase reporter assays (Promega) were done according to the 
manufacturer’s instructions. Fluorescence intensities were measured with an Orion II 
luminometer (Berthold) in a 96 well format and analyzed with the SIMPLICITY software 
package (DLR). All experiments were done in triplicates and at least two independent 
experiments were done. 
 
2.2.4.6 Chemoresistance assay 
To analyze changes of gene expression under 5-fluorouracil (5-FU) treatment, LS174T 
cells were incubated for 5 days in 6 well plates in the presence of 40 µM or 50 µM 5-FU 
(Sigma-Aldrich, dissolved in DMSO) or the corresponding concentration of DMSO. After 
5 days, cells were harvested and mRNA isolated for RT-qPCR analysis (see 2.2.2.1.2). To 
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compare the proliferation under 5-FU treatment, HCT116 cells were incubated for 3 days 
with the LC50 concentration of 5-FU (12.12 µM; information received from Arndt Stahler; 
dissolved in water (medac GmbH)) in 96 well plates and analyzed with the MTT assay (see 
2.2.4.7). At least three independent experiments were done. 
 
2.2.4.7 MTT assay 
MTT assays (CellTiter 96® Non-Radioactive Cell Proliferation Assay; Promega) were 
performed to measure cell viability by mitochondrial activity which is a surrogate for 
proliferation. For that purpose, 1.5–3x103 cells were seeded in triplicates in 96 well plates. 
Proliferation was measured every 24 h over 5 days, following the manufacturer´s 
instructions. For measuring chemoresistance, cells were seeded directly in medium 
containing 5-FU and proliferation was measured every 24 h over 3 days. To investigate the 
influence of CTNNB1 knockdown (see 2.2.4.4) on proliferation and chemoresistance, cells 
were seeded 48 h after the knockdown and measured as previously described. Absorbances 
were measured at the wavelength of 570 nm using an ELISA reader (Varioskan, Thermo 
Scientific). At least two independent experiments were done. 
 
2.2.4.8 Wound healing assay 
To measure the migration of cells, wound healing experiments were carried out. Cells were 
seeded in chambers (ibidi) according to the manufacturer´s instructions. 3 h before 
removing the chamber mitomycin C, that blocks proliferation, was added to a final 
concentration of 10 µg/ml. Thus, only the migration effect was detected in the subsequent 
assay. Then, the cells were washed twice with PBS and full culture medium or Wnt3a/Ctrl. 
conditioned medium was added. The defined gap between the cells was photographed at 
0 h and 24 h/48 h. Resulting images were evaluated using ImageJ-Software (NIH) by 
measuring the free gap with the “freehand selection” and comparing the resulting values 
with each other. At least two independent experiments were done. 
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2.2.4.9 Methyl cellulose assay 
To determine the transformation status of colorectal tumor cell lines, anchorage 
independent growth was analyzed by methyl cellulose assay. 500 µl of a cell suspension 
(included 250 cells) was mixed with 4.5 ml 0.01% methyl cellulose (Sigma-Aldrich). Per 
35 mm ø petri dish, 1 ml of this mixture was seeded in quadruplicates. After 12–16 days, 
200 µl Thiazolyl Blue Tetrazolium Bromide (MTT) solution (1 mg/ml; Sigma-Aldrich) 
was added on the petri dishes and incubated over night. The petri dishes with the colonies 
were photographed and analyzed by counting the blue colored colonies using ImageJ-
Software (NIH). At least two independent experiments were done. 
 
2.2.4.10 Flow cytometric analysis of cells (FACS)  
2.2.4.10.1 Aldefluor assay  
High levels of the enzyme ALDH1 are found in cells with CSC properties (Huang et al., 
2009) and therefore, measuring of ALDH1 activity is a suitable marker to determine 
stemness of tumor cells. ALDH1 activity was measured using the ALDEFLUORTM Kit 
(Stemcell Technologies) following the manufacturer’s instructions. To determine changes 
of the gene expression in the cells with ALDH1 high and low activity, cells were separated 
in aldefluor positive (ALDH1+) and negative (ALDH1-) cells by isolating 5 % of the cells 
with the highest and the lowest ALDH1 activity respectively, using a FACS Aria® Cell 
Sorter (Becton & Dickinson). The cells were lyzed, total RNA was isolated, reverse 
transcribed and RT-qPCR analysis were performed (see 2.2.2.1.2). Effects of ectopic 
OLFM4 overexpression and thus, high OLFM4 protein levels on ALDH1 activity were 
measured with the ALDEFLUORTM Kit following the manufacturer’s instructions by using 
a BD Accuri C6 flow cytometer (Becton & Dickinson) device with the corresponding C-
Flow Plus Software. To exclude the dead cells from the measurement, 1 µg/ml propidium 
iodide (PI) solution (Sigma-Aldrich) was added to the cells 30 sec before running the 
measurement. To define the threshold of aldefluor positivity, a portion of the cells was 
incubated with the ALDH1 inhibitor DEAB (diethylaminobenzaldehyde) as a background 
control. At least two independent experiments were done. 
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2.2.4.10.2 Antibody staining 
To determine the percentage of cells that express and synthesize a specific surface protein, 
cultured cells were trypsinized and centrifuged at 200  g for 5 min. Then, cells were 
counted, washed with PBS and diluted to 1x105 cells in 100 µl PBS. Subsequently, cells 
were stained with an antibody directed against a specific protein following the 
manufacturer’s instructions and analyzed using a BD Accuri C6 flow cytometer. For the 
analysis, a triplicate was utilized. At least three independent experiments were done. 
 
2.2.4.10.3 Cell cycle analysis with propidium iodide (PI) 
To analyze the distribution of the major phases of the cell cycle (G0/G1, S and G2/M-
phase) in colorectal tumor cell lines, the DNA content was measured by PI staining. Cells 
were seeded in 6 well plates and cultivated for 2–3 days. Then, cells were trypsinized, 
centrifuged at 200  g for 5 min and fixed for > 2 h on ice. Subsequently, fixed cells were 
washed with PBS and incubated with PI/TritionX100/RNaseA solution for 15 min at 37°C 
(Darzynkiewicz and Huang, 2004). The measurement was done with the AccuriC6 flow 
cytometer and analyzed with the C-Flow Plus Software. The DNA histogram gave 
information about the amount (%) of apoptotic cells (subG1 peak) as well as the 
distribution of the different cell cycle phases. At least two independent experiments were 
done. 
 
2.2.4.11 Sphere formation assay 
The ability to form spheres under serum-free and non-adherent conditions is a feature of 
cells with CSC characteristics (Kreso and O'Brien, 2008). For measuring the CSC 
character of tumor cell lines after OLFM4 overepression, cells were trypsinized and 2x104 
cells were seeded in 24 cluster well plates (Ultra-Low attachment surface) in 1 ml 
StemProR hESC SFM medium in the presence of 0.01 µg/ml FGFb. After 7 days, the 
formed spheres were documented and counted using phase contrast microscopy. 
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2.2.5 Methods used for working with mice  
2.2.5.1 Experimental procedure 
For the induction of CreERT2 induced recombination of floxed genes in mice, tamoxifen 
(TAM; 100 mg for stock solution 10 mg/ml, 150 mg for stock solution 15 mg/ml) was 
dissolved in 1 ml 100% EtOH (10 min heated at 55°C), 9 ml sunflower oil was added and 
mixed. The mixture was stored in aliquots (2 ml) at -20°C. Mice were injected 
intraperitoneally with TAM at 4 consecutive days: day 0 - 3 mg TAM (200 µl of the 
15 mg/ml stock solution); day 1, 2 and 3 - 2 mg TAM (200 µl of the 10 mg/ml stock 
solution). At day 21, mice were sacrificed and organs were harvested. The intestine was 
divided into four parts (small intestine into three equal parts, colon into one part) for a 
better handling and the cecum was removed. Then, all parts of the intestine were cleaned 
with PBS, put on Whatman paper, cut lengthwise and all organs were fixed over night in 
4% formalin. Subsequently, the tissue was dehydrated and embedded in paraffin. The 
paraffin blocks were cut with the microtome in slices (2 µm thick) and put on slides. 
 
2.2.5.2 LacZ and eosin staining 
Mice were injected intraperitoneally with tamoxifen (3 mg in 200 µl) at day 0. At day 5, 
the mice were sacrificed and the intestine was harvested. Each of the four parts of the 
intestine (see 2.2.5.1) was cut into 0.5 cm long pieces and fixed in fixative in a 12 well 
plate for 2 h at 4°C while shaking. Then, the tissue was washed two times at RT with PBS 
and stained over night at RT in staining solution, protected from light, while shaking. 
Subsequently, the tissue was washed in PBS 2 times, put in embedding cassettes and fixed 
over night in 4% formalin. Then, the tissue was dehydrated and embedded in paraffin. 
Paraffin blocks were cut with the microtome in slices (2 µm thick), put on slides and 
stained with eosin. For that purpose, the paraffin was removed from the slices by 
incubating 3 times for 10 min in xylene and 3 times for 10 min in absolute ethanol. Then, 
the slices were stained in eosin Y (containing 90% ethanol) for 3 to 5 min. Afterwards, the 
slices were put in 80% ethanol, in absolute ethanol and subsequently in xylene, covered 
with VectaMount mounting medium and fixed with cover slips. 
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2.2.5.3 Counting of adenomas by stereomicroscopy  
Number and size of adenomas of the four parts of the intestine (see 2.2.5.1) were counted 
macroscopically with the Stemi SV6 (Zeiss, objective S 1.6). The used magnification was 
12.8-80 fold, depending on the size of the adenomas. The size of the adenomas was 
measured with the help of a ruler. Areas from each part of the intestine were photographed 
at 32 fold magnification.  
 
2.2.6 Methods used for working with tissue 
2.2.6.1 Staining of mouse tissue 
2.2.6.1.1 Immunohistochemistry 
The antibody staining of the mouse tissue was performed following the subsequently 
description. 
Step Antigen Treatment 
Dewaxing all xylene 3x 10 min, 100% EtOH 3x 10 min 
Pretreatment β-catenin ProTaqs IV Antigen Enhancer (Quartett); 
   microwave 750 W 2x 15 min 
 KI-67 Target retrieval Solution (Dako); microwave 
   750 W 2x 15 min 
 cl. caspase 3 Citrate (Dako); microwave 750 W 2x 15 min 
 DICER1 ERS6 (Novocastra); microwave 750 W 2x 
   15 min 
 lysozyme Proteinase Type XXIV (Sigma-Aldrich), 10 min 
Blocking of endo- 
   genous peroxidase 
all hydrogen peroxide (7.5%); 10 min 
 
Blocking of unspeci- 
   fic binding sites 
β-catenin DCS Crystal Mouse Block Solution A (DCS), 
   30 sec; DCS Crystal Mouse Block Solution B  
   (DCS) for 5 min 
 KI-67 Protein Block (Dako), 10 min 
 cl. caspase 3, 
   DICER1,  
   lysozyme 
blocking serum (ImmPRESS Reagent Kit; 
   Vector), 20 min 
 
Antibody staining β-catenin 
 
primary antibody (anti-β-catenin; 1:300), 1 h at 
   RT; ImmPRESS Reagent Kit anti-mouse IgG 
   (Vector), 30 min at RT; chromogen DAB+ 
   (Dako), 3 min at RT 
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KI-67 primary antibody (anti-KI67/ TEC3; 1:150), 1 h 
at RT; biotinylated anti-rat IgG (Vector), 30 min 
   at RT; Streptavidin HRP (Novocastra) and 
   stained with chromogen AEC (Invitrogen) 
 cl. caspase 3 anti-cleaved caspase 3 1:100, for 1 h at RT 
   ImmPRESS Reagent Kit anti-rabbit Ig  
   (Vector) 30 min; chromogen DAB+ (Dako) 
   3 min 
 DICER1 anti-DICER1 1:80 1 h at RT; ImmPRESS  
   Reagent Kit anti-rabbit Ig (Vector) 30 min;    
   chromogen DAB+ (Dako) 3 min 
 lysozyme anti-lysozyme 1:14000 1h at RT; ImmPRESS 
   Reagent Kit anti-rabbit Ig (Vector) 30 min; 
   chromogen DAB+ (Dako) 3 min 
Counterstaining all hematoxylin (Vector) 
Fixation all Kaiser´s glycerin gelatine (Merck) 
 
 
The pictures of the sections stained by immunohistochemistry were taken with the Leica 
micro-photography system DMD108 with 200 and 400 fold magnification. The respective 
percent of positive stained cells in the adenomas were estimated per adenoma for at least 
32 adenomas per genotype. For the evaluation of positive cells for cleaved caspase 3 (cl. 
caspase 3), positive cells were counted per adenoma. Additionally, the adenoma size was 
measured using ImageJ-Software (NIH) (“freehand selection”) and the cell number was 
calculated relative to the adenoma area.  
 
 
2.2.6.1.2 H&E staining 
 
H&E stainings were done using the Tissue-Tek Prisma (Sakura), following the subsequent 
description. 
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2.2.6.1.3 PAS staining 
PAS stainings were done using the Tissue-Tek Prisma (Sakura), following the subsequent 
description. 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.6.2 Human tissue collection 
2.2.6.2.1 Characteristics of the tissue collection 
The classification of the colorectal tumors follows the standards of the UICC (Union 
internationale contre le cancer). Here, the tumors are graded by the TNM-system (T: 
primary tumor, N: lymph node metastasis, M: distant metastasis) (Table 2). The primary 
tumor is graded in different T-stadiums according to the infiltration: T1 means that the 
Step Time 
drying station 12 min 
xylene 2x  2 min 
100%, 96%, 70% EtOH each 1 min 
wash station 30 sec 
hematoxylin 6 min 
wash station 4 min 
70% EtOH 1 min 
eosin Y (alcoholic) 2 min 30 sec  
96%, 100% EtOH each 1 min 
xylene  2 min 30 sec 
Step Time 
drying station 12 min 
xylene 2x  2 min 
100 %, 96%, 70% EtOH each 1 min 
aqua dest. 30 sec 
periodic acid 5 min 
aqua dest. 1 min 
Schiff reagent 5 min 
wash station 5 min 
hematoxylin 5 min 
wash station 5 min 
96%, 100% EtOH each 1 min 
xylene 2 min 30 sec 
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tumor infiltrates the submucosa, T2 the muscularis propria, T3 the subserosa or 
pericolorectal tissue and T4 other organs or structures. Furthermore, the occurrence of 
lymph node metastases is classified as N0 (no regional lymph node metastases), N1 (1 to 3 
regional lymph node metastases) or N2 (4 or more regional lymph node metastases) 
whereby at least 20 lymph nodes have to be investigated. Distant metastases are graduated 
in M0 (no distant metastases) and M1 (distant metastasis). Additionally, tumors can be 
graded concerning the differentiation of the tumor cells (grading, G). Here, G1 means that 
the tumor displays a well-, G2 moderately-, G3 poorly- and G4 undifferentiated epithelial 
differentiation of the tumor cells (Bosman et al., 2010; Bruns et al., 2013; Sobin et al., 
2009). 
 
UICC stage T N M 
I T1, T2 N0 M0 
II T3, T4 N0 M0 
III every T N1, N2 M0 
IV every T every N M1 
 
Table 2. TNM-classification of the colorectal tumors, following the standards of the UICC (Union 
internationale contre le cancer).  
T: primary tumor, N: lymph node metastasis, M: distant metastases (according to (Bosman et al., 2010; 
Bruns et al., 2013; Sobin et al., 2009).  
 
In order to analyze the protein level of DICER1 during colorectal carcinogenesis and 
progression, formalin fixed and paraffin embedded (FFPE) samples of CRC specimens 
from 90 patients that underwent surgical tumour resection at the Hospital of the LMU 
München between 2003 and 2010 were obtained from the archives of the Institute for 
Pathology. The patients were selected randomly from the database of the Institute of 
Pathology according to their UICC stage (UICC stage I-IV) (Sobin et al., 2009). 
Furthermore, 27 endoscopically removed tubular colonic adenomas (15 with low grade and 
12 with high grade intraepithelial neoplasia) were assembled. The clinico-pathological 
parameters according to WHO 2010 and TNM Classification of Malignant Tumors 
(Bosman et al., 2010) are summarized in Table 3. The study was carried out according to 
the recommendations of the local ethics committee of the Medical Faculty of the LMU 
München. For comparative analysis normal colonic tissue (123 patients) adjacent to the 
adenoma or carcinoma was analyzed. 
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Parameter Number of patients (%) 
Normal colonic  mucosa  n=123 
Adenoma  n=27 
     low grade IEN 15 (12.8) 
     high grade IEN 12 (10.3) 
Carcinoma n=90 
     UICC I 23 (19.7) 
     UICC II 19 (16.2) 
     UICC III 24 (20.5) 
     UICC IV 24 (20.5) 
     T1 6 (5.1) 
     T2 22 (18.8) 
     T3 45 (38.5) 
     T4 17 (14.5) 
     N0 52 (44.4) 
     N+ 38 (21.5) 
    M0 66 (56.4) 
    M1 24 (20.5) 
     G1 3 (2.6) 
     G2 55 (47.0) 
     G3 31 (26.5) 
     G4 1 (0.9) 
 
Table 3. Patient details of the human tissue collection.  
This human tissue collection was used for the analysis of the DICER1 levels during cancer progression. IEN: 
intraepithelial neoplasia 
 
2.2.6.2.2 Immunohistochemistry 
5 µm sections from each paraffin block were stained with a DICER1 specific antibody 
(anti-DICER1, 1:75, Sigma–Aldrich). Staining was performed on a Ventana Benchmark 
XT autostainer with the XT ultraView DAB Kit (Ventana Medical Systems, Roche) 
following manufacturer´s instructions. Sections were evaluated by a pathologist. The 
staining of DICER1 was scored from 0 to 3, considering only the cytoplasmic reaction 
(Fig. 32). 
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2.2.7 Statistical analysis 
The statistical analyses were performed using the two-tailed Student´s t-test, except for the 
human tissue collection. For the human tissue collection, the χ²-test was used. Statistical 
significance was considered as follows: *p<0.05, **p<0.01, ***p<0.001. 
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3 Results 
CSCs are crucial for the tumor initiation as well as tumor progression and can escape 
classical chemotherapy whereby they cause tumor recurrence with few or no therapeutic 
alternatives (Fanali et al., 2014; Marjanovic et al., 2013). Thus, alternatives have to be 
developed. A promising therapeutic concept might be specific CSC targeted therapies that 
kill the source of the tumor and lead to regression of the tumor (Fanali et al., 2014; Frank 
et al., 2010). A therapeutic target for CSCs might be SC sustaining molecules. Their 
expression and synthesis is often restricted to SCs such as CSCs. As OLFM4 was 
described to be expressed in CBC cells of the human intestine, OLFM4 was discussed to 
be a SC marker and to possess a comparable role as the SC marker LGR5 (van der Flier et 
al., 2009). CBC cells can be transformed to CSCs by Wnt signaling pathway activation 
(Barker et al., 2009) and thus, the influence of OLFM4 as a sustaining molecule for CSC 
features might be a promising target for CSC therapy. As the CSC feature stemness is 
associated with the other CSC features metastasis, EMT and chemoresistance, the 
interference of stemness should also influence the other features. The role of OLFM4 as a 
CSC marker and its influence on CSC features and tumorigenesis are, however, not 
completely understood because of inconsistent studies (van der Flier et al., 2009; Ziskin et 
al., 2013). Therefore, the role of OLFM4 regarding stemness and tumorigenesis was 
investigated. Subsequently, all cells with properties of CSCs are termed CSCs for the sake 
of simplification. 
 
 
3.1 The role of OLFM4 in colorectal cancer cell lines 
Properties of OLFM4 were already investigated in various cancer tissues, with 
inconclusive results; both, tumor promotion (Liu et al., 2012; Zhang et al., 2004) as well as 
limitation (Chen et al., 2011; Liu et al., 2008) have been described. On the one hand, 
enhanced OLFM4 mRNA and OLFM4 protein levels were found in tumors (Luo et al., 
2011). Furthermore, OLFM4 was described to act as an anti-apoptotic protein (Kim et al., 
2010; Liu et al., 2012; Zhang et al., 2004) and to be necessary for proliferation and 
anchorage-independent growth (Kobayashi et al., 2007; Liu et al., 2012). On the other 
hand, OLFM4 has been found to be reduced or undetectable in prostate cancer cell lines 
Results 
 
73 
and tissues (Chen et al., 2011) and to suppress proliferation, tumor growth, invasiveness 
and metastases formation (Chen et al., 2011; Park et al., 2012). In CRC, OLFM4 was not 
expressed or downregulated at the invasion front as well as in poorly differentiated and 
metastatic tissues (Liu et al., 2008) which is not expected for a SC marker. Furthermore, 
the role of OLFM4 was investigated in the CRC cell line HT29 concerning proliferation 
and migration (Liu et al., 2008), however, in the latter study, the morphology and the 
migration capacity of the cell line HT29 was different from that found in other publications 
(Banning et al., 2008; Tsukahara and Murakami-Murofushi, 2012) and thus, has to be 
viewed critically. Therefore, I performed in this study subsequent experiments to clarify 
the role of OLFM4 concerning stemness and tumorigenesis in CRC.  
 
3.1.1 Expression of OLFM4 in CRC cell lines and in CSCs  
To clarify the role of OLFM4 concerning tumorigenesis, the expression pattern of OLFM4 
in 14 CRC cell lines was analyzed by RT-qPCR. Intriguingly, only two cell lines (SW1222 
and LS174T) showed a measurable expression of OLFM4 at the mRNA level (Fig. 15).  
 
 
 
 
 
 
 
 
 
 
Fig. 15. OLFM4 is endogenously expressed in the CRC cell lines SW1222 and LS174T.  
To determine the endogenous OLFM4 expression level in several CRC cell lines, different cell lines were 
harvested and mRNA isolated. Expression of the mRNAs was determined by RT-qPCR. The indicated values 
are the ratios of OLFM4 and ACTB (β-actin), calculated from the Cp values. Surprisingly, only in two 
(SW1222 and LS174T) out of 14 cancer cell lines endogenous OLFM4 expression was detectable.  
 
 
Based on this result, OLFM4 could possibly act as a tumor suppressor, as reported in 
prostate cancer (Li et al., 2013), and thus be inactivated or downregulated in CRC cell 
lines. Another explanation might be that OLFM4 is only expressed in CSCs which are a 
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small subpopulation of the tumor cells and therefore, the OLFM4 expression is not 
detectable in these cell lines. Thus, to clarify the latter possibility, I performed an aldefluor 
assay to separate CSCs. In this assay, the enzyme ALDH1 metabolizes the substrate 
ALDEFLUOR to a fluorescent product and, as a result, the fluorescent cells can be 
isolated. ALDH1 protein is present and enzymatically active in CSCs and responsible for 
the detoxification and thus oxidation of intracellular aldehydes (Huang et al., 2009). Thus, 
populations with high (ALDH1+) or low (ALDH1-) activity of ALDH1 were isolated from 
singularized spheroid tumor cells of the primary CRC cell lines coCSC-AS3 and -AS4 by 
aldefluor assay. As a proof of principle that the cell sorting (FACS) worked well, the 
expression of ALDH1 was analyzed at the mRNA level by RT-qPCR (Fig. 16A). As 
expected, ALDH1+ cells showed a higher expression of ALDH1 than ALDH1- cells. 
Moreover, RT-qPCR analysis revealed, as expected, a higher expression of the known 
stem cell markers LGR5 and PROM1 (Kemper et al., 2012; O'Brien et al., 2007) in the 
ALDH1+ cells since ALDH1+ cells are known to possess SC properties (Huang et al., 
2009). Surprisingly, OLFM4 expression decreased in these cells (Fig. 16A). Thus, no 
coexpression of OLFM4 with known SC markers and rather decreased expression of 
OLFM4 in the CSCs compared with the other tumor cells (non-CSCs) was detected. 
To examine this observation further in a second independent approach, cells were 
selected for chemoresistance by chemotherapy whereby SC properties are induced and 
CSCs are enriched (Dallas et al., 2009). Hence, LS174T cells presenting a high expression 
of OLFM4 (Fig. 15) were treated with the commonly used concentrations of 40 µM or 
50 µM 5-FU for 5 days and analyzed by RT-qPCR. 5-FU treatment led to a higher 
expression of the stemness markers PROM1 and CD44 (Dalerba et al., 2007), whereas the 
OLFM4 expression was decreased (Fig. 16B). Thus, this second approach revealed similar 
results as the aldefluor assay. Therefore, OLFM4 is not increased expressed in CSCs and 
thus, not a CSC marker. 
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Fig. 16. OLFM4 expression did not correlate with expression of characteristical CSC markers. 
(A) Singularized spheroid tumor cells of the primary CRC cell lines coCSC-AS3 and -AS4 were separated by 
aldefluor assay in cells with high and low activity of ALDH1 (ALDH1+ and ALDH1-, respectively). 
Subsequently, mRNA was isolated and expression of the indicated mRNAs was determined by RT-qPCR and 
normalized to the reference genes ACTB and HPRT1 (hypoxanthin phosphoribosyltransferase 1). ALDH1+ 
cells showed, compared to ALDH1- cells, increased expression of ALDH1 and of the SC markers LGR5 and 
PROM1, whereas OLFM4 expression decreased in ALDH1+ cells compared to ALDH1- cells. (B) LS174T 
cells were treated with rising concentrations of 5-FU. Cells treated only with DMSO (0 µM 5-FU) were taken 
as control samples. 5 days after treatment, cells were harvested, mRNA isolated, analyzed by RT-qPCR and 
normalized to ACTB. Upon 5-FU treatment, OLFM4 was downregulated, whereas the SC markers PROM1 
and CD44 were upregulated. Data are represented as mean ± SD from two or three biological replicates.  
 
3.1.2 OLFM4 was ectopically overexpressed in CRC cell lines and had no 
influence on marker expression 
Since OLFM4 was not expressed in CSCs, in contrast to the known SC markers, the 
question arose what kind of role OLFM4 has in CRC. Therefore, I ectopically expressed 
OLFM4 in cancer cell lines which do not express OLFM4 endogenously to investigate the 
functional influence of high OLFM4 protein levels in CRC cell lines. To do so, OLFM4 or 
chloramphenicol acetyltransferase (CAT) as control were overexpressed in the cell lines 
DLD1, HT29, HCT116, LOVO and SW480 because only two (LS174T, SW1222) of 14 
investigated CRC cell lines endogenously expressed OLFM4 (Fig. 15). I utilized a 
lentiviral vector system in which OLFM4 and CAT were expressed with a C-terminal V5-
tag to be able to easily detect the protein levels of OLFM4-V5 and CAT-V5. The 
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expression vectors were cloned, infectious lentivirus was made, the cell lines were 
lentivirally transduced and selected as bulk cultures by puromycin. The expression 
intensity of OLFM4-V5 was verified by RT-qPCR and the OLFM4-V5 protein amounts 
were measured by Western Blot. OLFM4-V5 was overexpressed at the mRNA level and 
also high OLFM4-V5 protein levels were present (Fig. 17A, B). With this a cellular system 
was generated that could be used in the following investigations if OLFM4-V5 
overexpression and thus, high OLFM4-V5 protein levels have effects on CRC cell lines. 
 
With the aforementioned generated cell lines, I explored in a first approach if the 
overexpression of OLFM4-V5 and thus, high OLFM4-V5 protein levels (OLFM4 and CAT 
are subsequently synonymes for OLFM4-V5 and CAT-V5) influenced marker 
expression/protein levels. In this analysis, different groups of markers were chosen known 
to influence or to be associated with several properties of tumor cells such as stemness, 
EMT and differentiation. Thus, to investigate marker expression concerning stemness, I 
chose the well known SC markers PROM1, CD44, LGR5 and ALDH1 (Barker et al., 2007; 
Dalerba et al., 2007; Huang et al., 2009) and analyzed the expression of these markers in 
the generated cell lines at the mRNA level by RT-qPCR. By forced expression of OLFM4 
and thus, high OLFM4 protein levels, the expression of the SC markers compared to the 
control cells (CAT) was unaffected (Fig. 17C). Additionally, I chose a set of differentiation 
and EMT markers for analysis since during tumorigenesis and the metastasis process a 
change in the expression of these markers occurs. EMT comprises a change from an 
epithelial phenotype to a more mesenchymal phenotype. An overexpression of OLFM4, 
however, did not change the expression of the cell adhesion molecule gene CDH1 
(cadherin 1; E-cadherin) that is associated with the epithelial phenotype, measured at the 
mRNA level by RT-qPCR and at the protein level by Western Blot (Fig. 17C, B). 
Furthermore, the differentiation markers KRT20 and MUC2 that characterize the epithelial 
state and are connected with terminal differentiation in the crypt were determined at the 
mRNA level by RT-qPCR and were also unaffected (Fig. 17C). Markers indicative for the 
mesenchymal differentiation are the mesenchymal marker VIM (vimentin) or the master 
switches of EMT such as SNAI1, SNAI2 or ZEB1. Consistent with the previous results, 
VIM expression was not influenced by a forced expression of OLFM4 compared to control 
cells (CAT), determined at the mRNA level by RT-qPCR and at the protein level by 
Western Blot (Fig. 17C, B). Likewise, the expression of SNAI1, SNAI2 or ZEB1 was not 
influenced by an OLFM4 overexpression, measured at the mRNA level by RT-qPCR (Fig. 
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17C). Thus, an overexpression of OLFM4/high levels of OLFM4 protein did not influence 
the expression of stemness, EMT and differentiation markers compared to control cells 
(CAT). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17. Viral transduction of CRC cell lines with OLFM4-V5 resulted in high OLFM4 mRNA and 
OLFM4 protein levels but did not alter marker expression/protein levels.  
(A) Different OLFM4 negative cell lines were transduced with a C-terminal V5-tagged OLFM4 or CAT (as a 
control) and selected via puromycin as bulk cultures. 48 h after seeding cells were harvested, mRNA was 
isolated, analyzed by RT-qPCR and normalized to ACTB. By a lentiviral vector system, high levels of 
OLFM4-V5 mRNA were reached in various cancer cell lines. Data are represented as mean ± SD from two 
biological replicates. (B) To determine the OLFM4-V5 and CAT-V5 amounts at the protein level, cells were 
harvested 48 h after seeding. Total cell lysates were analyzed by SDS-PAGE and immunoblotting. OLFM4-
V5 and CAT-V5 protein levels were detected with a V5-specific antibody; additionally, E-cadherin and 
vimentin were detected with specific antibodies; β-actin served as a loading control. Upon viral transduction, 
OLFM4-V5 and CAT-V5 could be robustly detected in several CRC cell lines at the protein level. However, 
high ectopic OLFM4 protein levels did not lead to a change of the markers E-cadherin and vimentin, both 
associated with EMT. (C) 48 h after seeding, cells with stable ectopic expression of OLFM4-V5 and CAT-V5 
(control) were harvested, mRNA was isolated and analyzed by RT-qPCR. Expression of the indicated 
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mRNAs was normalized to ACTB. The normalized values of the different genes were all calculated relative 
to the expression of the cell line HCT116-CAT-V5 and the resulting values were processed by the dChip 
software. OLFM4 did not significantly affect stemness, EMT and differentiation markers compared to 
control cells (CAT). Data are represented as mean (n= 3).  
 
3.1.3 OLFM4 had no influence on proliferation 
Because the investigation of the marker expression was only descriptive, in a next step 
functional assays were performed. In a first approach, the role of OLFM4 in the regulation 
of proliferation, an important hallmark of cancer, was investigated. Therefore, proliferation 
of the ectopically OLFM4 overexpressing CRC cell lines DLD1, HT29 and HCT116 was 
compared with CAT overexpressing cell lines employing the MTT assay. The MTT assay 
measures the cell vitality by mitochondrial activity. This is a surrogate for proliferation and 
therefore, MTT assay can be deployed to measure proliferation. High OLFM4 protein 
levels did not affect proliferation of the analyzed CRC cell lines (Fig. 18). Thus, OLFM4 is 
no driving force of proliferation. 
 
 
 
 
 
 
 
 
 
Fig. 18. High OLFM4 protein levels had no effect on proliferation.  
Proliferation was analyzed in OLFM4 stably overexpressing cell lines (DLD1, HT29, HCT116) via MTT 
assay for 5 days. CAT stably overexpressing cells served as control. Measurement was conducted 
immediately after seeding and subsequently every 24 h at the wavelength of 570 nm by an ELISA reader. 
Data are represented as mean ± SD from three biological replicates. High OLFM4 protein levels had no 
functional relevance for the proliferation of CRC cell lines.  
 
 
3.1.4 Wnt signaling pathway was not affected by OLFM4 
Besides the proliferation, nuclear β-catenin localization is another important property of 
CRC and CSCs. Hence, I investigated whether OLFM4 overexpression had an effect on the 
subcellular localization of β-catenin, a downstream transcription factor of the Wnt 
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signaling pathway. Nuclear localization of β-catenin implies transcriptional activity and is 
a known marker and inductor for stemness (Fodde and Brabletz, 2007; Vermeulen et al., 
2010). The subcellular localization of β-catenin was examined by immunofluorescence 
analysis. Overexpression of OLFM4 did not influence the subcellular localization of β-
catenin compared to CAT overexpressing cell lines (Fig. 19A). The cell lines DLD1, HT29, 
HCT116 and LOVO showed a cytoplasmic and membranous localization of β-catenin, 
whereas in SW480 cells β-catenin was localized in the nucleus, both in OLFM4 and CAT 
overexpressing cell lines. Thus, overexpression of OLFM4/high OLFM4 protein levels did 
not influence the subcellular localization and therefore, transcriptional activity of β-
catenin. 
To verify whether OLFM4 has an effect on the transcriptional activity of Wnt 
signaling pathway, I subsequently measured directly Wnt signaling pathway activity by 
luciferase reporter assay. Therefore, luciferase reporter plasmids with 7 TCF4 
(transcription factor 4)-consensus binding sites (TOPflash) were transfected. However, 
OLFM4 overexpression had no effect on the activity of Wnt signaling pathway (Fig. 19B).  
To increase possible effects of OLFM4 on Wnt signaling pathway activity and as 
some cell lines such as RKO have no strong endogenous Wnt signaling activity, I 
enhanced the Wnt signaling pathway activity by transfection of a constitutive active 
CTNNB1 (β-catenin) expression clone which is resistant to degradation (β-catenin-D45; 
(Morin et al., 1997)). This expression clone was transfected together with TOPflash 
luciferase reporter plasmids in OLFM4 and CAT overexpressing cell lines. The influence 
of high amounts of the OLFM4 protein on the Wnt signaling pathway activity was 
analyzed by luciferase reporter assay and compared to the control cells (CAT) in the 
context of a strongly active Wnt signaling pathway. However, the presence of OLFM4 had 
also no influence on the Wnt signaling pathway when Wnt signaling pathway was strongly 
activated (Fig. 19C). Thus, high amounts of the OLFM4 protein do not influence the 
activity of Wnt signaling pathway even in the context of a strongly activated Wnt signaling 
pathway. 
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Fig. 19. Ectopic OLFM4 expression had no influence on the cellular localization of β-catenin and the 
Wnt signaling pathway activity.  
(A) OLFM4 and CAT (control) stably overexpressing cells were fixed 72 h after seeding, stained with β-
catenin specific and secondary antibody (green), covered with ProLong Gold antifade reagent with DAPI 
(blue; nuclear DNA) and analyzed by fluorescence microscopy. In SW480 cells β-catenin was localized in 
the nucleus, in the other analyzed cell lines β-catenin was localized in the cytosol and at the membrane. High 
OLFM4 protein levels did not change the localization of β-catenin compared to the control cells (CAT). 
Scale bars represent 50 µm, 200  magnification. (B) Luciferase reporter assay with the firefly TOPflash 
luciferase reporter (contains 7 TCF4 (transcription factor 4)-consensus binding sites) indicating activity of 
the Wnt signaling pathway. FOPflash reporter (contains mutated TCF4 binding sites) served as control. 
OLFM4 and CAT stably overexpressing cells were transfected with either TOPflash or FOPflash reporter and 
additionally with a renilla luciferase vector for the normalization of the results. Luciferase activity was 
measured after 48 h, first normalized to renilla luciferase to exclude different transfection efficiencies and 
subsequently to the FOPflash reporter. The indicated values are TOP/FOP ratios. Wnt signaling pathway was 
not affected by high OLFM4 protein levels. (C) To intensify the activity of the Wnt signaling pathway, a 
constitutive active CTNNB1 (β-catenin) expression clone (β-catenin-D45) was transfected together with 
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TOP/FOPflash luciferase reporter and renilla luciferase vector and analyzed as decribed in (B). Wnt signaling 
pathway activity was enhanced by constitutive active β-catenin, however, the presence of OLFM4 had no 
influence on strongly activated Wnt signaling pathway. SW480 Ctrl. cells show a strong endogenous activity 
of the Wnt signaling pathway and thus, a high luciferase activity. Data are represented as mean ± SD (two 
independent experiments taken together, per experiment n=3).  
 
 
3.1.5 OLFM4 did not influence stem cell characteristics 
Since Wnt signaling pathway activity is not the only factor that is related to stemness and 
to find more evidence for the unexpected result that an overexpression of OLFM4 did not 
influence Wnt signaling pathway activity, a characteristic SC property, I employed the 
stemness indicating aldefluor assay. As mRNA expression of OLFM4 was inversely 
correlated with the ALDH1 activity (ALDH1+ cells; Fig. 16A), an influence of OLFM4 on 
the ALDH1 activity is conceivable. The forced expression of OLFM4 and thus, high 
OLFM4 protein levels in the cell lines, however, did not affect significantly the ALDH1 
activity compared to CAT overexpression (Fig. 20A, B).  
 Another feature of CSCs is the ability to form spheres under serum-free, non-
adherent conditions. Only CSC-like cells are capable to survive and proliferate under these 
conditions (Kreso and O'Brien, 2008). Therefore, by the sphere formation assay, the 
number of CSC-like cells in a population of tumor cells can be determined. OLFM4 and 
CAT overexpressing cells were seeded in serum-free SC medium and after 7 days, the 
number of formed spheres was counted. Enforced OLFM4 expression did not have a 
significant effect on the formation of spheres (Fig. 20C).  
 The sphere formation assay is considered to be a gold standard in the examination 
of the SC property in vitro. Another gold standard is the in vivo xenograft experiment. In 
this experiment, SW480 cells ectopically overexpressing OLFM4 or CAT, respectively, 
were subcutaneously injected in different concentrations in NOD/SCID-mice to get a 
limited dilution. By the limited dilution, the frequency of CSCs in a population of tumor 
cells can be calculated (Kreso and O'Brien, 2008). After 7 weeks, tumors were harvested. 
However, SW480-OLFM4 and SW480-CAT cells formed similar number of tumors. Thus, 
OLFM4 or CAT cells possess a similar number of CSCs (Fig. 20D). 
 Taken together, enhanced OLFM4 protein levels did not have an effect on CSC 
properties such as ALDH1 activity, sphere formation assay and in vivo xenograft 
experiments.  
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Fig. 20. OLFM4 did not change CSC features.  
(A) Different OLFM4-V5 and CAT-V5 (control) stably overexpressing cell lines were analyzed by aldefluor 
assay. 48 h after seeding, cells were harvested and stained with ALDEFLUOR substrate. A portion of the 
cells was incubated with the ALDH1 inhibitor DEAB (diethylaminobenzaldehyde) as a background control 
to define the threshold of aldefluor positivity. Representative examples of the FACS analysis are shown. (B) 
Evaluation of the FACS analysis of ALDH1 positive cells (%). Data are represented as mean ± SD (three 
independent experiments taken together, per experiment n=3). Stably ectopic overexpression of OLFM4-V5 
did not influence the ALDH1 activity that is associated with stemness features. (C) The capacity of OLFM4-
V5 expressing cells concerning sphere formation was analyzed compared to control cells (CAT). Cells were 
seeded in serum-free SC medium and after 7 days, sphere number was counted. The sphere number did not 
differ significantly between OLFM4 and CAT overexpressing cells. Data are represented as mean ± SD (two 
independent experiments, each experiment n=2). (D) SW480 cells, overexpressing OLFM4-V5 and CAT-V5 
respectively, were subcutaneously injected in NOD/SCID-mice in different cell concentrations (in vivo 
xenograft). After 7 weeks, the tumors were harvested. The tumor number is described as number of mice 
which developed tumors/total number of mice used. No significant difference in the tumor number was 
detected between OLFM4-V5 and CAT-V5 cells (cooperation with Anne Küchler and David Horst).  
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3.1.6 Metastatic characteristics were not affected by OLFM4 
Metastases formation is induced by tumor cells with CSC characteristics (Dieter et al., 
2011). Aforementioned assays showed that an overexpression of OLFM4 and thus, high 
amounts of OLFM4 protein did not influence CSC characteristics in cell lines. Therefore, it 
is conceivable that enforced OLFM4 expression also does not affect metastasis capacities. 
However, as OLFM4 seemed to be associated with metastasis in a human tissue collection 
(Liu et al., 2008) and to be sure if there is an effect or not, I analyzed the influence of 
OLFM4 on metastatic features in CRC cell lines. An influence of OLFM4 concerning 
metastasis was measured by wound healing assay (ibidi chamber) whereby cell migration 
can be investigated. In accordance to the former findings, an overexpression of OLFM4 did 
not affect the migration capacity of CRC cell lines because cells with high OLFM4 protein 
levels migrated in 24 h (DLD1, HCT116) or 48 h (HT29) with the same rate as the control 
cells (CAT) (Fig. 21A, B).  
During the metastatic process, cancer cells have to travel through the hemo- or 
lymphopoetic system and meanwhile, they have to tolerate the loss of stroma. Since 
tumorigenic cells develop the ability to grow autonomously, the tumor cells that are able to 
grow without anchorage are more tumorigenic and capable to metastasize. This state is 
imitated by anchorage-independent growth in methyl cellulose. The generated cell lines 
were seeded in methyl cellulose and allowed to grow for 12–16 days. However, the 
capacity to grow in methyl cellulose was not influenced by overexpression of OLFM4 
compared to control cells (CAT) (Fig. 21C, D).  
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Fig. 21. OLFM4 had no influence on metastatic characteristics.  
(A) To measure cell migration in wound healing assay, DLD1, HT29 and HCT116 cells which were either 
stably expressing OLFM4-V5 or CAT-V5 (control) were seeded in culture inserts (ibidi chambers). 24 h after 
seeding, mitomycin C was added to a final concentration of 10 µg/ml for 3 h, the chamber was removed, 
culture medium was added and the defined gap between the cells was photographed at 0 h and 24 h (DLD1, 
HCT116)/48 h (HT29).  Representative examples are shown. (B) Images were evaluated with ImageJ (NIH). 
Results represent the average (%) of wound closure ± SD (n = 3). Cells with high OLFM4-V5 protein levels 
migrated comparable to the control cells (CAT-V5). (C) Anchorage independent growth was analyzed in a 
colony formation assay. OLFM4-V5 expressing cells were seeded in methyl cellulose. 12–16 days after 
seeding, cells were stained with MTT over night and photos were taken. CAT-V5 expressing cells were 
analyzed as control cells. Representative examples are shown. (D) The colony number was analyzed with 
ImageJ (NIH). Data are represented as mean ± SD (two independent experiments, each experiment n=4). The 
capacity to grow in methyl cellulose was not influenced by OLFM4.  
 
 
Taken together, OLFM4 overexpression and thus, high amounts of OLFM4 protein did not 
have influence on proliferation, stemness or metastastatic features in CRC cells in cell 
culture. These results indicate that OLFM4 is not a CSC marker in CRC cell lines.  
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3.2 The role of DICER1 and thus, the miRNAome in intestinal cancer 
Besides CSC sustaining molecules, the miRNAome might also be a tool for CSC targeted 
therapies. Generally, miRNAs are downregulated in tumors (Lu et al., 2005). The 
downregulation of specific miRNAs leads e.g. to increased stemness caused by an 
activation of the Wnt signaling pathway (Bitarte et al., 2011; Vermeulen et al., 2010) and a 
less-differentiated state of tumor cells (Lujambio and Lowe, 2012). Mutations in or 
downregulation of molecules that are involved in the miRNA biogenesis (Lujambio and 
Lowe, 2012) can lead to a disruption of the miRNA biogenesis and thus, to a loss of the 
miRNAome. One molecule that has a central role in the miRNA biogenesis is DICER1. A 
downregulation or deletion of DICER1 was reported and mostly associated with advanced 
tumor stages, poorly differentiated tumors and reduced survival (Faggad et al., 2010; 
Karube et al., 2005; Kumar et al., 2009; Merritt et al., 2008). Furthermore, loss of DICER1 
was investigated in various mouse models. In most cases, a conditional knockout of Dicer1 
and following downregulation of miRNAs promoted tumorigenesis (Kumar et al., 2009; 
Lambertz et al., 2010; Yoshikawa et al., 2013). These results indicate that DICER1 and 
thus, the miRNAome act as a tumor suppressor. However, loss of DICER1 in Wnt driven 
adenomas and its influence on intestinal tumorigenesis has not been investigated. As 
human CRCs and CSCs are mostly driven by the Wnt signaling pathway (Pino and Chung, 
2010), investigations about the influence of the miRNAome on tumor promotion and CSC 
features in Wnt driven tumors might clarify the usefulness of the miRNAome as tool for 
CSC targeted therapy.  
For that purpose, I chose a mouse model in which the knockout of Apc takes place 
specifically in the SC compartment (CBC cells) by an inducible Cre recombinase (Lgr5-
EGFP-IRES-creERT2-Apcfl/fl) as deletion of the Apc gene in the TA cells of the crypts does 
not lead to adenoma formation (Barker et al., 2009). The Apc knockout leads to an 
activation of the Wnt signaling pathway in CBC cells and thus, to the generation of CSCs 
and efficient initiation of intestinal adenomas. In this mouse model, already after 8 days, 
the entire TA compartment is filled out with clusters of transformed cells which develop 
from microadenomas into macroscopic adenomas (Barker et al., 2009). This mouse model 
allows the analysis of the tumor initiation, a step in the early carcinogenesis. The crossing 
of this mouse model with a mouse strain with floxed Dicer1 genes (Dicer1fl/fl) (Harfe et al., 
2005) allows the additional deletion of Dicer1 in the CBC cells resulting in a reduction of 
miRNAs in these cells. The combination of the previously described mouse lines allows 
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the examination of the effect of the miRNAome loss on CSCs which were transformed by 
the activation of the Wnt signaling pathway. 
 
3.2.1 Design and system check of the Apc/Dicer1 mouse model  
For the generation of the aforementioned Apc/Dicer1 mouse model, two mouse strains 
were crossed in the beginning: One mouse strain expresses a Cre recombinase (CreERT2) 
under the Lgr5 promoter which can enter the nucleus only after tamoxifen induction; in the 
other mouse strain, exon 14 of the Apc gene is flanked by loxP sites and can be removed 
by Cre recombinase (Barker et al., 2009). These mice were next crossed with mice 
expressing a LacZ (β-galactosidase) gene after recombination (Fig. 22A). Thus, cells which 
underwent a recombination after tamoxifen treatment can be traced via LacZ staining (Fig. 
22B). Furthermore, mice in which the RNaseIII2 domain of the Dicer1 gene is flanked by 
loxP sites were additionally crossed in this mouse model, both hetero- and homozygous, to 
examine the influence of DICER1 on the intestinal carcinogenesis (Fig. 22A). The mouse 
lines which were required and used for this study are listed and described in Table 1. From 
now on, the abbreviations given in Table 1 are used for simplification. For a fair 
comparison between the mouse lines, only one factor was changed compared to another 
line. This ensures that the phenotype really occurs because of the presence or absence of a 
specific factor. 
The genotypes of the mouse lines used in this study were verified via PCR of 
mouse tail DNA (Fig. 22B). To examine tumor formation Lgr5(+)-Apc, Lgr5(+)-Apc- 
Dicer1het and Lgr5(+)-Apc-Dicer1hom mice were utilized. Additionally, Lgr5(+)-Dicer1het 
and Lgr5(+)-Dicer1hom mice were employed to analyze if a sole Dicer1 deletion in the 
stem cell compartment could also lead to adenoma formation. To control that adenoma 
formation is indeed due to the deletion of the floxed alleles, Lgr5(-) genotypes were used. 
To control after tamoxifen treatment the recombination at the crypt base where the LGR5 
positive cells reside, Lgr5(+)-Apc mice were injected with one dose of 3 mg tamoxifen. 
Mice were sacrificed after 5 days and the intestine was stained via LacZ staining. After 5 
days cells at the crypt base were stained (Fig. 22C). The recombined and stained cells 
migrated upwards the crypt indicating that the recombination worked in the LGR5 positive 
cells. 
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Fig. 22. Apc and Dicer1 gene can be conditionally deleted in mice.  
(A) Schematic diagram of the targeted loci the Apc/Dicer1 mouse model. The inducible Cre recombinase 
(CreERT2) is expressed under the Lgr5 promoter in CBC cells and can only get access to the nucleus after 
TAM (tamoxifen) treatment resulting in recombination. The lacZ gene is expressed under the ubiquitously 
expressed Rosa26 promoter after recombination due to a floxed stop cassette (LSL). The flox-sites of exon14 
of the Apc gene and of the RNAseIII2-domain of Dicer1 allow the targeted knockout of these genes. (B) 
Agarose gel of the PCR analysis of genomic DNA of the genotypes required for the analysis of adenoma 
formation. Lgr5(+) genotypes were examined regarding adenoma formation. Lgr5(-) genotypes were used as 
control. (C) Lgr5(+)-Apc mice were injected with a single dose TAM (3 mg). After 5 days mice were 
sacrificed, the intestine was harvested, fixed, stained with X-Gal and embedded in paraffin. Slices of the 
paraffin blocks were stained with eosin. 5 days after TAM injection, stained cells migrated from the crypt 
base upwards in the crypt. A representative example from the small intestine is shown. (D) To analyze the 
tumor formation in the different genotypes, mice were injected with TAM for 4 consecutive days and 
sacrificed 21 days after the first TAM injection. Organs were harvested, embedded in paraffin and paraffin 
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blocks were cut into slices. (E) Agarose gel of the PCR analysis deployed to verify the recombination of the 
Apc and Dicer1 genes after TAM induction. For that reason, tissue of regions containing adenomas or not 
was scratched out independently of each other, genomic DNA was isolated and utilized for the PCR analysis. 
The recombination of the Apc and Dicer1 genes was only detected in regions with adenomas indicating the 
specificity of the used mouse model. fl: floxed allel; +, WT: wildtype; rec: recombination. (F) The weight of 
the spleen (mg) was measured after organ removal. In Lgr5(+)-Apc and Lgr5(+)-Apc-Dicer1het mice, the 
spleen was significantly enlarged compared to mice without adenoma formation. Data are represented as 
mean. Error bars indicate standard errors from six mice per genotype, except for the genotypes without 
adenomas (n=9). For significance, a Student´s t-test was used. *p<0.05 
 
To investigate the adenoma formation in the different genotypes, mice were injected with 
tamoxifen (TAM) for 4 consecutive days (day 0: 3 mg TAM; day 1, 2, 3: 2 mg TAM). 
After 21 days all mice were sacrificed (Fig. 22D). Lgr5(+) genotypes had a group size of 
n=6, Lgr5(-) had a group size of n=3 as they functioned only as control. Since the 
recombination of the Dicer1 gene after tamoxifen treatment does not influence the stability 
of the DICER1 protein and DICER1 is still detected by the anti-DICER1 antibody (Harfe 
et al., 2005), a PCR was utilized to verify the recombination. Therefore, tissue of regions 
containing adenomas or not was scratched out independently of each other to ensure that 
adenoma formation was linked to recombination. Additionally, the recombination of Apc 
was controlled by PCR to link recombination in both sites to each other. Only in regions 
with adenomas, a recombination of Apc and Dicer1 took place (Fig. 22E).  
Adenoma formation in the intestine is often associated with anemia which comes 
along with an enlargement of the spleen. Since an enlargement of the spleen indicates that 
the mouse model is working well and is forming tumors, I compared the weight of the 
spleens of the genotypes 21 days after TAM induction. The spleens of Lgr5(+)-Apc as well 
as Lgr5(+)-Apc-Dicer1het had significantly more weight than the spleens of mice without 
adenomas (Fig. 22F). This result indicated that the mouse model was working well. 
 
Thus, with this mouse model the interaction of a conditional knockout of Apc and Dicer1 
in cells expressing the stem cell marker Lgr5 could be investigated.  
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3.2.2 An additional deletion of Dicer1 in an Apc knockout mouse model led to a 
higher adenoma number and a smaller adenoma size in the small intestine 
With this mouse model, it was now possible to investigate the tumor initiation which is a 
characteristic of CSCs. First, all genotypes (see Table 1) were injected with TAM for 4 
subsequent days and sacrificed after 21 days because the mice started to become moribund. 
The organs were harvested and divided into four parts (duodenum, jejunum, ileum, colon) 
for a better handling. The different parts of the small and large intestine were examined 
macroscopically using a stereomicroscope. Sections of the intestine are shown from the 
duodenum to the colon (Fig. 23). Only mice positive for Lgr5-CreERT2 (Lgr5(+)) as well 
as Apc showed adenoma formation which was limited to the small intestine. In the colon 
no adenomas were observed. In Apc conditional knockout mice with an additional deletion 
of Dicer1 in CBC cells, more adenomas than with a single deletion of Apc were observed. 
In contrast, Dicer1 conditional knockout mice (Lgr5(+)-Dicer1het and Lgr5(+)-Dicer1hom) 
with an intact Apc gene presented no adenoma formation (data not shown; comparable to 
pictures in the left column Fig. 23). Furthermore, Lgr5(-) mice did not develop adenomas 
even if they were positive for Apc (Fig. 23). Therefore, only the three genotypes with 
adenoma formation were considered for further analysis (Lgr5(+)-Apc, Lgr5(+)-Apc-
Dicer1het and Lgr5(+)-Apc-Dicer1hom) (Fig. 24). 
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Fig. 23. Dicer1 deletion resulted in a higher adenoma number in the small intestine of mice.  
To examine the adenoma formation in the different genotypes, mice were injected with TAM for 4 
consecutive days and sacrificed 21 days after the first TAM injection. Organs were harvested, the intestine 
was divided into 4 parts (duodenum, jejunum, ileum and colon), fixed and the adenoma formation was 
macroscopically analyzed by a stereomicroscope. The location of the pictures in the mouse intestine is 
reflected by the schematic drawing of the mouse intestine on the left side. Stereomicroscopical pictures of 
parts of the intestine of a mouse without adenomas (Lgr5(-)) and mice with adenomas (Lgr5(+)) are shown. 
Only mice in which Apc was conditionally knocked out (Lgr5(+)-Apc) developed adenomas in the small 
intestine, but not in the colon. Additional depletion of Dicer1 (Lgr5(+)-Apc-Dicer1het, Lgr5(+)-Apc-
Dicer1hom) resulted in an increased tumor load in the small intestine. Adenomas are indicated by black arrows 
and dotted lines. Scale bars represent 1 mm, 16  magnification.  
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The adenoma number in the small intestine was counted using a stereomicroscope. 
Conditional Apc knockout mice with an additional deletion of Dicer1 in CBC cells 
developed significantly more adenomas than conditional Apc knockout mice (Fig. 24A). 
This increase in the adenoma formation was dose-dependent of the DICER1 protein 
because mice with a homozygous deletion of Dicer1 developed even more adenomas than 
mice with a heterozygous deletion. The number of adenomas in Lgr5(+)-Apc mice was 
comparable to the number observed by another group (O. Sansom, Beatson Institute, 
Glasgow; personal communication). Besides the tumor number, the general tumor burden 
(shown in mm2; surrogate of tumor volume) was determined. This was done by adding up 
the size of all adenomas per mouse. Between these three genotypes, no significant 
difference was visible in the general tumor burden (Fig. 24B). Nevertheless, the mean size 
of the adenomas (shown in mm2) significantly varied between the genotypes (Fig. 24C). A 
loss of DICER1 led to a smaller adenoma size which was again dose-dependent.  
Taken together, an additional loss of DICER1 led in interaction with an activated 
Wnt signaling pathway in CBC cells to an increased tumor initiation but reduced growth of 
adenomas.  
 
 
 
 
 
 
 
 
 
 
Fig. 24. Dicer1 deletion led to an increased tumor initiation but slower tumor growth in the small 
intestine in the Apc/Dicer1 mouse model.  
(A) 21 days after TAM-induction the number of adenomas was macroscopically analyzed using a 
stereomicroscope in the indicated genotypes. Additional depletion of Dicer1 resulted in the development of 
significantly more adenomas compared to Lgr5(+)-Apc mice. (B) The general tumor burden (mm2) was 
calculated from the size of all adenomas taken together per mouse. The general tumor burden did not differ 
significantly between the three genotypes. (C) The mean score of the adenoma size (mm2) was calculated 
from the number of adenomas divided by the general tumor burden per mouse. In mice with an additional 
homozygous deletion of Dicer1 a significantly smaller mean score of the adenoma size than in Lgr5(+)-Apc 
mice was deteted. Only genotypes that developed adenomas are listed. For significance, a Student´s t-test was 
used. *p<0.05, **p<0.01 , n.s. non significant  
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3.2.3 Loss of DICER1 led to a reduced level of the proliferation marker KI-67 in 
adenomas 
Since a deletion of Dicer1 resulted in a higher number and smaller size of the adenomas, 
the adenomas were further analyzed with respect to morphology and marker amounts by 
immunohistochemical staining. For that purpose, the four parts of the intestine were 
embedded in paraffin blocks, the blocks were cut and slices of the ileum were stained 
immunohistochemically. The staining of the different genotypes (Lgr5(+)-Apc, Lgr5(+)-
Apc-Dicer1het, Lgr5(+)-Apc-Dicer1hom) were analyzed (200 x magnification) and the 
quantity of positive cells was counted for each staining (Fig. 25). Besides the three 
genotypes which developed adenomas, slices of a mouse without adenomas (Lgr5(-)-Apc) 
are shown as example. The latter presented an intestine without any transformations. The 
histology of the small intestine of mice with other genotypes that did not show any 
adenomas was comparable to the tissue histology of this mouse.  
To analyze the morphology and differentiation of the adenomas, H&E staining was 
performed. The H&E staining demonstrated that the adenomas showed the morphology 
and differentiation that is known from tumors driven by Wnt signaling pathway referred by 
the WHO as adenomas NOS (not otherwise specified) (Bosman et al., 2010). The 
adenomas were characterized by severe dysplasia and tubular differentiation. Both, 
morphology and differentiation, did not differ between the analyzed genotypes (Lgr5(+)-
Apc, Lgr5(+)-Apc-Dicer1het, Lgr5(+)-Apc-Dicer1hom) (Fig. 25). Thus, a deletion of Dicer1 
did not influence morphology and differentiation in Wnt signaling pathway driven 
adenomas. 
Since the adenomas were driven by Wnt signaling pathway caused by loss of Apc, 
the number of cells with nuclear β-catenin indicating activity of Wnt signaling pathway 
was analyzed. As the knockout of Apc leads to a strong activation of Wnt signaling 
pathway in the adenomas, adenomas from Lgr5(+)-Apc mice showed, as expected, in 
almost 100% of the cells a nuclear staining of β-catenin (Fig. 25). Therefore, adenomas 
from the genotypes Lgr5(+)-Apc-Dicer1het and Lgr5(+)-Apc-Dicer1hom did not differ in the 
number of cells positive for nuclear β-catenin compared to Lgr5(+)-Apc mice. As β-
catenin was nuclearly localized in almost 100% of the cells in the adenomas of the 
Lgr5(+)-Apc mice, no increase was possible by additional deletion of Dicer1. Besides the 
cells in the adenomas, also the cells at the crypt base of a normal crypt, the SCs, showed a 
nuclear localization of β-catenin. In cells with nuclear localization of β-catenin, no blue 
nucleus was visible. However, the vast majority of the cells in the normal, not transformed 
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crypts which did not undergo a recombination showed only a cytoplasmic localization of 
β-catenin and were characterized by a visible blue nucleus surrounded by a brown circle of 
β-catenin (Fig. 25; 200 and 400 x magnification). Thus, deletion of Dicer1 did not change 
the nuclear localization of β-catenin in Wnt signaling pathway driven adenomas. 
In adenomas, caused by an activation of Wnt signaling pathway, a deletion of 
Dicer1 resulted in reduced adenoma size. The main factor influencing size is the hallmark 
proliferation. The proliferation can be measured immunohistochemically by the 
proliferation marker KI-67. In untransformed crypts, KI-67 levels were strong at the crypt 
base whereas towards the top of the crypt the levels declined and the villi were negative for 
KI-67. The adenomas generally showed a strong KI-67 staining (Fig. 25). Loss of Dicer1 
led to a significantly lower number of KI-67 positive cells, meaning less proliferation in 
the adenomas. Since apoptosis is another hallmark of cancer and can negatively influence 
proliferation, I investigated next whether the loss of DICER1 had an influence on 
apoptosis. Apoptosis can be measured by the number of cleaved caspase 3 positive cells. In 
the different genotypes (Lgr5(+)-Apc, Lgr5(+)-Apc-Dicer1het, Lgr5(+)-Apc-Dicer1hom), no 
difference was detectable in the number of cleaved caspase 3 positive cells per relative 
adenoma area. Additionally, the number of the differentiated intestinal cell types Paneth 
and goblet cells were investigated. However, there was also no difference visible 
examining lysozyme, characteristical for Paneth cells, as well as PAS staining, typical for 
goblet cells, with regard to the influence of DICER1 loss (Fig. 25).  
Taken together, deletion of Dicer1 in Wnt signaling pathway driven adenomas 
(Lgr5(+)-Apc-Dicer1het, Lgr5(+)-Apc-Dicer1hom) led to decreased proliferation but did not 
influence apoptosis or differentiation compared to adenomas from Lgr5(+)-Apc mice. 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25. Dicer1 depletion resulted in less adenoma proliferation.  
Paraffin blocks were cut into slices and stained with H&E, PAS and β-catenin-, KI-67-, cleaved caspase 3- 
and lysozyme-specific antibodies, respectively. As shown macroscopically (Fig. 24), also microscopically no 
adenomas were detected in the small intestines of Lgr5(-) mice (left panel). In mice which were positive for 
Lgr5(+)-Apc, Lgr5(+)-Apc-Dicer1het and Lgr5(+)-APC-Dicer1hom adenomas were detected. Adenomas 
showed a nuclear localization of β-catenin, whereas in the normal mucosa, β-catenin was predominantly 
localized in the cytoplasm except at the crypt base. Cytoplasmic staining of β-catenin is indicated by blue 
nuclei (DAPI) because of the missing of nuclear staining of β-catenin (brown), nuclear staining of β-catenin 
is indicated by brown nuclei (for the difference between cytoplasmic and nuclear staining of β-catenin see 
Lgr5(+)-Apc-Dicer1het β-catenin). Quantifications of positive cells in adenomas are listed on the right side. 
Only the proliferation marker KI-67 showed a significant difference between the adenomas of the three 
genotypes. 200  magnification; black boxed regions 400  magnification. Error bars indicate standard 
error from more than 30 adenomas per genotype. For significance, a Student´s t-test was used.  ***p<0.001, 
n.s. non significant. 
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3.2.4 Validation of CRC cell lines with a disruption of DICER1 
The observation in the previously described mouse model that deletion of Dicer1 had an 
influence on tumor initiation as well as adenoma size was only descriptive. Therefore, I 
chose a cell culture model to shed more light onto the role of DICER1 and the underlying 
mechanism in the intestinal carcinogenesis. To do so, I utilized two human CRC cell lines 
(RKO, HCT116) with a homozygous disruption of the helicase domain (second RNAseIII 
domain; exon 5) of DICER1 (Fig. 26A; (Cummins et al., 2006)). By Cre recombination, 
Cummins et al. cut out the Neo gene whereby one loxP site (yellow triangle; Fig. 26A) is 
still present. Because of the remaining part of the inserted DNA, the DICER1 gene is 
disrupted. However, this disruption did not lead to a deletion of parts of the DICER1 gene. 
In these cell lines the ability to process pre-miRNAs to mature miRNAs is impaired.  
First, I verified the genotype of the cell lines via PCR analysis. Since all cell lines 
had the correct genotype (Fig. 26B), the functional effect on the miRNA biogenesis was 
checked via RT-qPCR. The two miRNAs miR-21 and miR-200a were chosen for this assay 
based on data in (Cummins et al., 2006). Cells with a disruption of DICER1 (hereafter 
referred to as ex5) showed reduced amounts of mature miRNAs compared to the parental 
cell lines (Fig. 26C). This revealed that the cell lines worked well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 26. Colorectal carcinoma cell lines with a homozygous disruption of the helicase domain (ex5) of 
DICER1 showed impaired miRNA processing.  
(A) Schematic diagram of the endogenous locus of the human DICER1 helicase domain. Insertion of an 
AAV-Neo targeting construct into exon 5 of DICER1 disrupted the DICER1 locus (Cummins et al., 2006). 
(B) Agarose gel of the PCR analysis of the genomic DNA of parental (+/+) and homozygous clones (ex5) of 
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RKO and HCT116 cells. Cells were harvested, genomic DNA isolated and analyzed by PCR. The binding 
sites of the primer pair (P1 and P2) for the PCR analysis are depicted in (A). PCR analysis with parental 
(+/+) cells resulted in a PCR product of 444 bp size, with homozygous clones (ex5) of 564 bp size in both 
RKO and HCT116 cells. (C) RKO and HCT116 cells were harvested, miRNA isolated and analyzed by RT-
qPCR. The relative expression of miR-21 and miR-200a was normalized to that of SNORD48 (small 
nucleolar RNA, reference). Depletion of DICER1 in colorectal carcinoma cell lines led to decreased levels of 
mature miR-21 and miR-200a, representative for the other miRNAs. Data are represented as mean ± SD from 
three biological replicates.  
 
3.2.5 Disruption of DICER1 led to enhanced expression/protein levels of CSC, 
metastatic and EMT markers 
In the beginning, I explored in a first approach on a descriptive level if disruption of 
DICER1 influenced marker expression/protein levels in HCT116 CRC cells. For that 
purpose, I chose CSC, metastastatic and EMT markers. The CSC marker CD133 and the 
metastasis marker CD26 were analyzed by antibody staining via FACS analysis. The 
glycosylated epitope of CD133, AC133, was shown to be connected with SC properties 
(Kemper et al., 2010), the marker CD26 was associated with metastasis (Pang et al., 2010). 
Loss of DICER1 resulted in increased levels of both markers, CD133 (Fig. 27A, B) and 
CD26 (Fig. 27C, D). As properties of SCs and metastasis are closely related to EMT (De 
Craene and Berx, 2013) the influence of DICER1 on the expression of EMT factors was 
studied by RT-qPCR. Consistent with the previous results the expression of the master 
switches of EMT, SLUG (SNAI2) and ZEB1, were upregulated at the mRNA level after 
loss of DICER1 (Fig. 27E). Taken together, disruption of DICER1 led to increased levels 
of CSC, metastatic and EMT markers. 
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Fig. 27. Loss of DICER1 increased the levels of CSC, metastatic and EMT markers in HCT116 cells.  
(A) HCT116 ex5 and parental (+/+) cells were harvested, stained with the isotype control (black) or an 
antibody against a glycosylated epitope of CD133, AC133, (red) and analyzed by FACS. A representative 
example is shown. (B) Quantification of CD133 positivity. Disruption of DICER1 increased the number of 
cells with the glocosylated epitope of CD133. (C) HCT116 ex5 and parental (+/+) cells were harvested, 
stained with the Isotype control (black) or an antibody against the metastatic marker CD26 (red) and 
analyzed by FACS. A representative example is shown. (D) Quantification of CD26 positivity. Disruption of 
DICER1 resulted in a higher positivity for CD26 in HCT116 cells. (E) 72 h after seeding, cells were 
harvested, mRNA was isolated and analyzed by RT-qPCR. The expression of the EMT markers snail family 
zinc finger 2 (SNAI2) and zinc finger E-box binding homeobox 1 (ZEB1) was normalized to the reference 
genes ACTB and HPRT1. In cells without DICER1, expression of the EMT markers SNAI2 and ZEB1 
significantly increased. Data are represented as mean ± SD from three biological replicates. A Student´s t-test 
was used.  * p<0.05, **p< 0.01, ***p<0.001  
 
 
3.2.6 A loss of DICER1 resulted in a slower proliferation and enhanced G0/G1 
arrest 
After the descriptive investigation of marker expression and marker protein levels, 
functional experiments were performed. Since deletion of DICER1 led to a smaller 
adenoma size in mice caused by less proliferation, the influence of DICER1 on 
proliferation was also investigated in cell culture. For that purpose, HCT116 cells with and 
without functional DICER1 were analyzed employing MTT assay for 5 days. Cells with 
loss of DICER1 proliferated significantly slower than the parental cells (Fig. 28A). Thus, 
DICER1 influenced proliferation not only in murine adenomas but also in human CRC cell 
lines. 
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Proliferation can be regulated by a multitude of factors among which the cell cycle 
is the most important. Therefore, a change in the cell cycle phases caused by a loss of 
DICER1 was examined. The cell cycle analysis was performed by PI staining and FACS 
analysis. In the ex5 cells, a significantly enhanced number of cells was in the G0/G1 phase 
compared to parental cells. As apoptosis is a counterbalance to proliferation, the apoptosis 
was investigated by the subG1 peak of the cell cycle analysis. However, apoptosis (subG1) 
was not influenced by loss of DICER1 (Fig. 28B). Thus, disruption of DICER1 in HCT116 
cells resulted in an increased number of cells in the G0/G1 phase whereas the apoptosis 
was not influenced. Another possibility besides proliferation might be the regulation by 
size control. In the intestine, tissue size and proliferation is controlled by Hippo pathway 
(Zeng and Hong, 2008). Hence, the smaller adenoma size in mice could also be influenced 
by the activity of the Hippo pathway. The Hippo pathway activity was investigated in cell 
culture by luciferase reporter assay. For that purpose, a synthetic YAP/TAZ-responsive 
luciferase reporter (YAP/TAZ are the transcription factors of the Hippo pathway) was 
used. Cells with a loss of DICER1 showed significant less activity of YAP/TAZ-
responsive promoters compared to parental cells, measured by a reporter assay (Fig. 28C), 
and consequently less proliferation. 
As in CRC cell lines proliferation is regulated by the Wnt signaling pathway via β-
catenin target genes (Clevers, 2006), the role of Wnt signaling pathway activity in CRC 
cell lines with disrupted DICER1 was investigated. The activity of the Wnt signaling 
pathway was impaired by knockdown of CTNNB1 (β-catenin) via siRNAs. siRNA-
mediated CTNNB1 knockdown in HCT116 cells was verified at the mRNA level by RT-
qPCR and at the protein level by Western Blot (Fig. 28D, E). Moreover, the expression of 
the β-catenin target gene AXIN2 was measured by RT-qPCR (Yan et al., 2001). Strikingly, 
CTNNB1 and AXIN2 were both downregulated. By the knockdown of CTNNB1, the 
parental cells proliferated slower than the cells transfected with control siRNA, examined 
by MTT assay. Cells with a loss of DICER1 (ex5) had a similar proliferation rate as the 
parental cells after β-catenin knockdown. When the ex5 cells were transfected with siRNA 
against CTNNB1, the knockdown of CTNNB1 led to an additional slowdown of the 
proliferation rate of the ex5 cells (Fig. 28F). 
Taken together, disruption of DICER1 in CRC cell lines led to less proliferation by 
G0/G1 cell cycle arrest, associated with reduced Hippo pathway activity. Additionally, an 
impaired Wnt signaling pathway activity decelerated the proliferation in parental and 
DICER1 disrupted CRC cell lines. 
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Fig. 28. Loss of DICER1 resulted in less proliferation and increased cell number in the G0/G1 phase, 
associated with reduced Hippo pathway activity in HCT116 cells.  
(A) Proliferation was investigated by MTT assay for 5 days. Cells were measured directly after seeding and 
subsequently every 24 h at the wavelength of 570 nm by an ELISA reader. Cells with a DICER1 disruption 
proliferated significantly slower compared to control cells. (B) For cell cycle analysis, cells were fixed, 
stained with propidiumiodide (PI) and analyzed by FACS. Loss of DICER1 led to a significantly enhanced 
number of cells in the G0/G1 phase compared to parental cells. (C) Hippo pathway activity was analyzed 
with an 8xGTIIC-luciferase reporter (firefly luciferase reporter with synthetic TEAD (TEA-domain-
containing family) binding sites; binding sites for the transcription factors YAP/TAZ) via luciferase reporter 
assay. Cells were transfected with 8xGTIIC firefly luciferase reporter or a control firefly luciferase reporter 
(without TEAD binding sites) and additionally with a renilla luciferase vector for the normalization of the 
results. Luciferase activity was measured 48 h after transfection, first normalized to renilla luciferase to 
exclude different transfection efficiencies and subsequently to the control firefly luciferase reporter. The 
indicated values are 8xGTIIC/control vector ratios. In cells without DICER1, the activity of the Hippo 
pathway was significantly reduced, indicating less proliferation. (D) 72 h after transfection with CTNNB1 (β-
catenin) siRNA or control siRNA HCT116 (+/+) cells were harvested, mRNA isolated and analyzed by RT-
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qPCR. The indicated genes were normalized to ACTB. Endogenous CTNNB1 and its target gene AXIN2 are 
efficiently silenced with CTNNB1 siRNA. (E) In parallel, total cell lysates were analyzed by SDS-PAGE and 
immunoblotting with a specific β-catenin antibody; β-actin served as a loading control. Similar to RT-qPCR 
analysis, immunoblotting confirmed an efficient knockdown of β-catenin. (F) Proliferation was investigated 
in a MTT assay for 5 days. 48 h after transfection of CTNNB1 siRNA or control siRNA, cells were again 
seeded and measured as in (A). Knockdown of CTNNB1 led to a decreased proliferation rate compared to 
cells transfected with control siRNA. A knockdown of CTNNB1 in the parental cells caused a similar 
proliferation rate as a disruption of DICER1 (ex5). A combined disruption of DICER1 and knockdown of 
CTNNB1 led to an additional slowdown of the proliferation rate of the ex5 cells. Data are represented as 
mean ± SD from three biological replicates. A Student´s t-test was used. *p<0.05, **p<0.01, ***p<0.001  
 
3.2.7 Loss of DICER1 increased chemoresistance 
Since loss of Dicer1/miRNAome influenced tumor initiating capacity in a conditional Apc 
knockout mouse model and moreover, DICER1 disruption in HCT116 cells led to 
increased levels of the SC marker CD133, I further analyzed the influence of DICER1 on 
SC properties. As chemoresistance is associated with SC properties (Dallas et al., 2009), I 
investigated the influence of DICER1 and thus, the miRNAome in this context. HCT116 
cells (+/+ and ex5) were treated for 3 days with the chemotherapeutic 5-FU (LC50 
concentration) and the vitality of the cells was measured by MTT assay. Impaired miRNA 
biogenesis (ex5) resulted in a higher number of viable cells and hence, more proliferation 
under 5-FU treatment. Thus, cells with loss of DICER1 showed a higher resistance against 
5-FU than parental cells (Fig. 29A).  
Since cells without DICER1 proliferated better under 5-FU treatment than parental 
cells, I analyzed if the higher resistance against 5-FU is reflected in the cell cycle phases. 
The cell cycle analysis was done by PI staining and FACS analysis. Consistent with the 
MTT assay, ex5 cells showed a significant higher number of cells in the G2/M phase and a 
significant lower number in the G0/G1 phase, compared to parental cells (Fig. 29B). Thus, 
under 5-FU treatment, cells without DICER1 proliferated better and fewer cells were in 
cell cycle arrest compared to control cells, indicating an increase in SC properties. 
Moreover, since β-catenin target genes are involved in chemoresistance (Yamada et 
al., 2000), I investigated further the influence of Wnt signaling activity on the increased 
chemoresistance caused by loss of the miRNAome. For that purpose, CTNNB1 was 
knocked down and chemoresistance was analyzed by MTT assay. Knockdown of CTNNB1 
(β-catenin) led to less chemoresistance in both cell lines (+/+ and ex5); but despite a loss 
of β-catenin the cells with an additional loss of DICER1 were still more chemoresistant 
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then the parental cells after CTNNB1 knockdown (Fig. 29C). Therefore, the increase of SC 
properties by loss of DICER1 is supported by an active Wnt signaling pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 29. Loss of DICER1 increased drug resistance in HCT116 cells.  
(A) HCT116 cells (ex5 and +/+, respectively) were seeded in medium containing 12.12 µM 5-FU and 
chemoresistance was investigated for 3 days by MTT assay. Cells were measured directly after seeding and 
subsequently every 24 h at the wavelength of 570 nm using an ELISA reader. In cells depleted for DICER1 
(ex5) drug resistance significantly increased compared to parental cells. (B) HCT116 cells (ex5 and +/+, 
respectively) were treated for 3 days with 12.12 µM 5-FU, subsequently fixed, stained with PI for cell cycle 
analysis and investigated by FACS analysis. During 5-FU treatment, loss of DICER1 led to a significantly 
increased number of cells in the G2/M phase and significantly less cells in the G0/G1 phase. (C) Proliferation 
was investigated under 5-FU conditions by MTT assay for 3 days. 48 h after transfection of CTNNB1 siRNA 
or control siRNA, cells were seeded in medium containing 12.12 µM 5-FU and measured as in (A). In both 
cell lines (ex5 and +/+), a knockdown of CTNNB1 led to less chemoresistance; ex5 cells were, despite the 
loss of β-catenin (ex5 si CTNNB1 1, ex5 si CTNNB1 2), still more chemoresistant than parental cells (+/+ si 
CTNNB1 1, +/+ si CTNNB1 2). Data are represented as mean ± SD from three biological replicates. A 
Student´s t-test was used. *p<0.05, **p<0.01  
 
3.2.8 Migration capacity was higher without DICER1 
As EMT and metastatic marker expression/protein levels (Fig. 27) indicate that cells 
without DICER1 might also possess increased migration capacities (De Craene and Berx, 
2013; Pang et al., 2010), the influence of DICER1 in this context was analyzed by wound 
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healing assay (ibidi chamber) whereby cell migration can be investigated. RKO cells were 
treated for 24 h with Wnt3a conditioned medium which increased significantly Wnt 
signaling pathway activity (luciferase reporter assay; Fig. 30A). These cells showed a 
significantly enhanced migratory capacity after disruption of DICER1 (ex5) compared to 
parental cells (Fig. 30B, C). This effect was also observed in RKO cells without an active 
Wnt signaling pathway. However, cells with a combination of an active Wnt signaling 
pathway as well as a loss of DICER1 showed the highest migratory capacity after 24 h 
(Fig. 30B, C). Thus, disruption of DICER1 and thus, the miRNAome increased cell 
migration capacity which is positively influenced by an active Wnt signaling pathway. 
 
 
 
 
 
Fig. 30. Loss of DICER1 resulted in enhanced migration capacity.  
(A) RKO +/+ cells were transfected with the TOPflash or FOPflash reporter as control. Additionally, a 
renilla luciferase vector was transfected for the normalization of the results. Wnt3a conditioned medium or 
control medium was added 24 h after transfection. 48 h after transfection, luciferase activity was measured, 
normalized to renilla and subsequently to the luciferase control vector (FOPflash). The indicated values are 
TOP/FOP ratios. Addition of Wnt3a conditioned medium led to an enhanced signal in RKO parental cells 
compared to control (Ctrl.) medium. (B) To measure cell migration by wound healing assay, RKO cells were 
seeded in culture inserts (ibidi chambers). 24 h after seeding, mitomycin C was added to a final concentration 
of 10 µg/ml for 3 h, the chamber was removed, Wnt3a conditioned medium or control medium was added 
and images of the defined gap between the cells were taken at 0 h and 24 h. (C) Images were analyzed with 
ImageJ (NIH). Results represent the average (%) of wound closure ± SD (n = 3). Disruption of DICER1 (ex5) 
led to a significantly enhanced migration capacity, and active Wnt signaling pathway had an additive effect 
on the enhanced migration capacity. Data are represented as mean ± SD from three biological replicates. A 
Student´s t-test was used. * p<0.05, **p< 0.01, ***p<0.001  
 
3.2.9 Wnt signaling pathway increased after loss of DICER1 
Since β-catenin target genes are involved in CSC properties such as stemness (Du et al., 
2008), proliferation (Clevers, 2006), chemoresistance (Yamada et al., 2000) and metastatic 
features (Vlad-Fiegen et al., 2012) and these features were all influenced by a loss of the 
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miRNAome, I tested whether the activity of the Wnt signaling pathway was consequently 
upregulated after loss of DICER1/miRNAome. For this experiment I used RKO and 
HCT116 cells, both parental (+/+) and ex5. As RKO does not have a mutation of the Wnt 
signaling pathway and hence, no active canonical Wnt signaling pathway, I activated this 
pathway by addition of Wnt3a conditioned medium. RKO +/+ and ex5 cells showed an 
increased activity in the Wnt signaling pathway after addition of Wnt3a conditioned 
medium compared to control (unconditioned) medium, measured by luciferase reporter 
assay. Additionally, the activity of the Wnt signaling pathway was enhanced in the ex5 
cells compared to the parental cells. The same was observed in HCT116 cells (Fig. 31A). 
To verify the enhanced activity of the Wnt signaling pathway, the expression of the β-
catenin target gene AXIN2 (Yan et al., 2001) was analyzed at the mRNA level by RT-
qPCR. AXIN2 was higher expressed after disruption of DICER1 in HCT116 cells (Fig. 
31B). 
 Thus, loss of DICER1 resulted in increased activity of Wnt signaling pathway and 
enhanced expression of the β-catenin target gene AXIN2. 
 
 
 
 
 
 
 
 
 
Fig. 31. Loss of DICER1 enhanced Wnt signaling pathway activity.  
(A) RKO cells were transfected with the TOPflash or FOPflash reporter as control. Additionally, a renilla 
luciferase vector was transfected for the normalization of the results. 24 h after transfection, Wnt3a 
conditioned medium or control medium was added. Luciferase activity was measured 48 h after transfection. 
HCT116 cells were transfected with TOP/FOPflash and renilla luciferase vector and likewise, luciferase 
activity was measured 48 h after transfection. Luciferase values were normalized to renilla luciferase activity 
to exclude different transfection efficiencies and subsequently to the luciferase control vector activity 
(FOPflash). The indicated values are TOP/FOP ratios. Addition of Wnt3a conditioned medium led to an 
enhanced signal in RKO +/+ and ex5 cells compared to control (Ctrl.) medium. Furthermore, loss of 
DICER1 caused an enhanced activity of the Wnt signaling pathway. The same effect was observed in 
HCT116 cells. (B) HCT116 cells were harvested 72 h after seeding, mRNA was isolated, analyzed by RT-
qPCR and normalized to the reference genes ACTB and HPRT1. Deletion of DICER1 led to a significantly 
increased expression of AXIN2 compared to the parental cells. Data are represented as mean ± SD from three 
biological replicates. A Student´s t-test was used. ** p<0.01, *** p<0.001 
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Taken together, loss of DICER1 and thus, the miRNAome influenced expression/protein 
levels of CSC, metastatic and EMT markers, affected cell proliferation, enhanced drug 
resistance and migratory capacity and led to a more strongly activated Wnt signaling 
pathway. An activated Wnt signaling pathway enhanced these effects.  
 
3.2.10 DICER1 levels were higher in adenomas compared to normal colonic 
mucosa but decreased during progression from adenoma to carcinoma in 
human CRC 
Since a deletion of Dicer1/DICER1 showed effects in a mouse model as well as in human 
CRC cells, I translated this result on human CRC tissue. Therefore, I next investigated if 
there was also a change of DICER1 levels during human colorectal carcinogenesis. For 
that purpose, I chose a human tissue collection of tissues including the different steps of 
colorectal carcinogenesis: normal colonic mucosa, adenoma and UICC stage I-IV (Table 2, 
3). A staining score was developed based on intensity of cytoplasmic DICER1 staining 
(Fig. 32A). Score 0 was defined as no staining, score 1 as weak staining, score 2 as 
moderate staining and score 3 as strong staining. Next, all cases were evaluated applying 
the score. Score 0 and 1 were grouped as low DICER1 levels/staining intensities, score 2 
and 3 as high DICER1 levels/staining intensities. In the human tissue collection, an 
increase of the DICER1 levels from normal mucosa to the adenoma was observed. Only 
40% of the cases of the normal mucosa showed high levels of DICER1 whereas more than 
86% of the adenomas with poor dysplasia showed high levels. However, during the 
progression from adenoma to carcinoma a decrease of the DICER1 levels was noted. The 
staining intensities of UICC stages III and IV were comparable to normal mucosa (Fig. 
32B).  
The loss of DICER1 during cancer progression complied with the results gained 
with the mouse model and cell culture thus indicating the value of the experimental results 
for describing the situation in humans. 
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Fig. 32. DICER1 levels were higher in adenomas compared to normal colonic mucosa but decreased 
during progression from adenoma to carcinoma in human CRC.  
(A) A human tissue collection was stained with a specific anti-DICER1 antibody. The score of the DICER1 
staining was determined according to intensity of cytoplasmic staining; score 0: no staining, score 1: weak 
staining, score 2: moderate staining, score 3: strong staining. (B) A human tissue collection consisting of 
normal colonic mucosa, adenoma and UICC stage I-IV was analyzed. Cases were graded in low (score 0 and 
1) and high (score 2 and 3) DICER1 levels/staining intensities. Compared to normal mucosa, adenomas 
presented an increase of DICER1 levels. However, during the progression from adenoma to carcinoma a 
decrease of the DICER1 levels was detected. The decreasing DICER1 levels from adenoma to carcinoma 
were statistically significant. A χ²-test was used; p<0.01.  
 
 
3.2.11 Expression of DICER1 was influenced by the Wnt signaling pathway 
Because the staining intensity of DICER1 increased from normal mucosa to adenoma in a 
human tissue collection I determined whether the same could be observed in a mouse 
model. Therefore, I compared normal mucosa and adenomas in Lgr5(+)-Apc mice 21 days 
after TAM induction. For that purpose, the intestine was embedded in paraffin blocks, the 
blocks were cut and stained with antibodies specific for β-catenin and DICER1. Strikingly, 
the adenomas in the mouse model showed higher levels of DICER1 than the normal 
mucosa (Fig. 33A, B).  
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Fig. 33. DICER1 expression was influenced by Wnt signaling pathway.  
(A) Paraffin blocks of Lgr5(+)-Apc mice were cut and slices were immunohistochemically stained with β-
catenin- and DICER1-specific antibodies. In adenomas, nuclear localization of β-catenin was observed. 
Additionally, the staining intensity of DICER1 was increased in adenomas compared to normal mucosa. 200 
 magnification; black boxed regions 400  magnification. (B) Quantification of DICER1 levels in normal 
mucosa (N) and adenomas (A) displayed higher DICER1 levels in adenomas than in normal mucosa (n= 6 
analyzed mice). (C) HCT116 (+/+) cells were transfected with si CTNNB1 siRNA or control siRNA 24 h 
after seeding. 72 h after transfection cells were harvested, mRNA was isolated, analyzed by RT-qPCR and 
normalized to ACTB. RT-qPCR verified a significant reduction of CTNNB1 mRNA and of the expression of 
the β-catenin target gene AXIN2. DICER1 expression was also significantly decreased. (D) Total cell lysates 
were analyzed by SDS-PAGE and immunoblotting with β-catenin- and DICER1-specific antibodies; β-actin 
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served as loading control. Western blot analysis confirmed efficient knockdown of CTNNB1/β-catenin and a 
decrease of DICER1 protein levels. (E) HCT116 +/+ cells were transfected with dnTCF4 to impair the Wnt 
signaling pathway activity. CAT served as control. Additionally, the cells were transfected with the TOPflash 
reporter (FOPflash reporter as control) or the DICER1 promoter reporter (an empty vector served as control). 
Furthermore, a renilla luciferase vector was transfected for the normalization of the results. Luciferase 
activity was measured 48 h after transfection. Luciferase signals were normalized to renilla luciferase and 
subsequently to the luciferase control vector. dnTCF4 led to a decreased activity of Wnt signaling (TOPflash) 
as well as of the DICER1 promoter. Data are represented as mean ± SD from three biological replicates. A 
Student´s t-test was used.  **p< 0.01, ***p<0.001  
 
 
Since formation of the majority of human CRC cases and the adenomas in this mouse 
model were driven by an activation in the Wnt signaling pathway, I supposed that 
Dicer1/DICER1 expression might be regulated by the Wnt signaling pathway. Thus, I 
confirmed this hypothesis in the human CRC cell line HCT116. Wnt signaling pathway 
activity was diminshed by siRNA-mediated CTNNB1 knockdown. The knockdown of 
CTNNB1 was verified at the mRNA level by RT-qPCR and at the protein level by Western 
Blot (Fig. 33C, D). Additionally, the expression of the β-catenin target gene AXIN2 was 
downregulated on mRNA level after CTNNB1 knockdown (Fig. 32C). By the knockdown 
of CTNNB1 and consequently loss of Wnt signaling pathway activity (measured by 
luciferase assay; data not shown), DICER1 mRNA expression as well as DICER1 protein 
levels were diminished (Fig. 33C, D).  
Finally, the influence of the Wnt signaling pathway on the activity of the DICER1 
promoter was measured employing a luciferase reporter assay. To impair the activity of the 
Wnt signaling pathway, dominant negative TCF4 (dnTCF4) was utilized. Transfection of 
dnTCF4 reduced Wnt signaling pathway activity measured by TOPflash activity. 
Furthermore, the activity of the DICER1 promoter was also decreased (Fig. 33E).  
Hence, these results convincingly demonstrated that DICER1 mRNA expression as 
well as DICER1 protein levels were influenced by Wnt signaling pathway, observed in 
murine tissue as well as in human CRC cell lines in cell culture. 
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4 Discussion 
4.1 The role of OLFM4 in colorectal cancer 
Due to their progression driving activity in tumors, CSCs are crucial for the process of 
tumorigenesis. CSCs are characterized by the features cancer stemness, EMT, metastasis 
and chemoresistance. As the CSC features chemoresistance and metastasis are connected 
with cancer death, specific CSC targeted therapies might be an approach for future cancer 
therapies. By directly targeting and killing CSCs, the tumor should regress and cases of 
cancer death might be reduced. As the interference of SC sustaining molecules might be a 
tool for CSC targeted therapies, these molecules are one focus of the current research. One 
of these molecules is the adult SC marker OLFM4. OLFM4 was described to be a 
surrogate for the CSC marker LGR5 (van der Flier et al., 2009). However, conflicting 
results were published (van der Flier et al., 2009; Ziskin et al., 2013) whereby doubts arose 
concerning the role of OLFM4 as a CSC marker. Furthermore, conflicting result exist 
about the expression of OLFM4 in cancer depending on the tissue. Whereas in some 
studies, OLFM4 was higher expressed in breast, lung and colon cancer compared to normal 
tissue (Koshida et al., 2007; Zhang et al., 2004), other studies reported, that reduced or 
undetectable OLFM4 expression was associated with prostate cancer (Chen et al., 2011), 
advanced prostate tumor stages (Li et al., 2013) and worse survival rate for CRC cancer 
(Seko et al., 2010). To clarify the role of OLFM4 as a SC marker and in CRC, I 
investigated in this study the expression pattern of OLFM4 in CRC cell lines and CSCs and 
its functional role on CSC features.  
 
4.1.1 OLFM4 was not a marker of cells with CSC properties 
Since the expression of OLFM4 in cancer might depend on the organ and has not yet been 
clarified for CRC, I examined first the expression pattern of OLFM4 in CRC cell lines as a 
model system to clarify the expression intensity of OLFM4 in CRC cell lines. The finding 
that only two out of 14 CRC cell lines expressed OLFM4 (Fig. 15) indicated that OLFM4 
was downregulated as it acts as a tumor suppressor or as it is possibly difficult to detect in 
these cell lines since it is only expressed in stem cells as previously reported (van der Flier 
et al., 2009). Hence, the latter hypothesis was further investigated in this study, however, 
could not be confirmed by two independent experiments in which specifically CSCs were 
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enriched. Selection for CSCs (Fig. 16) showed that OLFM4 expression was reduced in 
CSCs and therefore, not coexpressed with other SC markers such as LGR5, PROM1 or 
CD44. These results demonstrated that OLFM4 is not a surrogate of LGR5 and not a 
marker of CSCs which agrees with another group that reported that OLFM4 was not 
associated with CSCs in CRC (Ziskin et al., 2013). The reduced expression of OLFM4 in 
CRC cell lines and the association of OLFM4 with non-CSCs might indicate that OLFM4 
has a prognostic impact in CRC. This assumption was further supported by studies in 
which reduced or low levels of OLFM4 were associated with poorly differentiated colonic 
tumors and metastasis (Besson et al., 2011; Liu et al., 2008) and reduced OLFM4 levels 
were detected at the invasion front of colorectal tumors (Liu et al., 2008) where CSCs are 
located (Brabletz et al., 2009). However, this assumption was disproved as recent 
investigations showed that high OLFM4 protein levels were not associated with survival 
and metastatic spread (unpublished data of Neumann et al.; manuscript in preparation 
which includes the results of this study). The staining of OLFM4 at the protein level (IHC) 
was verified at the mRNA level by in situ hybridization. As both stainings showed perfect 
concordance, the immunohistochemical detection of OLFM4 was reliable corroborating 
the validity of the findings. Furthermore, Neumann et al. found out that high OLFM4 
protein levels correlated with low grade (G2) and thus, epithelial differentiation. The 
findings of this study and from Neumann et al. demonstrate that OLFM4 is neither a SC 
marker nor a prognostic marker for survival and metastatic spread. However, OLFM4 
expression in non-CSCs coincides with the finding that OLFM4 correlates with 
differentiation. Thus, OLFM4 expression/OLFM4 protein levels are only associated with 
low grading of colorectal tumors (Fig. 34). 
 
4.1.2 OLFM4 possessed no functional role in CRC cells 
Since OLFM4 was absent or lowly expressed in the majority of CRC cell lines and CSCs, I 
investigated whether this was due to tumor suppressive and stemness reducing effects of 
OLFM4. To test this hypothesis, I ectopically overexpressed OLFM4 in five CRC cell lines 
without endogenous OLFM4 expression. The overexpression of OLFM4 did not influence 
the expression/protein levels of CSC, EMT nor differentiation marker (Fig. 17). This 
descriptive approach was confirmed by functional assays. Proliferation which is an 
important hallmark of cancer cells (Hanahan and Weinberg, 2011) was not influenced by 
OLFM4 overexpression (Fig. 18). Thus, OLFM4 does not play a role in the proliferation of 
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CRC cells and thus, does not seem to be involved in the tumor growth. This finding is 
supported by another study showing that proliferation was not affected in mouse melanoma 
cells by overexpression of OLFM4 (Park et al., 2012). However, the role of OLFM4 
concerning proliferation is tissue dependent as, in contrast to CRC cell lines, high OLFM4 
protein levels increased proliferation in gastric (Liu et al., 2012) and pancreatic (Kobayashi 
et al., 2007) cancer cell lines and suppressed proliferation in prostate cancer (Chen et al., 
2011).   
 Since the Wnt signaling pathway is mechanistically the main driving force of CRC 
and influences CSC features by β-catenin target genes (Barker et al., 2007; Brabletz et al., 
1999; Sanchez-Tillo et al., 2011; Yamada et al., 2000), the activity of the Wnt signaling 
pathway is a crucial feature of the tumor. Therefore, I investigated if the Wnt signaling 
pathway activity is correlated with OLFM4 overexpression. It turned out that OLFM4 did 
not influence the activity of the Wnt signaling pathway (Fig. 19). In contrast to OLFM4, 
two members of the olfactomedin family, MYOC and OLFM1, were described to be 
associated with the modulation of the Wnt signaling pathway (Kwon et al., 2009; Nakaya 
et al., 2008). The other way round, an active Wnt signaling pathway did also not affect 
OLFM4 expression (unpublished data of D. Horst, manuscript in preparation). Thus, there 
is no correlation between OLFM4 and the Wnt signaling pathway indicating that OLFM4 
did not interact with one of the most important pathways in CRC. The missing association 
between OLFM4 and the Wnt signaling pathway and thus, with CSC features is further 
supported by the finding that high OLFM4 protein levels were not associated with other 
stemness properties such as ALDH1 activity and the gold standards of defining CSCs: 
sphere formation and subcutaneous growth of cells in mice (in vivo xenograft) (Fig. 20). 
Whereas ALDH1 activity was associated with a reduced OLFM4 expression (Fig. 16), this 
was not the case vice versa which confirmes the solely association of OLFM4 in CSCs and 
CRC cells. Besides the stemness features, I investigated finally the influence of OLFM4 on 
the metastatic feature migration (Fig. 21). Like proliferation and stemness features, 
metastatic features were not influenced by an overexpression of OLFM4 in CRC cell lines 
in contrast to prostate cancer (Chen et al., 2011) and melanomas (Park et al., 2012) in 
which OLFM4 suppressed migration and invasion. In contrast to my data, another study 
described previously that migration was suppressed by OLFM4 in the CRC cell line HT29 
(Liu et al., 2008). However, the morphology of the HT29 cell was different and the 
migration capacity was much faster in Liu et al. compared to the HT29 cells used in this 
study and in other publications (Banning et al., 2008; Tsukahara and Murakami-Murofushi, 
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2012). Thus, it might be that Liu et al. have been used a subclone of HT29 or another cell 
line and therefore, the results from Liu et al. have to be viewed critically. In this study, five 
different CRC cell lines (all verified by DSMZ) were investigated and all attained the same 
results which underlines the validity of this study.  
 
Taken together, these results demonstrate that OLFM4 expression is reduced in CRC cell 
lines, ALDH1 positive CSCs and chemoresistant CSCs. The cause for the reduced 
expression of OLFM4 in CRC cell lines and CSCs, however, is not yet resolved as the 
reduction of OLFM4 does not take place due to a tumor suppressive role on cancer cells. 
Furthermore, OLFM4 is correlated with differentiation and low grading of CRC 
(unpublished data of J. Neumann). Thus, OLFM4 is only associated with differentiation 
and non-CSCs, does not have a prognostic impact concerning survival and metastatic 
spread and is not a stem cell marker in CRC. The missing prognostic relevance of OLFM4 
in CRC is reflected by the missing functional relevance of high OLFM4 protein levels on 
CSC features such as proliferation, cancer stemness and metastatic features. Therefore, 
OLFM4 does neither exert tumor promoting nor tumor suppressing influences on CRC 
cells and CSCs and does not contribute to tumor initiation, growth or the process of tumor 
progression. These data demonstrate that OLFM4 is not a stemness sustaining molecule 
and thus, is not a suitable tool for CSC targeted therapy. Thus, this study contributes to 
reveal the lack of a role of OLFM4 as a CSC marker and in the process of carcinogenesis 
of CRC (Fig. 34).  
 
 
 
 
 
 
 
 
 
 
Fig. 34. The impact of OLFM4 in CRC.  
OLFM4 is associated with differentiation, low grade and non-CSCs. However, OLFM4 is not associated with 
CSCs, has no prognostic impact in CRC and no functional impact on CSC features in CRC cell lines. 
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4.2 The role of DICER1 in intestinal cancer 
Besides stemness sustaining molecules, the miRNAome might be also a target for CSC 
targeted therapy since the downregulation of miRNAs resulted in a less-differentiated state 
of tumor cells (Lujambio and Lowe, 2012). The less-differentiated state leads to increased 
stemness features and chemoresistance (Singh and Settleman, 2010) whereby the cells 
become more tumorigenic. Recent studies revealed that knockout of Dicer1 and 
subsequently downregulation of miRNAs in mouse models promoted tumor initiation 
(Kumar et al., 2009; Lambertz et al., 2010; Yoshikawa et al., 2013). As the majority of the 
human CRCs is driven by the Wnt signaling pathway (Pino and Chung, 2010), the 
knowledge about the role of the miRNAome on tumor promotion and CSC features in Wnt 
driven tumors might be a crucial tool for the development of CSC targeted therapy.  
 
4.2.1 Loss of DICER1 led to increased adenoma formation but reduced adenoma 
size in a murine intestinal cancer model 
As most of the CRC cases are thought to be driven by an APC mutation in the SC 
compartment, I used a mouse model (Lgr5(+)-Apc) in which the knockout of Apc in CBC 
cells led to the generation of CSCs and subsequently, very efficiently to the formation of 
adenomas (Barker et al., 2009). For the investigation of the loss of the miRNAome, the 
Apc mouse model was combined with another mouse model in which a conditional 
knockout of the miRNA generator Dicer1 leads to miRNA loss. The validity of the Apc 
mouse model was examined in this study by three different approaches: (1) tracing of the 
cell recombination at the crypt base (LGR5 positive SCs) and characteristical migration of 
these cells from the crypt base crypt upwards by X-Gal staining (Fig. 22C), (2) verification 
of the Apc recombination in adenomas by PCR analysis (Fig. 22E) and (3) determination 
of the weight of the spleens that is typically increased after adenoma formation (Fig. 22F). 
All approaches confirmed that the Apc mouse model reproducingly presents adenoma 
formation similar to what was described in other studies (Barker et al., 2009; Qian et al., 
2005) indicating the validity of the Apc mouse model in this study. Additional knockout of 
Dicer1 in this mouse model led to downregulation of the miRNAome and thus, to a loss of 
tumor suppressive and oncogenic miRNAs. The loss of the miRNAome resulted in a 
significant higher number of adenomas which agreed with the aforementioned studies 
(Kumar et al., 2009; Lambertz et al., 2010; Yoshikawa et al., 2013). Thus, loss of the 
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miRNAome enables cells, which were transformed by Apc knockout, to achieve a higher 
rate of tumor initiation. In this study, I detected a higher adenoma number after both, 
hetero- and homozygous deletion of Dicer1 (Fig. 24 A). This observation agrees with 
another study in which enhanced tumor numbers after homozygous deletion of Dicer1 
(Kumar et al., 2007) were described and additionally, sarcoma cell lines were more 
tumorigenic after both, hetero- and homozygous deletion of Dicer1 (Ravi et al., 2012). 
However, other studies reported that only heterozygous but not homozygous deletion of 
Dicer1 resulted in a higher tumor number (Kumar et al., 2009; Lambertz et al., 2010; 
Yoshikawa et al., 2013). Furthermore, in human tumors only heterozygous mutations of 
DICER1 are reported (Hill et al., 2009). Thus, it is controversially discussed if a 
homozygous and/or only heterozygous deletion of Dicer1 in vivo leads to tumor formation. 
One reason that only heterozygous deletion of Dicer1 can lead to tumor formation might 
be that homozygous deletion of Dicer1 and therefore, complete ablation of miRNA 
biogenesis is disadvantageous for tumor formation (Kumar et al., 2009). However, this 
hypothesis is contrary to other tumor suppressor genes in which only a homozygous 
mutation or loss of the gene/protein advances tumorigenesis. Thus, my data showed novel 
evidence that both, hetero- and homozygous deletion of Dicer1, leads in combination with 
a deletion of Apc to increased adenoma numbers indicating that the less miRNAs are 
processed the higher the tumor promoting impact is. Reduction of the protein level of 
DICER1 could not be demonstrated because the recombination and therefore, the deletion 
of the RNAseIII2 domain of Dicer1 does not disturb the stability of the DICER1 protein 
with the result that this protein can still be detected by the anti-DICER1-antibody (Harfe et 
al., 2005). Thus, an antibody specific against the RNAseIII2 domain would be necessary 
for the verification of the loss of the DICER1 protein by recombination. Therefore, I chose 
PCR analysis by which I verified that the recombination of Apc and Dicer1 took place only 
in adenomas but not in normal mucosa (Fig. 22E). However, the proof that a complete 
recombination of both alleles of Dicer1 took place in the adenomas of the homozygous 
Dicer1 knockout mice, meaning that there is no floxed allele left in the adenomas, is 
missing. Therefore, it might be possible that the recombination of Dicer1 took place only 
in one instead of both alleles of Dicer1. Additionally, even if only a heterozygous 
recombination of Dicer1 took place in the adenomas, a second hit in Dicer1 might take 
place leading to a homozygous deletion of Dicer1. To clarify this thought, the tumors have 
to be deeper investigated concerning spontaneous mutations by e.g. next generation 
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sequencing. Furthermore, measurement of the miRNAome in the adenomas would show 
whether there are still mature miRNAs generated by a remaining Dicer1 allele or not. 
 Loss of DICER1 in CBC cells without an activated Wnt signaling pathway did not 
lead to adenoma formation suggesting that loss of DICER1 leads to tumor formation only 
in a background with an activated oncogenic pathway. This is supported by the findings of 
several recent studies of mouse models in which Dicer1 deletion resulted only in tumor 
formation in combination with an activated oncogenic pathway. This was the case for 
retinoblastoma formation in a retinoblastoma-sensitized background (Lambertz et al., 
2010), lung tumor formation in combination with a mutated KRAS (Kumar et al., 2009) 
and intestinal tumor formation in an intestinal inflammation background (Yoshikawa et al., 
2013). Thus, the miRNAome as a whole exerts a tumor suppressive influence on intestinal 
cells in mice that are transformed by an oncogene. This tumor suppressive effect is absent 
after loss of the miRNAome resulting in increased tumor formation. 
 
Loss of the miRNAome resulted, besides the increased tumor initiation, also in smaller 
adenoma size (Fig. 24 C) caused by less proliferation (Fig. 25). Apoptosis, however, did 
not influence the smaller adenoma size as indicated by cleaved caspase 3 staining. The 
lower proliferation rate complied with observations in breast (Bu et al., 2009) and sarcoma 
(Ravi et al., 2012) cell lines. Therefore, the regulation of the miRNAome affects 
proliferation and thus, the growth of the tumor. Furthermore, as Wnt signaling drives 
adenoma formation and loss of DICER1 led to increased adenoma numbers, a higher 
activity of the Wnt signaling pathway would be expected after loss of DICER1 which was 
here not the case. The cause for this result is that the knockout of Apc in the stem cells led 
to a maximal activation of the Wnt signaling pathway and thus, to a nuclear localization of 
β-catenin in almost 100% of the cells in the adenomas which cannot be further increased. 
Further characterization of the adenomas did not reveal any morphological difference 
between the genotypes Lgr5(+)-Apc, Lgr5(+)-Apc-Dicer1het and Lgr5(+)-Apc-Dicer1hom 
(Fig. 25). All adenomas exhibited tubular differentiation (H&E staining) and showed the 
same differentiation status indicated by the frequency of Paneth (lysozyme staining) and 
goblet cells (PAS staining). Therefore, Dicer1 deletion did not lead to a transition towards 
another subgroup of tumor differentiation such as villous, tubulovillous or mucinous 
(Lanza et al., 2011). However, future studies might possibly show whether loss of DICER1 
is favoring the transition to another, more malignant subtype of differentiation which 
would occur by additional mutations. Then, deletion of Dicer1 would not be causal for the 
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development of the adenomas to carcinomas but would contribute to the process of 
carcinogenesis. Loss of miRNAs might therefore facilitate the process of carcinogenesis as 
an additive element in a context of additional mutations. A future project might clarify this 
question by investigating this mouse model to a later time point in which loss of DICER1 
might possibly contribute to the development of carcinomas by the accumulation of 
additional mutations. 
 
Taken together, this study shows that deletion of Dicer1/loss of the miRNAome in CSCs in 
combination with the activated Wnt signaling pathway leads to increased adenoma 
formation. Furthermore, loss of the miRNAome decelerates proliferation and thus, tumor 
growth. However, the tumor morphology is not influenced by the loss of the miRNAome 
after 21 days. These observations are the case for hetero- and homozygous deletion of 
Dicer1 whereby a dose-dependent effect of DICER1 is visible. In this study, deletion of 
Dicer1 results in the loss of the whole miRNAome which includes tumor suppressive 
miRNAs and oncogenic miRNAs. As deletion of Dicer1/loss of the whole miRNAome 
leads to increased tumor initiation, the loss of the tumor suppressor miRNAs has in this 
context more effect then loss of the oncogenic miRNAs. Although for the tumor formation, 
both, the suppression of tumor suppressive miRNAs as well as the activation of oncogenic 
miRNAs are important, the suppression of tumor suppressive miRNAs seems to be more 
relevant for the tumor. Furthermore, the decreased proliferation after loss of the 
miRNAome indicated that the loss of miRNAs that lead to increased proliferation by 
targeting mRNAs has a high influence on the tumor growth (Fig. 35). 
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Fig. 35. Model of the impact of DICER1 on adenoma formation.  
DICER1 is involved in the biogenesis of miRNAs whereby a balance between tumor suppressive and 
oncogenic miRNAs exists. An Apc mutation in CBC cells and thus, activation of the Wnt signaling pathway 
and generation of CSCs leads to adenoma formation. Loss of DICER1 leads to a downregulation of tumor 
suppressive and oncogenic miRNAs. In combination with an Apc mutation, the downregulation of miRNAs 
in CSCs leads to an increased tumor formation and decreased proliferation. Despite downregulation of both, 
tumor suppressive and oncogenic miRNAs, the loss of tumor suppressive miRNAs has a higher impact as 
tumor formation is increased. Letter and arrow size reflect the amount of activity or loss. 
 
4.2.2 Loss of DICER1 resulted in slower proliferation but increased stemness 
and metastatic capacities in CRC cell lines 
The previous findings of the mouse model showed that loss of the miRNAome in CSCs, 
which originated by APC mutation in CBC cells, promotes tumor initiation. However, 
knowledge of the mechanistical background is crucial to develop CSC targeted therapies. 
Furthermore, in the mouse model, the influence of the miRNAome loss was investigated 
concerning adenoma formation. To translate this investigation to a carcinoma model, CRC 
cell lines are an appropriate tool for these examinations. Moreover, the influence on CSC 
features is easier to examine in cell culture than in a mouse model. The further 
investigation of the mechanistical background might help to understand the influence of 
the miRNAome on CSC features and on the process of carcinogenesis. I chose the CRC 
cell lines RKO and HCT116 with a homozygous disruption of DICER1 (Cummins et al., 
2006) which are impaired in miRNA maturation leading to a reduction of mature miRNAs 
(Fig. 26). However, it is remarkable that mature miRNAs are strongly reduced but still 
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present despite complete loss of DICER1. Possibly, there are other DICER1 independent 
miRNA-biogenesis mechanisms as described in (Dueck and Meister, 2010).  
Since deletion of Dicer1 in a mouse model resulted in a reduced size of the 
adenomas by less proliferation, I investigated also the influence of DICER1 on 
proliferation of CRC cell lines. As in the mouse model, loss of DICER1 led to a slower 
proliferation in HCT116 cells (Fig. 28A). Consistent with my data, another group (Iliou et 
al., 2014) reported the same result during preparation of this thesis. This finding was 
further verified in this study by cell cycle analysis in which DICER1 disruption led to a 
higher number of cells in the G0/G1 phase (Fig. 28B) indicating cell cycle arrest and by 
Hippo pathway analysis which showed a decreased transcriptional activity of YAP/TAZ 
(Fig. 28C). Thereby it is crucial to know that Hippo pathway regulates the size of organs. 
Since both, cell cycle (Calabrese et al., 2007; Wang et al., 2008) and Hippo pathway (Lee 
et al., 2009) are regulated by specific miRNAs, the loss of these miRNAs might contribute 
to these changes. In total, the reduction of both, tumor suppressive and oncogenic miRNAs 
influences these changes. As previously observed in adenomas of the mouse model, 
apoptosis, measured by the subG1 phase, was not influenced by loss of DICER1 in CRC 
cell lines (Fig. 28B).  As in the mouse model, the loss of the whole miRNAome in CRC 
cell lines has a suppressive function on the proliferation. Among the plethora of lost 
miRNAs, the loss of the growth promoting miRNAs dominates whereby proliferation is 
decreased, cell cycle arrest enhanced and YAP/TAZ-activity reduced. These cellular 
changes lead to slower cell and thus, tumor growth. The decreased proliferation and 
increased cell cycle arrest in the cellular system and in the mouse model might further be 
associated with the increased expression of the cell cycle inhibitor CDKN2A which is a β-
catenin target gene (Wassermann et al., 2009) and thus, might be expressed in both, the 
Apc mouse model and HCT116 cells. The expression of CDKN2A can repress the 
proliferation promoting effect of the β-catenin target genes MYC and CCND1. Thus, the 
enforced expression of CDKN2A which is associated with the CSC features EMT and 
metastasis (Brabletz et al., 2005) might decrease the proliferation rate after loss of the 
miRNAome however also increase CSC features such as stemness, EMT, metastasis and 
chemoresistance. This hypothesis would explain the increased tumor initiaton (increased 
stemness) and the decreased proliferation after loss of the miRNAome in the Apc mouse 
model. However, this has to be proved by further investigations. 
Moreover, as loss of DICER1 increased tumor initiation I investigated the impact of 
the miRNAome loss on CSC features to understand the influence of the miRNAome on the 
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process of carcinogenesis. In a first descriptive approach, I determined that CSC and EMT 
markers were upregulated in HCT116 cells after DICER1 disruption (Fig. 27) thus 
indicating more pronounced stemness and EMT properties of the cells after loss of 
DICER1 as the expression of CSC and EMT markers is associated with SC properties 
(Mani et al., 2008). This is supported by results from another group (Iliou et al., 2014). 
This finding is corroborated by chemoresistance that is known to be connected with 
stemness (Dallas et al., 2009). CRC cells were more chemoresistant against 5-FU after loss 
of the miRNAome (Fig. 29A, B) and thus, the miRNAome as a whole suppresses 
mechanisms that lead to chemoresistance. Hence, loss of the miRNAome might contribute 
to the chemoresistance and consequently, to a worse response on chemotherapy in patients. 
This supposition is supported by the finding that low DICER1 protein levels led to a worse 
response to 5-FU in oral squamous cell carcinoma (Kawahara et al., 2014). 
Chemoresistance is one of the major reasons for the nonresponse of patients and is 
associated with increased expression of EMT markers (Dean et al., 2005; Frank et al., 
2010; Singh and Settleman, 2010) or ABC transporters (Dean et al., 2005; Zinzi et al., 
2014). As both, EMT factors (Gregory et al., 2008; Siemens et al., 2011) and ABC 
transporters (Bitarte et al., 2011) are downregulated by miRNAs, loss of the miRNAome 
might lead to the upregulation of EMT factors and ABC transporters and consequently, to 
increased chemoresistance. Metastastatic features which characterize CSC besides the CSC 
features stemness, EMT and chemoresistance were also increased after loss of DICER1 
and thus, of the whole miRNAome. The levels of the metastatic marker CD26 (Pang et al., 
2010) (Fig. 27C, D) and migration were enhanced after loss of the miRNAome (Fig. 30B, 
C). The loss of DICER1 and thus, of the whole miRNAome leads to the downregulation of 
migration inhibiting miRNAs (Korpal et al., 2008) whereby the cells are enabled to 
migrate. Consistent with this, increased DICER1 expression by the tumor suppressor tumor 
protein p63 suppressed metastasis (Su et al., 2010). As β-catenin target genes are involved 
in the crucial features of CSCs such as cancer stemness, metastasis, EMT and 
chemoresistance and these features are all influenced by disruption of DICER1, I 
investigated whether DICER1 disruption influenced also the activity of the Wnt signaling 
pathway. Indeed, the loss of the miRNAome increased the activity of the Wnt signaling 
pathway (Fig. 31), possibly by downregulation of miR-451 (Bitarte et al., 2011).  
 
Taken together, the loss of most of the miRNAome leads to increased expression/protein 
levels of CSC, EMT and metastatic markers, enhanced chemoresistance, migration and 
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Wnt signaling pathway activity. Thus, the downregulation of the whole miRNAome 
promotes features that are characteristic for CSCs. These results agree with the finding that 
loss of the miRNAome in mice leads to increased tumor initiation and thus, increased 
stemness. As both, tumor suppressive and oncogenic miRNAs are downregulated, the 
influence of the tumor suppressive miRNAs dominates in intestinal cancer and hence, the 
loss of the miRNAome is advantageous for the tumor formation and the process of 
carcinogenesis. Based on the results in this study I conclude that DICER1 and thus, the 
miRNAome acts as a tumor suppressor. 
 
4.2.3 Loss of DICER1 led to tumor formation and provides cancer properties in 
combination with an active oncogenic pathway  
Since target genes of the Wnt signaling pathway are involved in CSC properties such as 
tumor initiation (Du et al., 2008), proliferation (Clevers, 2006), chemoresistance (Yamada 
et al., 2000) and metastasis (Vlad-Fiegen et al., 2012), I investigated the impact of the Wnt 
signaling pathway on these features which were influenced by loss of the miRNAome. The 
effects of the loss of the miRNAome on CSC features were enhanced by an active Wnt 
signaling pathway (Fig. 28F; 29C; 30B, C). In the CRC cell lines, the combination of an 
active Wnt signaling pathway and a loss of the miRNAome showed the largest effects on 
the cancer cell properties. However, the effects, which caused by a loss of the miRNAome, 
on proliferation, chemoresistance and migration, were also visible with a reduced Wnt 
signaling pathway activity and thus, an active Wnt signaling pathway was dispensable for 
these effects. In the mouse model, the combination of an active Wnt signaling pathway and 
deletion of Dicer1 resulted also in the highest number of adenomas (Fig. 24A). However, 
in contrast to the cell lines, an activation of the Wnt signaling pathway was indispensable 
for the adenoma formation in the mouse model. This might be the case because the stem 
cells, in which the activation of the Wnt signaling pathway by Apc deletion took place, 
contained no further mutation or activation of another oncogenic pathway. These cells 
were only transformed by the activation of the Wnt signaling pathway. Therefore, the cells 
that possessed only a deletion of Dicer1 did not develop adenomas. In contrast to the 
mouse model, the cancer cell lines RKO and HCT116 possess also mutations in other 
oncogenic pathways. Both cell lines show mutations in PIK3 (Ahmed et al., 2013) and 
additionally, BRAF (RKO) or KRAS mutations (HCT116) (Ahmed et al., 2013) which 
increase cell proliferation, survival and chemoresistance (Fruman and Rommel, 2014; 
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Hirschi et al., 2014; Maurer et al., 2011; Sunaga et al., 2011). Consequently, these cell 
lines possess activated oncogenic PI3K/AKT and RAS/RAF/MAPK pathways and thus, 
tumor promoting features. An additional activation of the Wnt signaling pathway increased 
the effects in the cell lines after disruption of DICER1. However, the cell lines were not 
completely dependent on the Wnt signaling pathway. Thus, I suggest that DICER1 and 
thus, the miRNAome acts as a tumor suppressor in CRC cell lines as well in the mouse 
model and loss of DICER1 leads in combination with an activated oncogenic pathway such 
as the Wnt/β-catenin, PI3K/AKT or RAS/RAF/MAPK to tumor formation and increased 
CSC properties.  
 
The aforementioned hypothesis (see 4.2.1) that loss of DICER1 and therefore, loss of 
miRNAs in the mouse model might lead to carcinomas at later time points is supported by 
the cell culture results. The investigations in the mouse model take place at an early time 
point of the tumorigenesis where the cells did not accumulate additional mutations because 
of the short time span. In contrast, the further experiments in cell culture were performed 
in carcinoma cell lines which already accumulated additional mutations directing the cells 
into a more malignant route and further in cancer progression. A loss of DICER1 in the 
carcinoma cells can therefore enhance the malignancy of the carcinogenesis as the cells did 
already pursue this route, in contrast to the mouse model. Thus, deletion of DICER1 and 
thus, of the miRNAome in the carcinoma cells led to enhanced stemness and malignancy 
whereas in the mouse model, a higher tumor initiation was indeed detectable, however, no 
shift towards increased malignancy.  
 
4.2.4 DICER1 mRNA expression and protein levels increased in adenomas 
mediated by Wnt signaling pathway but decreased during progression 
from adenoma to carcinoma in human CRC  
Since the finding that DICER1 and the miRNAome function as a tumor suppressor was 
gained in a mouse model and in cell culture, I next translated this result to human CRC 
tissue. The animal and cell culture systems are very useful to investigate gene deletions or 
activations and the mechanistical background. However, the translation of the findings to 
human tissue is the next step as the final aim of the investigations is the investigation of the 
relevance for human tumors. As in humans, tumor suppressors are often inactivated during 
cancer development and progression (Fearon and Vogelstein, 1990) I investigated in this 
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study the levels of DICER1 during CRC progression. As expected from the previous 
results in this study, DICER1 decreased continually from adenoma during carcinoma 
progression in a collection of normal and tumorous colonic tissues (Fig. 32B). Consistent 
with my data, another group reported also a decrease of DICER1 during human colorectal 
carcinogenesis (Faggad et al., 2012). This result supports the previous findings since loss 
of DICER1 increased stemness features in cancer cells which are involved in progression 
and advanced tumor stages (Frank et al., 2010). The result that DICER1 levels decreased 
during carcinoma progression demonstrated that loss of DICER1 contributed to this 
progression. The mechanism for the downregulation of DICER1, however, is not yet 
clarified. In previous studies, no methylation of the DICER1 promoter was found (Karube 
et al., 2005; Melo et al., 2009) that could lead to silencing (Issa, 2004) of the DICER1 
gene. However, mutations in the DICER1 gene were detected (Hill et al., 2009) and in 
advanced CRC, loss of heterozygosity occurs frequently on the long arm (q) of 
chromosome 14 (Young et al., 1993) on which DICER1 is located. Additionally, mutations 
in TARBP2 (Melo et al., 2009) or loss of TARBP2 (Chendrimada et al., 2005), the 
interaction partner of DICER1, led to a destabilization of the DICER1 protein. Thus, 
further studies are required to unveil the mechanism for the downregulation of DICER1 
during CRC progression. 
 Furthermore, it turned out unexpectedly in the human tissue collection used here 
that adenomas showed an increase of DICER1 levels compared to normal mucosa 
(Fig. 32B) which was confirmed in murine adenomas (Fig. 33A). Since the murine 
adenomas in this study and likewise, the majority of the human CRCs (Pino and Chung, 
2010) are driven by the Wnt signaling pathway, both show a higher Wnt signaling pathway 
activity compared to normal mucosa. Therefore, the influence of Wnt signaling on 
DICER1 expression was further investigated namely in cell culture as cells are more suited 
for this investigation than tissue. I determined in CRC cells that a reduction of the Wnt 
signaling pathway activity by knockdown of CTNNB1 or transfection of dnTCF4 reduced 
the expression of DICER1 and also the activity of the DICER1 promoter (Fig. 33). From 
this result I conclude that the Wnt/β-catenin signaling pathway is involved in the regulation 
of the DICER1 expression. This finding is supported by a recent study that DICER1 is a 
target gene of β-catenin in the brain (Dias et al., 2014). The result that DICER1 is a β-
catenin target gene connects the Wnt signaling pathway with the miRNA biogenesis and 
shows an additional function of β-catenin and its target genes besides the other differential 
functions. β-catenin target genes regulate many different features in the cancer cells such 
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as proliferation (MYC (He et al., 1998), CCND1 (Shtutman et al., 1999) but also CDKN2A 
(Wassermann et al., 2009)), stemness (CD44 (Wielenga et al., 1999), LGR5 (Barker et al., 
2007)), chemoresistance (ABCB1 (Yamada et al., 2000), EMT (VIM (Gilles et al., 2003), 
ZEB1 (Sanchez-Tillo et al., 2011)) and invasion (MMP7 (Brabletz et al., 1999), PLAU 
(Hiendlmeyer et al., 2004) and TNC (Beiter et al., 2005)). Additionally, I identified TERT 
as a β-catenin target gene (Hoffmeyer et al., 2012; Jaitner et al., 2012) that mediates the 
hallmark replicative immortality to cancer cells (see also 1.2.3.2). Thus, Wnt signaling 
pathway regulates, besides other important cancer properties, also the miRNA biogenesis 
(Fig. 36). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 36. The influence of β-catenin on hallmarks of cancer and its target genes.  
Besides the already known target genes (grey), I demonstrated in this study that β-catenin regulates 
additionally the expression of DICER1 (red) and thus, the miRNA biogenesis. 
 
 
The result that DICER1 is downregulated during carcinogenesis (Fig. 32B) was also 
observed for other genes such as DKK-1 (Gonzalez-Sancho et al., 2005) or ITF-2 (Herbst 
et al., 2009) which are both also β-catenin target genes but downregulated in colorectal 
tumors. This finding demonstrates that the role of DICER1 and thus, the miRNAome is 
very complex in CRC. Notably, the upregulation of DICER1 in adenomas leads to an 
increase of oncogenic miRNAs whereas the downregulation of DICER1 and consequently, 
of tumor suppressive miRNAs was more favorable for advanced tumor stages. Another 
explanation might be that DICER1 is induced by β-catenin at the beginning of the 
tumorigenesis, in the adenomas, as DICER1 has a tumor protective function and is 
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upregulated by β-catenin as an endogenous protective mechanism. However, at later time 
points, DICER1 and miRNAs are not further relevant but rather unfavorable whereby 
DICER1 and thus, miRNAs are downregulated during the process of colorectal 
carcinogenesis.   
 
Taken together, the findings gained from cell culture experiments and results from the 
human CRC tissue collection demonstrate that the regulation of DICER1 and thus, the 
miRNAome is complex during the process of colorectal carcinogenesis. The initial hit in 
this process of cancer formation is a mutation in the APC gene and thus, an activation of 
the Wnt signaling pathway leading to adenoma formation. The β-catenin target gene 
DICER1 and thus, the miRNAome increases and supports adenoma formation. However, 
during the process of carcinogenesis, DICER1 is downregulated/inactivated and leads to a 
downregulation of the miRNAome which supports the process of carcinogenesis. As an 
activated Wnt signaling pathway and loss of the miRNAome increase CSC features, both 
promote the process of carcinogenesis (Fig. 37). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 37. Model of DICER1 protein levels during the process of colorectal carcinogenesis.  
The initial hit, the APC mutation and thus, activiation of the Wnt signaling pathway, leads to adenoma 
formation. Furthermore, the Wnt signaling pathway increases DICER1 expression/DICER1 protein levels 
and thus, the miRNAome which supports adenoma formation. During the process of carcinogenesis, DICER1 
is downregulated/inactivated leading to a downregulation of the miRNAome and thus, to a promotion of 
carcinogenesis. Both, Wnt signaling pathway activity and loss of the miRNAome increase CSC features 
which again support the process of carcinogenesis. 
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4.2.5 Future investigations 
The human situation in which DICER1 is upregulated in adenomas and subsequently, 
downregulated during the process of carcinogenesis in CRC, is difficult to translate into a 
mouse model for further investigations. To answer the questions whether the complex 
regulation of DICER1, which was observed in a human CRC tissue collection (Fig. 32, 
37), supports the process of carcinogenesis and drives adenomas to carcinomas at a later 
time point, a suitable mouse model has to be generated. The generation of a multistep 
carcinogenesis mouse model (Schonhuber et al., 2014) might better reflect the human 
situation. Therefore, a mouse model should be generated in which Apc and Dicer1 can be 
knocked out inducible at different timepoints. To do so, two different recombinase systems 
have to be used (Fig. 38) (Collins et al., 2012; Schonhuber et al., 2014). In this multistep 
carcinogenesis mouse model, two systems (rtTA (recombinant tetracycline controlled 
transcription factor) and CreERT2) are expressed under the Lgr5 promoter in CBC cells. 
Thus, the FLP (flippase) recombinase which is controlled by TetO (tet operator) can be 
induced by the administration of doxycline (dox), e.g. administration in drinking water. By 
the expression of FLP, Apc could be knocked out at timepoint 1 (day 0) via the FRT 
(flippase recognition target) sites to activate the Wnt signaling pathway in CBC cells. After 
the formation of adenomas, Dicer1 could be knocked out by TAM injection at a second 
timepoint (day x) whereby CreERT2 could translocate to the nucleus and Dicer1 could be 
knocked out by the flox sites. In the Apc mouse model, the knockout of Apc leads very fast 
to adenomas. At day 8 after the Apc knockout, microadenomas become evident, at day 14 
after the Apc knockout, large adenomas are visible and at day 36 after the Apc knockout, 
the mice have to be killed because of the high tumor burden (Barker et al., 2009). Thus, the 
additional knockout of Dicer1 should take place between day 8 and day 14 after the Apc 
knockout to make sure that the mice live long enough for further inverstigations. This 
mouse model would allow the investigation of the effects of DICER1 on the process of 
carcinogenesis at later time points. This might reflect the human situation in which 
DICER1 was upregulated in adenomas by β-catenin but later in tumorigenesis, DICER1 
was downregulated. 
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Fig. 38. Multistep carcinogenesis mouse model.  
In this mouse model rtTA (recombinant tetracycline controlled transcription factor) and CreERT2 are 
expressed under the control of the Lgr5 promoter. Thus, both, rtTA and CreERT2 can be induced in Lgr5 
expressing cells (CBC cells). Administration of doxycycline (dox) at timepoint 1 (day 0) leads to binding of 
rtTA to TetO (tet operator) and thus, to expression of the FLP (flippase) recombinase. By the expression of 
the FLP recombinase, recombination of Apc can take place. Injection of TAM to a second timepoint (day x) 
leads to recombination of Dicer1 in CBC cells.  
 
 
The adenomas and possibly carcinomas from this mouse model might be further isolated 
and used to investigate the changes of the targeted mRNAs by transcriptome analysis. 
These investigations might shed light on the altered expression of mRNAs after loss of the 
miRNAome. The investigations of the changes in the transcriptome might be used to 
identify the corresponding miRNAs whose loss is responsible for the process of 
carcinogenesis. Furthermore, transcriptome analysis of the cell lines (HCT116/RKO 
+/+/ex5) might be a promising tool to identify responsible miRNAs whose loss promotes 
the process of carcinogenesis by targeting specific mRNAs. These identified miRNAs 
might further be tested as possible targets for therapies. The identified miRNAs might be 
delivered to the mouse model (Fig. 38) at a specific timepoint 3 to examine whether the 
administration of specific tumor suppressive miRNAs can inhibit the process of 
carcinogenesis in this Wnt driven mouse model. In previous studies the restoration of some 
tumor suppressive miRNAs that were downregulated in the tumor were tested for the 
treatment of tumors in mouse models (Melo and Kalluri, 2012). Promising effects had e.g. 
the delivery of the miRNA let-7b which targeted enhanced proliferation, invasion and 
metastasis formation in a mouse model which were caused by overexpressed oncogenes 
(Trang et al., 2010; Trang et al., 2011). Furthermore, the application of miR-34a (Liu et al., 
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2011; Trang et al., 2011) and miR-143/145 inhibited tumor growth (Pramanik et al., 2011). 
Besides the single miRNA based therapy, also the promotion of the miRNA biogenesis and 
thus, upregulation of multiple miRNAs by application of small molecules is possible (Melo 
and Kalluri, 2012). These increased level of miRNAs, among them also tumor suppressive 
miRNAs, inhibited tumor growth (Melo et al., 2011; Shan et al., 2008) which could be 
more effective for therapeutic success than the application of a single miRNA (Melo and 
Kalluri, 2012). However, since miRNA biogenesis is promoted by this application, no 
mutation or inactivation of the miRNA biogenesis components such as DICER1 may exist 
in the latter approach. Furthermore, the application of miRNAs might lead to sensitization 
of tumors for chemotherapy and therefore, to growth inhibition and shrinkage of the tumor 
(Melo and Kalluri, 2012). This decrease of chemoresistance might be mediated e.g. by 
delivery of miRNAs which reduce the expression of ABC transporters (Jeon et al., 2011) 
or increase the sensitivity for tamoxifen (Cittelly et al., 2010). Besides the application of 
tumor suppressive miRNAs, miRNA based tumor therapy is also possible by inhibition of 
oncogenic miRNAs. Of course, nonspecific side effects might appear since one miRNA 
can target a high number of mRNAs. Methods that deliver the miRNAs or small molecules 
to the appropriate cell types or tissues might help to reduce side effetcs (Melo and Kalluri, 
2012). Delivery methods were already improved whereby the therapeutic miRNAs can be 
delivered intranasally, intratumorally or systemically. The improvement of the delivery 
methods to get safer delivery vehicles such as lipid-based nanoparticles was a good step 
towards clinical application. However, it has to be validated in clinical trials whether the 
success of miRNA application can also be recapitulated in human patients (Kasinski and 
Slack, 2011). Nevertheless, the application of tumor suppressive miRNAs or inhibition of 
oncogenic miRNAs is a promising tool for the therapy of tumors. Therefore, further studies 
are required to clarify the success of these therapies, to enhance efficacy, to reduce side 
effects (Melo and Kalluri, 2012) and finally, to translate these findings to human tumors. 
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